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The number of peptide drugs in the industry pipelines has significantly increased in 
the last decades due to their high therapeutic efficacy and excellent selectivity. 
However, their utility has been limited due to their difficulties for crossing mucosal 
barriers, making it virtually impossible to deliver them by the oral route. The aim of 
this work was to design and develop protamine-based nanocapsules (NCs), capable of 
encapsulating insulin, protecting it from the harsh intestinal environment and 
promoting its absorption across the epithelial wall. The NCs consisted of an oily core, 
containing Miglyol and sodium glycocholate (SGC), surrounded by a polymer layer 
made of protamine and PEG-stearate. The NCs were also provided with a double 
protamine/polysialic acid (PSA) layer. These polymer layers were intended to 
enhance the stability against intestinal degrading enzymes and to facilitate the 
interaction of the NCs with the epithelial mucosa. 
Protamine and PSA/protamine NCs exhibited a size between 300-400 nm, with a 
spherical shape and the capacity to load insulin. The provision of the NCs with a PSA 
layer reinforced their colloidal stability in different simulated intestinal media and 
preserved the loaded insulin from enzymatic degradation when incubated in fed-state 
simulated intestinal fluid. In addition, both formulations released insulin in a 
controlled manner. These NCs could also be lyophilized and stored as a thermostable 
powder formulation up to 6 months at 25 °C, while preserving insulin stability.  
The interaction of the protamine and PSA-protamine NCs with the Caco-2 cells was 
found to occur at the transcellular and paracellular level. The NCs were able to cross 
the monolayer and, simultaneously open the tight junctions between cells. Moreover, 
both systems interacted with the epithelium of human intestinal tissue without any 
cytotoxic effects. Finally, in vivo efficacy studies showed a moderate decrease (20% 
reduction) of blood glucose levels in non-diabetic rats. Overall, these results highlight 
the potential for protamine-based NCs to interact with intestinal mucosa and promote 








El número de biofármacos presentes en las “pipelines” de las industrias farmacéuticas 
se han incrementado significativamente en las últimas décadas debido a su alta 
eficacia terapéutica y a su excelente selectividad. Sin embargo, su utilidad se ha visto 
limitada debido a las dificultades inherentes a dichas moléculas para cruzar barreras 
mucosas, imposibilitando de esta forma su administración por vía oral. El objetivo de 
este trabajo consiste en el desarrollo de nanocápsulas basadas en protamina (NCs), 
capaces de encapsular insulina, protegerla de la degradación en el desfavorable 
ambiente del tracto gastrointestinal y promover su absorción a través de la barrera 
epitelial. Las NCs están constituidas por un núcleo oleoso, formado por Miglyol® y 
sodio glicocolato (SGC), y rodeadas por una cubierta polimérica a base de protamina 
y PEG-estearato. Una doble cubierta con protamina/ácido polisiálico (PSA) ha sido 
explorada asimismo con el objetivo de aumentar la estabilidad frente a enzimas 
digestivas y facilitar la interacción de las NCs con la mucosa epitelial. 
Ambas NCs, recubiertas con protamina o PSA-protamina, muestran un tamaño 
comprendido entre 300-400nm, una forma esférica y capacidad de incorporación de 
insulina. La presencia de la cubierta de PSA en las NCs refuerza su estabilidad 
coloidal en diferentes medios intestinales simulados y preserva la insulina 
incorporada en las nanoestructuras frente a la degradación enzimática cuando estas 
son incubadas con FeSSIF-V2. Adicionalmente, ambas formulaciones demuestran 
una liberación controlada de insulina y pueden ser liofilizadas y almacenadas como 
polvo seco durante al menos 6 meses a 25ºC  preservando la estabilidad de la insulina 
durante todo este periodo.  
La evaluación de las NCs de protamina y PSA-protamina en células Caco-2 ha 
demostrado que la interacción de los nanosistemas con las células se produce a nivel 
transcelular y paracelular. Las NCs son capacers de cruzar la monocapa de células y 
simultáneamente abrir las uniones estrechas entre las células. Ambos sistemas 
interaccionan con el epitelio intestinal humano sin presentar efectos citotóxicos. 
Finalmente, estudios de eficacia in vivo han demostrado una reducción moderada (20% 
de reducción) de los niveles de glucosa en sangra en ratas no diabéticas. Estos 
resultados remarcan el potencial de estos nanositemas para interaccionar con la 




























Según la Federación Internacional de Diabetes, 415 millones de personas en todo el 
mundo padecen diabetes y se espera que este  número aumente hasta 642 millones en 
el año 2040 [1]. Se distinguen dos tipos principales de diabetes, denominadas tipo I y 
tipo II en función del origen y características de la enfermedad. Por un lado, la 
diabetes tipo I tiene su origen en una reacción autoinmune que provoca que el sistema 
de defensa del organismo ataque a las células beta pancreáticas productoras de 
insulina y como consecuencia, el organismo no produce la insulina necesaria. En el 
caso de la diabetes tipo II, el organismo es capaz de producir insulina, pero con el 
tiempo va desarrollando resistencia a esta hormona. A la larga, esta situación puede 
acabar desembocando en unos niveles de insulina insuficientes. Ambas causas, tanto 
la deficiencia de insulina como la resistencia a la misma, generan niveles elevados de 
glucosa en sangre, que generalmente son controlados mediante terapia de sustitución 
con insulina [2].  
La insulina humana es una hormona (peso molecular de 5808 Daltons) compuesta por 
51 aminoácidos organizados en dos cadenas polipeptídicas (A y B), unidas entre sí 
por puentes disulfuro. La estructura primaria de la insulina humana, con 21 
aminoácidos en la cadena A y 30 en la cadena B, se representa en la Figura 1A [3]. 
Esta hormona juega un papel fundamental en la regulación de los niveles de glucosa 
en sangre. La elevación de la glucemia se produce como consecuencia de la absorción 
intestinal de glucosa a partir de la degradación de hidratos de carbono de la dieta, 
como el almidón o la sacarosa. Dicho aumento estimula la secreción de insulina del 
páncreas hacia el torrente sanguíneo y la actividad biológica de la misma se inicia 
cuando ésta se une a sus receptores celulares de membrana, desencadenando así 
distintas cascadas de activación proteica (Figura 1B). A través de ellas, esta hormona 
promueve la absorción, la utilización, el almacenamiento y el transporte de glucosa 
desde la sangre hacia las células de los tejidos-diana, como hígado, músculo 
esquelético o tejido adiposo (Figura 1B) [4].  
 
La terapia actual, a base de insulina, es eficaz en cuanto a que consigue una reducción 
de la glucemia  en pacientes diabéticos, pero su utilización se ve restringida debido a 




parenteral de insulina evita su paso por el hígado  introduciéndola directamente en el 
torrente sanguíneo, lo que a la larga puede provocar un estado de hiperinsulinemia 
asociada a hipertensión periférica, que finalmente puede traducirse en el desarrollo de 
aterosclerosis, hipoglucemia y otros efectos metabólicos adversos [5]. Asimismo, los 
pacientes diabéticos tienen que soportar múltiples inyecciones diarias, con los 
consiguientes efectos indeseados tales como dolor, invasión de tejidos, posibles 
infecciones y daños nerviosos, lo que conduce a una baja adherencia al tratamiento. 
Como consecuencia, el uso de la insulina inyectable es claramente inferior al deseable 
y se cree queel desarrollo de terapias alternativas, menos invasivas, ha de ser un 
objetivo prioritario en la innovación farmacéutica [6]. 
 
Figura 1: A) Secuencia de aminoácidos de la insulina humana, B) Ilustración 
esquemática de los efectos de la insuficiente producción de insulina en la diabetes tipo 
I; ilustración de la función fisiológica de la insulina en la absorción y metabolismo de 
la glucosa (la insulina se une a su receptor, iniciando diversas cascadas de activación 
proteica incluyendo la translocación de GLUT-2 hacia la membrana plasmática, 





1.2 El reto de administrar insulina por vía oral 
A pesar de los grandes avances en la tecnología asociada aldesarrollo de 
formulaciones inyectables, se estima que más del 5% de la población mundial 
continúa teniendo fobia a estos dispositivos. Asimismo, de entre todas las vías de 
administración no invasivas (oral, nasal, pulmonar, bucal y transdérmica), la oral es la 
preferida. Por ello, el desarrollo de formulaciones de péptidos que permitan la 
administración oral de los mismos es muy importante ya que cuando se trata de una 
terapia crónica, la administración parenteral desemboca en una baja adherencia al 
tratamiento, reduciendo así su eficacia [7]. La administración oral de insulina 
permitiría, además, el acceso de este fármaco a la circulación portal, alcanzando el 
hígado antes de llegar a circulación sistémica, de forma similar a lo que ocurre con la 
insulina secretada fisiológicamente por el cuerpo humano [8].  
Sin embargo, la administración de insulina por vía oral sigue siendo un gran reto 
debido a las dificultades inherentes al desarrollo de una formulación destinada a este 
propósito. Los fármacos administrados por vía oral deben soportar las condiciones 
agresivas del estómago, estando expuestos a la degradación por parte de ácidos y de 
enzimas. En el entorno gastrointestinal el fármaco queda expuesto a la degradación 
por enzimas como las proteasas pancreáticas, entre las que se incluyen la tripsina, α-
quimotripsina, elastasa, exopeptidasas, carboxipeptidasas A y B. Los fármacos que 
resisten estas condiciones deben posteriormente atravesar la capa de mucus que 
recubre la superficie de absorción del tracto gastrointestinal (TGI) y pasar a través de 
las células epiteliales para lograr acceder al torrente sanguíneo. Como la insulina es 
una molécula peptídica, puede ser fácilmente degradada a su paso por el TGI debido a 
las condiciones hostiles del mismo, lo que conlleva que su biodisponibilidad oral se 
vea ampliamente disminuida. Además, su elevado peso molecular (sobre 6 kDa), su 
carga y su hidrofilicidad limitan su absorción por las vías paracelular y transcelular 
[9]. 
Se han explorado distintas estrategias para mejorar la biodisponibilidad oral de la 
insulina, entre las que se incluyen su modificación química, su co-administración con 
promotores de la absorción y/o inhibidores enzimáticos y su incorporación en 
sistemas de liberación [10]. En esta línea, la nanotecnología ha mostrado resultados 
prometedores en el diseño de nanotransportadores con potencial para la 




consiga mejorar sustancialmente el diagnóstico y tratamiento de la diabetes en el 
futuro [11].  
 
1.3. Nanotransportadores para la administración oral de insulina  
La principal estrategia en el área de la nanotecnología para lograr la administración 
oral de péptidos y proteínas va dirigida a conseguir la encapsulación de los mismos en 
vehículos de tamaño nanométrico (10-1000 nm) que los protejan frente a la 
degradación, controlen su liberación en los tejidos diana y faciliten su transporte 
transepitelial. Los nanosistemas utilizados para el transporte de insulina incluyen  
nanopartículas, nanocápsulas, micelas y liposomas (Figura 2) [13], entre otros. 
Algunos de estos nanotransportadores han sido ampliamente estudiados para la 
administración oral de insulina, llegando incluso a ensayos clínicos, tema analizado 
en detalle en el capítulo 1. 
Características como  el tamaño, la carga superficial y la hidrofobicidad/hidrofilicidad 
de las partículas han sido identificadas como factores determinantes para lograr su 
internalización en las células del organismo [13, 14]. La modificación de estas 
propiedades de superficie puede conseguirse, bien a través de un recubrimiento de los 
nanosistemas con polímeros biodegradables hidrofílicos, o bien a través de la 
inclusión de surfactantes adicionales en la formulación. Por ejemplo, debido a sus 
propiedades estabilizantes, se ha utilizado ampliamente el polietilenglicol (PEG) 
como material de recubrimiento o como componente de la matriz en nanosistemas 
cargados con insulina. Esto se debe a que las cadenas de PEG forman una barrera 
estérica en la superficie de las nanopartículas que incrementa su estabilidad frente a 
proteasas, previene su opsonización y reduce su inmunogenicidad [15]. También ha 
sido demostrado que en algunos casos la combinación de ambas estrategias (el uso de 
polímeros y de surfactantes en el mismo sistema) podría llevar a una potenciación de 
sus propiedades y, consecuentemente, a un aumento de la biodisponibilidad oral del 







Figura 2: Diferentes tipos de nanotransportadores para liberación de insulina.  
 
 
1.4 La protamina como biomaterial en el desarrollo de nanotransportadores de 
fármacos 
De entre los diferentes biomateriales explorados, los poliaminoácidos con capacidad 
de penetrar en las células constituyen una estrategia prometedora para la 
administración oral de insulina [16].Las principales razones son su capacidad para 
interactuar con estas moléculas, reducir su degradación enzimática y promover su 
absorción oral [17], propiedades que comparten con los péptidos de penetración 
celular (CPPs). Morishita et al. fueron pioneros a la hora de mostrar el potencial de 
las oligoargininas como CPPs, para mejorar la absorción de insulina a través de la 
pared intestinal  [18] través de membranas mucosas, logrando así alcanzar niveles 
muy efectivos de biodisponibilidad [19]. La adsorción electrostática de la octarginina 
a los proteoglicanos presentes en la superficie celular y su subsecuente internalización 
han sido asociadas con su efecto promotor en la absorción de insulina en mucosas. 
 
Por otro lado, la protamina es una proteína nuclear de pequeño tamaño rica en 
arginina, que juega un papel esencial en la condensación nuclear de los 
espermatozoides y en la estabilización del ADN [20]. Una vez combinada con la 
insulina, la protamina retrasa el inicio la actividad biológica de esta hormona, además 
de aumentar la duración de su actividad (ver insulina NPH). Debido a su capacidad de 
natural para condensar ácidos nucleicos, la protamina también es un biomaterial 
atractivo y ampliamente utilizado en aplicaciones de terapia génica  [22], [23].  
 
Nuestro grupo de investigación tiene experiencia en el empleo de biomateriales ricos 
en arginina, como poliarginina [24] y protamina [25] en el diseño de sistemas de 
liberación de fármacos con capacidad para transportar distintas moléculas terapéuticas. 




nanopartículas y nanocápsulas, demostrando gran potencial para interactuar con 
células y promover la internalización de antígenos [25]. Asimismo, nanopartículas 
multicapa (técnica “layer-by-layer”) han sido también desarrolladas para la co-
encapsulación y liberación de agentes inmunoestimulantes y antígenos, utilizando una 
combinación de poliarginina y protamina con polisacáridos como el sulfato de 
dextrano o el alginato [26]. Nuestro grupo también ha diseñado recientemente 
nanocápsulas de protamina con estructura lipídica de tipo núcleo-cubierta, con núcleo 
oleoso de vitamina E, para la encapsulación de curcumina como molécula anti-
inflamatoria. Con este sistema se logró aumentar de forma significativa  la 
permeabilidad de este fármaco en células Caco-2 [27]. En todos los casos, los efectos 
positivos observados con la utilización de protamina se atribuyen a la presencia de 
una secuencia repetitiva de arginina en su estructura (sobre el 70%) (Figura 3), la 
cual otorga a este polipéptido una eficiente capacidad de translocación a través de 
membranas biológicas, incluyendo las células epiteliales intestinales [28]. Se sabe que 
esta capacidad de translocación se produce principalmente por endocitosis, como 
consecuencia de la interacción entre las unidades de arginina cargadas positivamente 
y las cargas negativas presentes en la superficie de las membranas [29].  
 
 
Figura 3: Representación esquemática de la estructura convencional de la 
protamina, conteniendo los aminoácidos prolina, arginina, serina, valina y glicina.  
 
2. Hipótesis 
En base a las evidencias aportadas por estudios anteriores, se han formulado las 
siguientes hipótesis:  




nanocápsulas para una eficaz administración oral  de macromoléculas como la 
insulina. La capacidad de este polipéptido para translocarse a través de 
membranas celulares podría verse potenciada al combinarlo con otros 
promotores de la penetración celular (lípidos y surfactantes), aumentando así 
la absorción intestinal de la insulina.  
2. La combinación racional de protamina con polímeros estabilizadores y 
mucopenetrantes, como el poliácido siálico (PSA) y derivados del PEG, 
podría conducir al desarrollo de un nanosistema optimizado capaz de asociar 
el péptido, protegerlo de la degradación enzimática y transportarlo a través de 
la barrera epitelial.  
3. Objetivos 
El principal objetivo de este trabajo es el diseño racional y desarrollo de un nuevo 
nanosistema basado en la combinación de protamina, con otros biomateriales 
seleccionados para incrementar sus propiedades promotoras de la absorción y mejorar 
su estabilidad. Tomando la  insulina como péptido modelo, el objetivo último de este 
nanosistema es conseguir una eficaz administración oral de péptidos. Con este fin, el 
objetivo global se divide en los siguientes objetivos específicos:  
1. Desarrollo y caracterización in vitro de nanocápsulas de protamina 
cargadas con insulina. 
2. Evaluación de los mecanismos de acción in vitro y de la toxicidad de las 
nanocápsulas de protamina en células epiteliales.  
3. Evaluación de la interacción de las nanocápsulas de protamina con la 
barrera epitelial, incluyendo su biodistribución y eficacia in vivo.  
 
4. Resultados y discusión  
Las nanocápsulas de protamina fueron preparadas mediante la técnica de 
desplazamiento de disolvente [8]. Se incorporó ácido polisiálico (PSA) como cubierta 
externa a través de interacciones iónicas con la protamina, confirmando su presencia 
con la inversión de la carga superficial de los nanosistemas (Tabla 1, Figura 4). Las 
nanocápsulas de protamina, recubiertas o no con PSA, presentaron un tamaño de 300-






Figura 4: Representación esquemática de las nanocápsulas de protamina con y 
sin recubrimiento de ácido polisiálico (PSA). 
 
Tabla 1: Propiedades fisicoquímicas, eficacia de asociación de insulina (AE%) 
y capacidad de carga (LC%) de las nanocápsulas de protamina en comparación con la 






(mV) AE % LC % (w/w) 
NE 345 ± 13 0.3 -21 ± 1 35 ± 11 0.67 ± 0.03 
NCs Protamina  382 ± 59 0.2 +6 ± 3 62 ± 16 1.0 ± 0.06 
NCs PSA-Protamina  301 ± 34 0.2 -4 ± 1 51 ± 9 0.82 ± 0.01 
 
Las nanocápsulas demostraron ser estables en medios intestinales simulados, 
especialmente las recubiertas con PSA. Además, para ambas formulaciones se 
observó un patrón de liberación de insulina bifásico en FaSSIF, con una liberación 
gradual durante la primera hora, seguida de una liberación constante hasta liberar 
aproximadamente un 70% de la insulina encapsulada tras las 6 h de estudio. La 
presencia de la cubierta externa de PSA reforzó la estabilidad de las nanocápsulas, 
protegiendo así a la insulina encapsulada de la degradación enzimática (Figura 5). 
Además, la inclusión de SGC, sal biliar conocida por inhibir la actividad proteasa, 
también mejoró la estabilidad de las formulaciones y contribuyó significativamente a 





Figura 5: Perfil de estabilidad de la insulina encapsulada en los distintos 
nanosistemas tras la incubación en FeSSIF-V2, conteniendo enzimas pancreáticas 
(media ± SD, n=3 diferencia significativa ( p < 0,05 ) para PSA-PrNCs + SGC en 
comparación con *PSA-PrNCs + SC y #PrNC sin colato / insulina libre. 
 
Ambas formulaciones demostraron no ser toxicas en células Caco-2 y en tejido 
intestinal humano a las concentraciones de 2 y 5 mg/mL respectivamente, 
confirmando la seguridad de estos nanosistemas para administración oral. Las células 
Caco-2:HT29-MTX sembradas en una relación 3:1 exhibieron una capa homogénea 
de mucus que no afectó a las propiedades promotoras de la absorción de estos 

































Figura 6: Transporte de nanocápsulas de protamina con y sin cubierta de PSA en 
monocapas de células Caco-2 y Caco-2/HT29-MTX tras 2 horas de incubación 
(media ± SD, n=3). 
 
Finalmente, la eficacia in vivo de las formulaciones desarrolladas fue evaluada 
mediante la administración intraduodenal (50 IU/kg) a ratas sanas, tras 4 horas de 
ayuno [18], [30], [31]. Los resultados relativos a los niveles de glucosa en sangre 
mostraron un descenso moderado pero significativo de los mismos (≈20 %), el cual se 
mantuvo durante el todo estudio (Figura 7). Esta respuesta moderada si la 
comparamos con otros estudios publicados en la literatura, se atribuyó al modelo 
animal utilizado (ratas no diabéticas), al corto periodo de ayuno (4 h) y a la elevada 
viscosidad de la formulación administrada que puede dificultar la miscibilidad de las 























Figura 7: Efecto hipoglucémico estandarizado tras la administración 
intraduodenal de nanocápsulas de protamina cargadas con insulina (50IU/kg, n=11), 
nanocápsulas de protamina recubiertas de PSA y cargadas con insulina (50IU/kg, 
n=15), nanocápsulas de protamina vacías (placebo) (n=12) a la misma concentración 
y solución salina de insulina (50IU/kg, n=16) a ratas no diabéticas. (Media ± SEM, *p 
< 0.05 nivel de significación al comparar nanocápsulas de protamina y nanocápsulas 
de protamina recubiertas de PSA con el placebo).  
 
5. Conclusiones  
El presente trabajo de tesis se ha centrado en el diseño y desarrollo de un nanosistema 
a base de protamina, con estructura formada por un núcleo oleoso y una cubierta 
polimérica, para una eficiente liberación oral de insulina (y otras macromoléculas 
similares). Los resultados obtenidos del trabajo experimental han permitido extraer las 
siguientes conclusiones:  
1. Nanocápsulas (NCs) con una sola cubierta de protamina o una doble de 
protamina y ácido polisiálico (PSA) fueron eficazmente preparadas usando el método 
de desplazamiento del solvente. Estas nanocápsulas, protamina y PSA/protamina, 
presentaron una buena capacidad para encapsular insulina (62 y 51 %) y un tamaño 
nanométrico (382 y 301 nm). Ambos sistemas resultaron en poblaciones homogéneas 
de forma esférica y con una carga superficial cercana a la neutralidad.  
2. Las nanocápsulas de protamina y protamina/PSA demostraron ser estables en 
medio intestinal simulado protegiendo a la insulina encapsulada frente a la 
degradación enzimática. La cubierta extra de PSA junto con la presencia de la sal 
biliar glicocolato de sodio como surfactante (SGC), incrementaron la estabilidad del 
nanosistema y minimizaron la degradación enzimática de la insulina encapsulada.  
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3. Los estudios in vitro fueron llevados a cabo en diferentes modelos celulares 
que simulan el epitelio intestinal, poniendo de manifiesto que las nanocápsulas de 
protamina y protamina/PSA exhiben una baja toxicidad celular. Además, estos 
estudios indican que ambos tipos de NCs interaccionan con la monocapa de células 
principalmente mediante dos mecanismos, que posiblemente sean responsables tanto 
del transporte transcelular como paracelular del péptido asociado. 
4. Estudios in vivo realizados en ratas no diabéticas confirman que las NCs son 
capaces de preservar la insulina encapsulada en la formulación, mantener su actividad 
biológica y minimizar su degradación enzimática. Ambas formulaciones han sido 
capaces de promover la absorción de insulina e inducir un descenso moderado (20%) 
de los niveles iniciales de glucosa en sangre después de una administración intra-
intestinal. 
5. Los nanosistemas desarrollados en este estudio fueron liofilizados a polvo 
seco, mostrando una estabilidad durante almacenamiento y a temperatura ambiente 
(25ºC) así como preservando la insulina asociada durante al menos 6 meses.   
 
En términos generales, el trabajo presentado en esta tesis plantea a las nanocápsulas a 
base de protamina como potenciales nanosistemas para la administración oral de 
péptidos. La extensiva caracterización in vitro de estas NCs ponen de manifiesto su 
estabilidad tanto en fluido intestinal como durante almacenamiento, propiedades 
ambas de mucha relevancia para el uso de estos nanosistemas en la administración 
oral. Por otra parte, es evidente que las NCs pueden modularse y adaptarse para 
mejorar la estabilidad y el perfil de liberación del péptido incluido. El perfil de 
toxicidad, tanto in vitro como en tejido intestinal humano, junto con el efecto de 
aumento de la penetración son propiedades igualmente interesantes de estos 
nanosistemas. Si bien los estudios de eficacia in vivo han mostrado una modesta 
variación en los niveles de glucosa en sangre, los datos presentados en este trabajo 
son alentadores, considerando que un mejor desarrollo de modelos animales y 
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1. Diabetes therapy  
Diabetes mellitus (DM) is a chronic condition that occurs when the body cannot 
produce enough insulin or cannot use insulin. DM is considered a metabolic disorder 
since reduced or inactive insulin results in imbalanced food metabolism, characterized 
by the accumulation of glucose in the blood (known as hyperglycaemia). The 
resulting high levels of glucose in the blood causes damage to many tissues in the 
body, and with progression of the disease pathological changes like nephropathy, 
retinopathy and cardiovascular complications start occurring in the body [1, 2].  
According to the International Diabetes Federation, 415 million people worldwide are 
diagnosed with diabetes and this number is expected to rise to 642 million by 2040 [1]. 
There are two main types of diabetes: type I and type II. Type 1 diabetes is caused by 
an autoimmune reaction, in which the body’s defense system attacks the insulin-
producing beta cells in the pancreas. As a result, the body does not produce the insulin 
it needs. In type II diabetes, the body is able to produce insulin but develops 
resistance over time so that insulin levels may subsequently become insufficient. Both 
the insulin resistance and deficiency lead to high blood glucose levels. The primary 
goal for the treatment of type I and type II diabetes is to cure the symptoms related to 
hyperglycemia. Type 1 is generally monitored through insulin replacement therapy 
[3]. 
2. Advances in insulin therapy  
Human Insulin is a hormone (molecular weight of 5808 Daltons) composed of 51 
amino acids arranged into two polypeptide chains (an A chain and a B chain), which 
are linked by disulfide bonds. The primary structure of human insulin, which contains 
21 amino acid residues in chain A and 30 amino acid residues in chain B, is shown in 
(Figure 1A) [4]. Insulin plays a key role in the regulation of blood glucose levels. The 
intestinal absorption of glucose generated from the degradation of dietary 
carbohydrates including starch or sucrose, leads to elevated blood glucose levels, 
which stimulates the secretion of insulin from the pancreas into the blood stream. The 
biological actions of insulin are initiated when insulin binds to its cell surface receptor, 
which is followed by many protein activation cascades (Figure 1B) through which, 
insulin promotes the transport, intake, utilization and storage of glucose from the 
blood to the cells in the target tissues, such as liver, skeletal muscles and adipose 




Figure 1: a) Amino acid sequence of human insulin, b) Schematic illustration of the 
physiological function of insulin on glucose uptake and metabolism. [Insulin binds to 
its receptor (1), which starts protein activation cascades (2) including translocation of 
GLUT-2 to the plasma membrane and influx of glucose (3), and glycogen synthesis 
(4)], c) Schematic illustration of the effects of insufficient insulin production in type 1 
diabetes.  
 
2.1. Injectable insulin  
Current administration of insulin for diabetes treatment is almost entirely via 
subcutaneous injection and different insulin formulations have their unique 
pharmacokinetics. Human insulin preparations on the market can classified as (i) 
rapid-acting insulin:  insulin lispro (Humalog®), insulin aspart (Novolog®), and 
insulin glulisine (Apidra®), (ii) regular or short-acting insulin: Humulin®R and 
Novolin®R (iii) intermediate-acting insulin: Neutral Protamine Hagedorn (NPH) 
insulin (Humulin N®), and Lente insulin, (iv) long-acting insulin: Ultralente, insulin 
glargine (Lantus®) and insulin detemir (Levemir®) (Figure 2) [4].  
Rapid-acting insulins are inherited from the human insulin and characterised by a 
modification in the B chain e.g. for insulin lispro, the B28 (proline), B29 (lysine) 
amino acid sequence is reversed to be lysine-proline. In insulin aspart, the B28 amino 
acid proline is substituted with aspartic acid and finally for insulin glulisine (Apidra®) 
the amino acid aspargine at position B3 is replaced by lysine and the lysine in position 
B29 is replaced by glutamic acid. These modifications induce rapid dissociation of 
hexamers into dimers and monomers after injection. This rapid dissociation leads to 
rapid absorption after administration. Their onset peaks are sooner and they have 
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short durations compared to regular human insulin. Regular or short-acting insulin, on 
the other hand, is the basic human insulin without any modifications, (depicted in 
Figure 1A). It reaches the bloodstream within 30 minutes after injection, peaks at 2 - 
3 hours after injection and is effective for approximately 3 to 6 hours [6].  
The formulation Neutral Protamine Hagedorn (NPH) on the other hand, is a 
suspension of crystalline zinc-insulin combined at neutral pH with a positively 
charged, arginine-rich polypeptide, protamine. Its duration of action is intermediate 
due to delayed absorption of the insulin because of its conjugation with protamine, 
forming a less soluble complex. NPH blood absorption begins 1.5 h after 
subcutaneous injection; it has a peak plasma concentration at 4 to 12 h and disappears 
within 24 h (Figure 2) [4].  
Long-acting insulin analogs attempt to replicate the body's basal insulin secretion. 
Insulin glargine consists of two modifications to human insulin. First, two arginines 
are added to the C-terminus of the B chain shifting the isoelectric point of the insulin 
from a pH or 5.4 to 6.7, making the insulin more soluble at an acidic pH. Secondly, 
the asparagine at position A21 is replaced by glycine.  This substitution prevents 
deamidation and dimerisation that would occur with acid-sensitive 
asparagine.  Insulin glargine is formulated at a pH of 4.0 and when it is injected into 
subcutaneous tissue (pH 6.8) the acidic solution is neutralized and microprecipitates 
of insulin glargine are formed, from which small amounts of insulin are released 
throughout a 24-hour period, resulting in a low level of insulin throughout the day 
(Figure 2) [3]. Insulin detemir, on the other hand, is a long acting insulin analog in 
which the B30 amino acid is omitted and a C14 fatty acid chain (myristic acid) is 
bound to the B29 lysine amino acid. It is slowly absorbed due to its strong association 
with albumin in the subcutaneous tissue and when it reaches the bloodstream it binds 




Figure 2: Idealized activity profiles of human insulin and analogues. Adapted with 
permission from [7]. 
 
The current therapy with insulin is effective at lowering blood glucose in patients with 
diabetes, but its use is constrained by the need to be injected subcutaneously and 
because of the concerns regarding interference with patients’ lifestyle, risk of 
hypoglycemia. Parenteral administration bypasses the liver and goes directly into 
blood circulation leading over time to peripheral hyperinsulinemia, associated with 
peripheral hypertension, the development of atherosclerosis, cancer, hypoglycaemia 
and other adverse metabolic effects [2]. Moreover, diabetic patients have to endure 
multiple injections a day i.e. rapid acting insulin before meals to meet prandial insulin 
secretion and a supplemental injection of long acting insulin to mimic basal secretion 
levels. These repeated injections may bring about pain, tissue invasion, infections and 
nerve damage, which lead to poor patient compliance. Therefore, less invasive 
options for insulin therapy (and other similar peptides) are highly desirable and 
represent a priority objective in pharmaceutical innovation [8]. 
2.2. Oral insulin  
Despite great improvements in needle technology, it is still estimated that >5% of the 
population are needle-phobic. Amongst all the alternative, noninvasive routes of 
administration (nasal, pulmonary, buccal and transdermal), oral insulin delivery 
remains the most preferred. Developing oral peptide formulations is important 
because parenteral administration by patients over a chronic period results in poor 




and stress free and this route would allow for the insulin to enter the portal circulation, 
reaching the liver before entering the systemic circulation, which resembles the 
pathway of physiologically secreted insulin [10].  
Nevertheless, this ideal insulin delivery route has so far been elusive due to the 
difficulties faced in designing such a formulation. Orally administered drugs need to 
survive harsh gastric conditions in which they are exposed to acidic and enzymatic 
degradation. Subsequently, intestinal conditions further expose the drugs to a myriad 
of digestive enzymes; pancreatic proteases consisting of the serine endopeptidase 
(trypsin, α-chymotrypsin, elastase and exopeptidases, carboxypeptidases A and B), 
responsible for the degradation of proteins. The drugs that survive these conditions 
then need to penetrate the mucus layer overlying the absorptive surfaces of the 
gastrointestinal tract (GIT) and pass through the epithelial cells to enter the blood 
stream. Insulin, being a peptide molecule, is easily degraded by the conditions in the 
GIT, which significantly delimitates its oral bioavailability. Furthermore, the large 
molecular size (about 6 KDa), its charge and its hydrophilicity all preclude insulin 
absorption by paracellular and transcellular route [11]. 
To improve the bioavailability of insulin, different approaches have been explored, 
including chemical modification, co-administration with absorption enhancers and/or 
enzyme inhibitors and incorporation into carriers [12]. Nanotechnology has shown 
promising results in the design of potential oral peptide nanocarriers, and it is 
expected to lead to further improvement in the diagnosis and treatment of diabetes 
[13]. Nanoparticles have been engineered for the oral delivery of labile proteins and 
peptides for release into the systemic circulation [14].  
 
3. Nanocarriers for oral insulin delivery  
For insulin delivery the general idea is to encapsulate the peptide into carriers at a 
nanoscale range (10 – 1000 nm), allowing its protection from degradation, controlled 
release at target sites and transepithelial transport. Nanocarriers used for insulin 
delivery could broadly be categorized into: nanoparticles [15] (matrix-type particles), 
nanocapsules [16, 17], micelles [18] and liposomes [19] (Figure 3). Recently, a 
number of insulin nanocarriers for oral delivery have been investigated and a few 
have undergone clinical trials. This issue has been analyzed in detail in chapter 1. 
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Several properties have been identified as important for the uptake of nanoparticles, 
including the size, surface charge and surface hydrophobicity [20]. However, when it 
comes to increasing the bioavailability and pharmacological efficiency of the loaded 
peptide, the particle surface properties are of outmost importance for their interaction 
with intestinal mucosa and maintaining the integrity of the encapsulated peptide [21]. 
The modification of nanoparticle surface properties can be achieved either by a 
coating process with hydrophilic biodegradable polymers, incorporating stabilizing 
surfactants [22]. For example, PEG has been employed as a coating/matrix material in 
insulin nanoparticulate delivery for its stabilizing properties. PEG chains form a steric 
barrier at the surface of nanoparticles, which improves stability towards proteases and 
prevents opsonisation and reduce immunogenicity [23]. In some unique cases it was 
evident that a combination of one or two strategies, polymers or surfactants in one 
system resulted in enhanced properties and consequently, improved oral 
bioavailability. New materials allow the possibility of engineering nanoparticles with 




Figure 3:  Different types of nanocarriers for insulin delivery.  
 
 
Among the different biomaterials investigated, polyaminoacids with a cell-
penetration capacity hold promise as a strategy for oral insulin delivery. 
Polyaminoacids and are polydisperse structures that, contrary to proteins, cannot fold 
into globular structures. In addition, they can carry versatile reactive functional 
groups at their side chains (such as carboxylic acids, hydroxyl, amines and thiol 
groups) that allow for a variety of chemical modifications and they are generally 





Polyaminoacids have recently been explored to increase the oral bioavailability of 
peptides and proteins e.g. insulin, by exploiting their ability to interact with the 
protein molecules, to reduce their degradation by digestive enzymes and to promote 
their oral absorption [25], a feature also exhibited by cell penetrating peptides (CPPs). 
Morishita et al. pioneered the potential of oligoarginine CPPs as peptides that 
improve the absorption of poorly membrane permeable macromolecules that 
otherwise do not cross the cell membrane [26]. In this work, Morishita et al. described 
that arginine-rich CPPs such as octaarginine, have the ability to enhance insulin 
delivery across mucosal membranes safely by non-covalent cargo interaction strategy, 
and with highly effective bioavailability [27]. The electrostatic adsorption of 
octaarginine onto the cell surface proteoglycans and subsequent energy-dependent 
internalization pathway was associated with the uptake of the CPP itself by epithelial 
membranes and its enhancing effect on the mucosal insulin absorption. 
 
On the other hand, protamine is a small, arginine-rich, nuclear protein that replace 
histones late in spermatogenesis and is essential for sperm head condensation and 
DNA stabilization [28]. When mixed with insulin, protamine slows down the onset 
and increases the duration of insulin action (see NPH insulin). In gene therapy, 
protamine's ability to condense plasmid DNA along with its approval by the U.S. 
Food and Drug Administration (FDA) as drug to neutralize the anti-clotting effects of 
heparin [29] have made it an appealing candidate to increase transduction rates by 
both viral and nonviral (e.g. utilizing cationic liposomes) mediated delivery 
mechanisms [30, 31].  
 
Our group has used arginine-rich biomaterials including polyarginine [32] and 
protamine [33] for designing drug delivery systems with the ability to deliver 
different therapeutic compounds. Protamine in particular, was initially used for the 
preparation of protamine nanoparticles, where Protamine nanoparticles and 
nanocapsules were developed and showed a great potential to interact with cells and 
internalize antigens [33]. Thereafter, multi-enveloped nanoparticles were also 
developed (by the layer-by-layer approach) for the co-delivery of immunostimulants 
and antigens using the adsorptive polymers, polyarginine and protamine in 
combination with polysaccharides: dextran sulfate and alginate [34]. Lipid core-shell 
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protamine nanocapsules containing vitamin E and loaded with curcumin as anti-
inflammatory drug were also prepared in our group and remarkably enhanced 
curcumin permeability in Caco-2 cells [35]. In all cases the use protamine and its 
positive effects of were attributed to the repetitive sequence of arginine present in the 
protamine structure (about 70%) (Figure 4), which provides this polypeptide with an 
efficient translocation activity through biological membranes including the intestinal 
epithelial cells [36]. Protamine molecules are known to translocate through cell 
membranes mainly by mediated endocytosis following the interaction between the 




Figure 4: A schematic representation of a typical protamine structure. 
 
4.  Conclusion  
Great efforts and progress have been made so far in the development of oral insulin 
delivery systems, however, the formulation and synthesis of more efficient 
nanoformulations is still required for commercial significance. Recently, a number of 
insulin nanocarriers have undergone clinical trials among which only a handful are in 
the market (see chapter 1 for an elaborated discussion). The use of natural 
polyaminoacids which are non-toxic and generally regarded as safe (GRAS) and have 
the highly sought after advantage to promote absorption of oral peptides is a feasible 
concept. For this goal to materialize in terms of the oral delivery of insulin, the use of 
polyaminoacids as cell penetrating polymers should be accompanied by the careful 
consideration of critical aspects for drug delivery such as: optimum particle-sized 
nanocarriers, the stability of the nanocarriers in biological fluids after in vivo 
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administration, and surface chemical composition.  
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Protein and peptide based therapeutics are typically administered by injection due to 
their poor uptake when administered via non-parenteral routes. Despite the low 
frequency of clinical breakthroughs with non-invasive protein drug delivery this far, it 
remains an active research area with renewed interest not only due to its improved 
therapeutic potential, but also due to the attractive commercial outcomes it offers. 
Currently, a number of technologies are adopted, including mixtures of penetration 
enhancers with protease inhibitors and/or nanotechnology-based products are under 
clinical development. This review provides a critical overview of current strategies of 
non-invasive mucosal delivery routes for therapeutic proteins, with emphasis on their 
advantages and limitations. Selected new trends and interesting novel formulations in 
advanced preclinical and clinical development stages for the pulmonary, nasal and the 
oral route are discussed for the most relevant peptide and protein drugs in function of 






1. Introduction  
Proteins and peptides are building blocks of life and are now evolving as a very 
promising brand of therapeutic drugs. Once a rarely used subset of medical treatments, 
therapeutic proteins have increased dramatically in number and frequency of use since 
the introduction of the first recombinant protein therapeutic; human insulin, more than 
33 years ago [1]. 
Peptides can bind large macromolecular targets with high potency and great 
selectivity, which translates into fewer off-target side effects and less potential for 
toxicity than conventional low molecular weight drugs [2]. Unlike other drug 
molecules, which often trigger side effects by producing toxic metabolites that 
accumulate in different organs, peptides simply degrade into amino acids, which 
minimizes the risk of toxicity [3]. These features arise from their macromolecular 
nature, which provides the structural complexity that is often required for specificity. 
However, this structural complexity also makes them some of the most challenging 
molecules to formulate and deliver. Loss of activity due to environmental factors such 
as moisture or temperature, during storage or in the body, puts a substantial burden on 
peptide formulation technologies. Whilst, the high molecular mass and hydrophilicity 
of these peptide/protein drugs creates delivery challenges, including substantial 
reduction in permeability across biological barriers and mucosal membranes.  
2. Therapeutic proteins and peptides  
Since the 1980s, peptides have been studied as treatments for a wide variety of 
problematic diseases [4]. Recombinant technology has allowed the production of 
many potential peptide drugs at an acceptable cost, paving the way for the treatment 
of severe, chronic and life threatening diseases such as cancer, hypertension, arthritis, 
and metabolic diseases e.g. diabetes and obesity. Most of currently available peptide 
drugs are delivered by injection, but several biopharmaceuticals have undergone 
extensive research towards alternative administration routes, particularly peptide 
hormones, such as insulin, vasopressin, calcitonin and luteinizing hormone-releasing 
hormone (LHRH), and small proteins, such as human growth hormone and interferon 
α [5]. 
 
Peptide therapeutics research and development is dynamic, with increasing numbers 
of candidates entering clinical evaluation in a wide variety of therapeutic categories. 
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[1]. Overall, there is a notable increase in the number of successfully marketed 
peptides as compared to the 1980s and 1990s when only 2 % and 11 % of peptide 
therapeutics were marketed, respectively [8]. Peptides approved in 2013 alone, were 
notable for their number and diversity of use, with the top two therapeutic areas being 
oncology (21%) and metabolic diseases (15%) [2]. The clinical pipeline was 
composed of 128-peptide therapeutics, with 40 in phase I, 74 in phase II and 14 in 
phase III studies. The number of peptides and diversity of therapeutics areas 
represented was higher in phase II and I compared to phase III, which indicates an 
increase and expansion for therapeutic peptide research, with a steady growth of 
marketed peptides [7]. More than 15 candidates are currently in Phase 3 clinical 
studies or under regulatory review, which suggests that peptide therapeutic products 
will continue to be approved at an increasing rate in the near future [7]. This steady 
increase is an indication of the progress in the use of peptides as therapeutic drug.  
Injections (i.e. intravenous, intramuscular or subcutaneous route) remain the most 
common means for administering protein and peptide drugs. Patient compliance with 
drug administration regimens by any of these parenteral routes is generally poor and 
severely restricts the therapeutic value of the drug. Although, direct systemic delivery 
of these therapeutics overcomes the issue of absorption associated with other routes, 
other factors limit the chemical potency of peptide and protein therapeutics including: 
systemic proteases; rapid metabolism; opsonization; conformational changes; 
dissociation of subunit proteins; and non-covalent complexation with blood products 
[8]. Moreover, in the specific case of insulin delivery for example, diabetic patients, 
have to endure multiple injections a day i.e. rapid acting insulin before meals to meet 
prandial insulin secretion and a supplemental injection of long acting insulin to mimic 
basal secretion levels. These repeated injections may bring about pain, allergic 
reactions, infections and nerve damage, which lead to poor patient compliance. 
Therefore, less invasive options for insulin therapy (and other similar peptides) are 
highly desirable and represent a priority objective in pharmaceutical innovation [9]. 
3. Mucosal delivery of biopharmaceuticals 
Owing to the above detailed limitations of injections, alternative delivery routes 
including; pulmonary, nasal, oral, vaginal and ocular, for biopharmaceuticals have 
been explored to increase patient compliance. These specific routes are collectively 
known as noninvasive mucosal routes of administration and each route offers unique 
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advantages and limitations [5]. Mucosal delivery of therapeutic peptides and proteins 
faces formidable barriers. These obstacles to efficient delivery can broadly be 
categorized as either the enzymatic barriers, which the peptide drug encounters after 
administration and the physical barriers, which prevent efficient transport of proteins 
and peptides across epithelial surfaces. Overall these barriers inevitably lead to low 
bioavailability [10, 11].  
 
The primary barrier (chemical barrier) to mucosal absorption of peptide drugs is the 
enzymatic barrier in the form of degradation enzymes. Proteolytic enzymes are 
present all over the human body and they act by hydrolyzing the peptide bonds in 
polypeptides [12]. Hence, the peptide drugs may degrade, loose their functionality or 
aggregate prior to reaching the absorption membrane. These peptides are further 
subjected to digestion by aminopeptidases located in the cell membranes during their 
transportation through the epithelial layer of cells [13, 14]. 
 
The mucosa comprises the epithelial layer covered by a firmly adherent viscous layer 
of mucus and a less viscous, loosely adherent mucus layer on the surface. The mucus 
layer covering the epithelium represents the first physical barrier to be encountered by 
a drug prior to absorption and the thickness of the layer varies greatly throughout the 
body [15, 16]. Regardless of the localization, the function of the mucus is to lubricate 
and protect the underlying tissue [11]. The mucus clearance rate also varies between 
tissues and it has been estimated to be less than 30 minutes at different sites in the 
respiratory system and around 5 hours in the GI-tract. The detailed composition of 
mucus is dependent on the specific mucosal site, disease state as well as influenced by 
variance between individuals. Mucus contains approximately 95 % (w/w) water, 2-5 % 
(w/w) mucin proteins and a small amount of lipids and electrolytes [15, 16]. In 
addition to the physical diffusion barrier provided by the mucus network, the 
hydrophilic nature and the presence of a strong negative charge allow for drug 
interactions with the mucus components, which have also shown to retard or hinder 






Table 1: Physical properties and surface area of the different mucosal surfaces  
 Nasal Pulmonary Oral 
Surface area 150 cm2 80-140 m2 >200 m2 
Histological 
properties 
Thin mucus layer 
Ciliated, 
pseudostratified 
epithelium (10 μm) 
Thin mucus layer 
Bronchioles: Ciliated columnar 
pseudostratified epithelium (10-60 μm) 
Alveoli: squamous epithelial monolayer 
(<1μm) 
Thick mucus layer 
Columnar epithelial 
monolayer (10 μm) 
 
 
The morphology of the epithelial absorption barrier varies according to the specific 
anatomical site (Table 1). The nasal, lung and intestinal epithelia are commonly 
comprised of a monolayer of cells interconnected by tight junctions (Figure 1) [10]. 
The mechanism of transport through the epithelial barrier depends mainly on the 
physiochemical properties of peptide molecules. Common transport mechanisms in 
all sites include active and passive transport, which can be described by a 
combination of two processes; 
i) Paracellular transport: involves the transport of molecules via water filled 
pores or channels between cells. The paracellular route is restricted to 
relatively small hydrophilic molecules of <100-200 Da, by the presence of 
tight junctions or zonula occludins between epithelial cells [18]. Unfortunately, 
most therapeutic proteins have molecular weights much greater than 500 Da 
and hence exhibit low permeability. 
ii) Transcellular transport: involves the diffusion of drug molecules through the 
apical and basolateral membrane. This route is ideal for lipophilic drugs, 
which express relatively high affinity for the lipid bilayer of cell membranes. 
On the contrary, the transport of hydrophilic proteins/peptides through this 
path poses a significant challenge [19].  
Transcytosis, is a specific type of transcellular transport i.e. the manner by 
which macromolecules or particles are taken up and transported across the cell 
to the basolateral side and it occurs through different energy dependent 
endocytic pathways (Figure 1) [22], [23]. Phagocytosis is used for uptake of 
large particles such as bacteria, and is generally the first step in the uptake and 
degradation of particles larger than 0.5 μm [22]. Clathrin-mediated 
endocytosis (CME) is the uptake and transport of particles from the cell 
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surface mediated by clathrin-coated vesicles (100 to 120 nm in diameter) to 
the basolateral side. Clathrin-coated vesicles (CCVs) are found in virtually all 
cells and cause the endocytosed material to end up in degradative lysosomes. 
Whilst caveolae-mediated endocytosis (CvME), involves the formation of 
small (50 to 100 nm) lipid raft-enriched, flask-shaped pits in the cell 
membrane surface. Unlike CME, CvME is a highly regulated process 
involving complex signaling, which may be driven by the cargo itself and it 
bypasses lysosomes [23].  
 
 
Figure 1: Schematic representation of the different pathways employed by molecules 
to penetrate cells and cross the cell barrier into the systemic circulation.  
 
Tremendous efforts have been dedicated to improving the permeation of the 
proteins/peptides through the epithelial membranes whilst protecting them against 
enzymatic degradation. Hence the principal approaches for mucosal delivery include; 
the use of absorption enhancers [24] and protease inhibitors [25], modification or 
conjugation of peptides with biological entities that show stabilizing [25–27] and cell-
penetrating capabilities [28, 29] and the design of multifunctional [30] and 
nanoparticulate drug delivery systems [31, 32] that help peptide trafficking across the 
fore-mentioned epithelial barriers and these strategies have been extensively review 
elsewhere.  
In recent years new delivery strategies including alternative administration routes 
integrated with emerging nanotechnologies have attracted increased attention in quest 
of shifting from the parenteral route of administration [33]. Alternative routes for 
 
 58 
controlled peptide delivery such as nasal, pulmonary, and oral epithelia have been 
explored [10]. It is evident that the currently successful and promising peptides are 
either small, with a molecular weight between 1,000-3,400 Da or they have been 
adapted by a technology that improves absorption or protection from enzymes [31]. 
However, despite these advances, the long-awaited dream of “needle-free” delivery of 
larger peptides such as insulin remains a challenge due to their poor permeability 
across different barriers and low bioavailability. The next sections are focused on the 
most common mucosal routes of administrations and recent efforts or advances in this 
field in terms of peptides/proteins currently on clinical trials.  
 
3.1. Nasal delivery 
The nasal route has gained importance as a non-invasive, and easily accessible route 
that offers many advantages for the introduction of drugs into systemic circulation. 
Compared to other biological membranes the nasal mucosa is a rather porous and thin 
endothelial basal membrane. It also has a rapid blood flow, with a highly vascularized 
epithelial layer and a vast absorption area (150 cm2) with ciliated epithelial cells 
(Figure 2) [34], Due to these characteristics, it offers many advantages such as fast 
absorption of drugs [35]. In addition, nasal delivery avoids gastric degradation, 
hepatic first-pass effect and may also allow for strategies to circumvent the obstacles 
for blood-brain barrier (BBB). It has also been considered for the administration of 







Figure 2: Schematic illustration of the nasal mucosa, depicting how a drug is 
absorbed into the systemic circulation.  
 
Small hydrophilic drugs with low molecular weight are absorbed via the nasal mucosa 
at a rate that is almost comparable to intravenous application. Nevertheless, the nasal 
mucosa is an obstacle for the passage of large molecules, particularly for those above 
1,000 Da in size, and therefore, the nasal bioavailability of peptides and proteins is 
usually less than 1%. This low bioavailability of these drugs is associated with the 
weak mucosal membrane permeability (restricted to paracellular and transcellular 
transport) and the presence of proteolytic enzymatic activity in the nasal mucosa [35]. 
Another reason is the mucociliary clearance, through which drugs are rapidly 
removed from the nasal area [37].  
 
3.1.1 Systemic delivery via the nasal route 
Intranasal delivery has allowed successful and improved delivery of certain peptide 
drugs. For instance, Desmospray®, is a solution for nasal use containing desmopressin; 
an antiduretic hormone used for the treatment of nocturia associated with multiple 
sclerosis where other treatments have failed. For instance in; i) the diagnosis and 
treatment of vasopressin-sensitive cranial diabetes insipidus and ii) in establishing 
renal concentration capacity. Initially, orally administered desmopressin showed 
minimum absorption from the GI tract (bioavailability = 0.08-0.16%) that improved 
to 10-20% from nasal mucosa highlighting the increased efficiency for nasal delivery 




Salmon calcitonin is a polypeptide (32 amino acids), which is highly potent in 
humans for the treatment of bone diseases. Injectable and nasal calcitonins are 
commercially available for the treatment of osteoporosis and a number of studies are 
currently on going for the treatment of other medical conditions [39–41]. Shiraz 
University of Medical Sciences evaluated the effectiveness of long-term 
administration of intranasal calcitonin for the treatment of central giant cell 
granuloma of the jaws. After 28 months of treatment, all lesions decreased in size 
with a high degree of calcification and there were no recurrences (phase II clinical 
trials), hence intranasal calcitonin spray could be considered as a future alternative to 
surgery [42]. 
Aegis, recently used its patented Intravail® technology to formulate a novel 
exenatide formulation, which provides equivalent blood levels using a simple metered 
nasal spray to replace each of the two daily injections of exenatide [43]. Intravail® 
comprises a broad class of chemically synthesizable transmucosal absorption 
enhancing agents (non-disclosed) that open tight junctions without causing any 
toxicological effects on the mucosal membrane. On the other hand, GLP-1 was 
incorporated into capsules coated with corn-starch and calcium carbonate with a mean 
particle diameter of 60 μm by Asubio Pharma Co., Ltd. The capsules were set in a 
special device (by Shirasu Porous Glass Technology, Miyazaki, Japan) (patent no. 
2007-331207) and intranasal administration resulted in rapid peripheral appearance of 
active GLP-1 in diabetic patients. Furthermore, GLP-1 induced early-phase insulin 
secretion, inhibited inappropriate glucagon secretion, and improved intermediate-term 
markers of glycemic control without severe adverse events. Long-term treatment with 
this new nasal GLP-1 will soon be evaluated in larger trials as a novel treatment for 
type 2 diabetes [44].  
CP024 is a spray-dried nasal powder formulation comprising the human growth 
hormone (hGH), Solutol® HS15, a gelling agent, and other excipients (non-disclosed), 
manufactured by Critical Pharmaceuticals in its propriety CriticalSorb technology. In 
Phase 1 clinical trials, CP024 was well tolerated and able to induce insulin-like 
growth factor-1 (IGF-1) to the same levels as a subcutaneous injection of the 
marketed product, somatropin. Somatropin is currently available as an injection and 
not absorbed through nasal mucosa. Interestingly, the CriticalSorb technology 
enhances the absorption of somatropin and thereby makes it possible to deliver the 
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drug by nasal spray [45]. CriticalSorb is a novel absorption enhancer based on 
Solutol® HS15 approved by the FDA as generally regarded as safe (GRAS) and used 
in currently marketed products as a solubility enhancer for intravenous and oral 
administration. In preclinical toxicology studies, CriticalSorb has been found to be 
nontoxic and not irritating to the skin or eyes and was well tolerated by the nasal 
mucosa. It is available as liquid or powder formulations and promotes absorption of 
other peptides and proteins such as teriparatide (parathyroid hormone PTH 1-34) and 
insulin (~6kDa) across the nasal mucosa in phase I clinical trials and preclinical 




Table 2: Intranasal peptide formulations on the market or under clinical development.  
 











Nasal spray – high and 
rapid absorption 




Fortical Salmon calcitonin 
Nasal spray – high and 
rapid absorption 











Glucagon Glucagon Nasal spray 










Calcitonin Calcitonin Nasal aerosol 
X-linked 
Hypophosphatemia (XLH) 
Phase I Yale University [41] 
CP024 and CP046 
human growth 
hormone (hGH) and 
parathyroid hormone 
CriticalSorb technology 
































Autism Spectrum Disorder Phase II OptiNose AS [51] 
Insulin Insulin detemir 
ViaNase electronic 
atomizer 
Alzheimer Phase II 








Calcitonin Calcitonin Nasal spray 
Central Giant Cell 
Granuloma 
Phase II 
















Phase II Lytix Biopharma AS [54] 
GHB01L1 Influenza Antigen Intranasal aerosol Human Influenza A Virus Phase I 
AVIR Green Hills 
Biotechnology AG 
[55] 
Vacc-4x HIV antigen 
Lipid-based 
nanoparticles (Endocine) 







3.1.2. Nose-to-brain delivery  
Intranasal delivery provides a practical, non-invasive method of bypassing the blood-
brain barrier (BBB) to deliver therapeutic agents to the brain and spinal cord. This 
route allows drugs that do not cross the BBB to be delivered to the central nervous 
system within minutes. This is possible because of the unique connections that the 
olfactory and trigeminal nerves provide between the brain and external environment. 
A growing body of evidence suggests that insulin plays a role in cognitive processes 
and that insulin abnormalities may contribute to memory and brain changes associated 
with Alzheimer disease. Interestingly, the university of Washington recently 
demonstrated in phase II clinical trials, that regular insulin administered to the nasal 
cavity is transported within a few minutes into the brain, without affecting blood 
sugar or insulin levels [57]. A similar study is on going with insulin in phase II trials 
by Wake Forest School of Medicine [52]. 
 
Oxytocin is a small, naturally occurring peptide that acts mainly as a neuromodulator 
in the brain. Recently the effect of intranasal oxytocin on pain sensitivity and 
threshold has been evaluated. Participants received nasal sprays into each nostril of 4 
Units up to 32 units of oxytocin prior to Thermal Evaluation System Testing and they 
reported lower pain intensity. This study (currently on phase IV clinical trials, 
Northwestern University) suggests that oxytocin might represent a novel, safe, and 
effective analgesic for acutely painful procedures [50, 51]. The university of Alabama 
at Birmingham is currently undergoing clinical trials for intranasal oxytocin for the 
treatment of pain associated with interstitial cystitis [58].  
 
Although intranasal delivery does not necessarily require any modification to 
therapeutic agents the location of deposition of the drug product inside the nasal 
cavity may affect absorption rate. Hence modification of the administration technique 
to optimize droplet size, deposition fraction and, thus, volume of administration is 
crucial in nasal drug delivery [59]. Novel nasal delivery technologies suitable for both 
liquid and powder peptide drugs are currently being developed. These novel concepts 
combine knowledge of both functional nasal anatomy and aerodynamics. On this 
regard, OptiNose undertook a Phase I trial in late 2013 to investigate “nose-to-brain” 
transport of oxytocin via the patented OptiNose Bi-Directional™ Breath Powered 
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delivery technology. The OptiNose device offers the potential for a more efficient and 
consistent direct transport of oxytocin into the brain itself, using relatively low doses, 
which will significantly reduce drug levels in the rest of the body, reducing the risk of 
side-effects [51]. Other companies such as Kurve technology recently developed the 
ViaNase electronic atomizer, based on Controlled Particle Dispersion (CPD)® 
designed to deliver most formulations with efficient nasal cavity saturation and 
minimal deposition to the lungs and stomach [60]. Other similar devices include; the 
Teleflex VaxINator™ [61], and the LMA® MAD NasalTM Device [62].  
 
Intranasal vaccines  
The nasal route has also been proposed as an option for mucosal vaccination, with the 
possibility to induce both systemic and mucosal immune responses. Endocine is a 
delivery system specifically developed for intranasal vaccines (by Eurocine Vaccines, 
Sweden). It is a lipid-based (mono-olein and oleic acid) dispersion with particles less 
than 100 nm. Intranasal administration of Vacc-4x with Endocine (as an adjuvant) 
was safe and induced dose-dependent T cell responses and both mucosal and systemic 
humoral responses, in patients on effective antiretroviral therapy (Phase I clinical 
trials) [56].  
 
3.2. Pulmonary delivery 
Aerosol administration of therapeutics to the pulmonary epithelium for systemic 
delivery represents a significant opportunity in the delivery of macromolecules since 
it allows: (i) rapid absorption into the systemic circulation (this may be especially 
important for drugs where fast onset of action is critical), and (ii) higher 
bioavailability than with other non-invasive modes of administration [63]. This can be 
attributed to the considerable absorptive surface area at the air interface, covered by 
an extremely small volume of fluid (10–20 ml) and with the entire cardiac output 
flowing through the underlying capillary network [64]. Due to this physiological and 
anatomical peculiarity, an inhaled aerosol drug can be widely dispersed and deposited 
in high concentrations in close proximity to the blood stream (Figure 3). 
 
The fate of drugs following inhalation depends on their site of deposition within the 
lungs. Aerosol particles deposited in the tracheobronchial tree come into contact with 
 
 66 
the mucus, and the peptide or protein within the particle dissolves in the mucus. The 
macromolecules can either be eliminated by the mucociliary clearance towards the 
gastrointestinal tract or diffuse in the mucus and cross the airway epithelium. On the 
other hand, particles deposited in the alveolar region initially come into contact with 
the thin layer of fluid lining of the alveolar epithelium and are able to cross much 
more efficiently [63–65]. 
 
 
Figure 3: Schematic representation of the lung a description of the absorption process 
in the alveolus.  
 
The presence of proteases in the lung and the barrier between capillary blood and 
alveolar air (air-blood barrier) and clearance by alveolar macrophages impede 
pulmonary delivery of peptide drugs. The use of absorption enhancers such as oleic 
acid, oleyl alcohol, Span 85 and protease inhibitors e.g. sodium glycocholate and 
surfactin have been reported to be useful approaches for improving pulmonary 
absorption of biologically active drugs like peptides [11, 66]. Pulmonary technology 
is the process of making drugs inhalable (e.g. conversion into dry-powder) in order to 
deliver them to and through the lungs for both systemic and local lung applications 
whilst PEGylation is their chemical modification to enhance peptide/protein drug 
performance i.e. improve stability and solubility, increase half-life and reduce 
immune responses. These technologies form the basis for most industrial products 
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that have received FDA approval [67].  
 
3.2.1. Systemic delivery via the pulmonary route 
AFREZZA™ is an FDA approved (Mannkind corporation, 2014) ultra-rapid acting 
insulin comprising Technosphere® insulin powder in unit-dose inhaler cartridges. 
Technosphere® is a drug delivery system made up of fumaryl diketopiperazine 
(FDKP), which forms microspheres with 2–5μm sizes. The powder formulation is 
prepared by precipitating insulin from solution onto the preformed particles, which 
readily dissolve once in the lung environment, releasing insulin. It rapidly reaches 
systemic circulation and attains maximum plasma concentration in 15 minutes, which 
is much earlier compared to injectable insulin (i.e. 1h). AFREZZA® has a relative 
bioavailability of 21–25% compared to SC regular insulin and is also eliminated 
quickly (within 2h) from the blood circulation. This pharmacokinetic/dynamic profile 
mimics what happens with endogenous insulin released in a person without diabetes 
and the result is significantly less hypoglycemia [68]. 
 
Nektar ś PEGylation technology™ used in nine approved partnered products for 
other administration routes, in the U.S. including UCB's Cimzia® for Crohn's Disease, 
Roche's PEGASYS® for hepatitis C and Amgen's Neulasta® for neutropenia, has 
also been investigated for lung delivery. This conjugation technology improves 
peptide stability and reduces immune responses [47]. Nektar also showed that the 
administration of liposome-encapsulated drugs by aerosols seems to be a feasible way 
to deliver them via the lungs. Leuprolide acetate, is a potent agonist of luteinizing 
hormone-releasing hormone (LHRH) currently used for the treatment of prostatic 
cancer, endometriosis, and precocious puberty, administered solely by injection. In an 
exploratory study, leuprolide peptide was entrapped in liposomes (3.5 μm in size) 
containing sorbitan monooleate (Span 80) and administered as a dry powder resulting 
in a relative bioavailability of 18 %, compared to injectable systemic delivery. The 
results suggested that clinical doses of leuprolide could be given as once-a-day single 
inhalation dose, thanks to the liposomes that increased residence time and promoted 
absorption of the hormone. [55]. However, no further updates have been published on 




Baxter Healthcare Corporation, recently completed phase I clinical trials where they 
investigated the PK and PD properties of recombinant human insulin inhalation 
powder (RHIIP), manufactured with PROMAXX® technology, which allows the 
formation of protein microspheres of uniform size and shape suitable for inhalation by 
a temperature-controlled precipitation from an aqueous insulin solution in the 
presence of polyethylene glycol without the use of absorption enhancers. This 
microparticulate powder formulation showed a faster onset of action than SC Insulin 
[69]. 
 
In recent years the development of new and improved devices for administration of 
peptides and proteins has intensified since the site of deposition is crucial for the 
efficacy of inhaled drugs. Prominent examples of such devices are the AERx® from 
Aradigm (CA, USA) [70], Respimat® from Boehringer Ingelheim (Ingelheim, 
Germany) [71] and AeroDose® from Aerogen Inc. (Galway, Ireland) [72]. Some of 
the most recent developments with these devices are included in Table 3. The 
Aerodose® insulin inhaler for example, resulted in a dose-dependent increase in serum 
insulin concentration and a corresponding glucose lowering effect that were similar in 
proportion to that obtained for increasing doses of subcutaneously injected insulin. 
This novel device is a small hand-held breath-actuated inhaler that contains Aerogen’s 
electronic aerosol generator. When liquid is placed onto the aerosol generator, a 
micropumping action creates a fine-droplet low-velocity aerosol that is suited for deep 
lung delivery [72].  
 
3.2.2. Local delivery to the lung 
Although the efforts made in the field of pulmonary delivery of peptides and proteins 
have been tremendous, there are still a very limited number of inhaled 
macromolecules available on the market. As expect, inhaled peptide drugs developed 
for local therapy are the most promising and the fastest growing group under 
development [73]. One of the candidates worth mentioning is being developed by the 
University of Maryland, a new liposomal cyclosporine A (L-CsA) solution consisting 
of unilamellar liposomes of about 50 nm with a narrow size distribution inhaled 
through a nebulizer, in phase 1 clinical trials completed in 2015, for the treatment of 
bronchiolitis obliterans syndrome after lung transplantation. The treatment was well 
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tolerated, and no drug-related side effects were observed. Once or twice daily dosing 
of 10 mg aerosol L-CsA would result in a sufficient peripheral lung deposition of 
approximately 14 and 28 mg/week, respectively signifying the improvement of 
pharmacokinetics through encapsulation in liposomes [74]. 
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Table 3: Inhaled peptide formulations on the market or under clinical development. 
 










AFREZZA™ Insulin Technosphere® Diabetes Market, 2015 Mannkind corporation [68] 










PROMAXX® in a dry powder 
inhaler  
Diabetes mellitus  Phase I Baxter Healthcare Corporation [69] 
Alveair® Insulin Alveair™ (Liquid inhaler) Diabetes 
Preclinical 
trials 
Coremed Inc [76] 



















Children’s Oncology Group & 
















4 receptor (IL-4R) 
Aerosol inhaler  Asthma  Phase II 
National Institute of Allergy 





AVONEX® Interferon β-1a ANOVEX inhaler 
Multiple 
sclerosis 
Phase I Trio Medicines Ltd [47] 




Inhalation solution Cystic Fibrosis Phase I CSL Behring [81] 
MVA85A Antigenic peptide  Aerosol inhaler  
Tuberculosis 
Vaccine 








Phase I University of Maryland [83] 
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3.3. Oral delivery 
Systemic delivery of drugs via the nasal and pulmonary routes, circumvents the liver 
and, thus, avoid hepatic first-pass metabolism, which may be advantageously 
exploited for many peptides drugs [84]. However, the oral route of administration is 
often preferred due to the easy accessibility of the large surface area available for 
absorption to the systemic circulation. Furthermore, the pharmacological rationale for 
administering specific peptides such as insulin via the oral route supports this 
approach, as the oral delivery of insulin results in absorption directly to the liver 
(hepatic portal circulation), before it reaches the peripheral tissues (Figure 4) [85, 86].  
 
 
Figure 4: Schematic illustration of the large surface area for absorption and first pass 
metabolism associated with the oral route of administration. 
 
Indeed, when the drug of interest must be used repeatedly administered, the oral route 
inevitably becomes the route of choice for patients since it is painless and convenient 
[87]. To achieve successful and satisfactory therapeutic results by the oral route, there 
must be minimal degradation and significant absorption of the protein molecules in 
the GIT [32]. Most of current approaches target the GIT barrier in an attempt to 
overcome its restrictive nature and subsequently increase oral bioavailability [88]. 
The main challenge is to improve the oral bioavailability to be higher than 1%. New 
approaches are mostly driven by the necessity to design an approach that not only 
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protects the protein/peptide from enzymatic degradation but also aids in enhancing its 
absorption without altering its biological activity [89]. The following tables portrays 
recent efforts of various pharmaceutical companies in making the transition towards 
oral peptide delivery by developing innovative technologies and testing multiple drug 
candidates based on these technologies (Table 3). The tables are intended to give a 
broad overview of the numerous strategies and applications currently in evaluation 
and are organized from a practical point of view as a function of developmental stage 
and intended site of action (i.e. systemic and local action). Given the large body of 
information, the discussion is limited to the most promising and interesting examples. 
3.3.1. Systemic delivery using the oral route 
Desmopressin, is one of the marketed oral peptides. Its oral bioavailability is low (< 
1%) but only a very low dose is required to elicit its therapeutic effect [90]. 
Desmopressin and cyclosporine (another marketed oral peptide), have cyclic 
structures, which render them stable and less prone to degradation in the GIT. 
Moreover their small molecular weight allows for faster and less constrained 
intestinal absorption. Astellas Pharma Inc, also developed new cyclic peptides with 
anti-hepatitis C virus action, which take advantage of this strategy [91]. 
The most promising and basic approaches reaching clinical development for oral 
delivery are enteric-coated formulations that include muco-interactive polymers 
encapsulating a peptide-drug with enzyme inhibitors and absorption enhancers, 
capable of rapidly and reversibly increasing epithelial permeability. In this strategy, 
excipients (chemicals that are added to the formulation that make up capsules, tablets 
or liquids) are used to shield the native drug chemically or physically and promote 
absorption. This strategy has been in existence for a while now in pharmaceutical 
industries and it is being improved progressively by the addition of novel enhancing 
excipients and polymers [92]. Enteris BioPharma Inc (formerly known as Unigene) 
developed the clinically proven Peptelligence™ technology that enables the oral 
delivery of peptides. This technology entails an enteric-coated tablet with two key 
components; an organic acid enzyme inhibitor (citric acid in the form of coated beads) 
and a permeation enhancer (acylcarnitine), which penetrates the mucus layer. The 
enteric coating prevents the tablet from disintegration within the stomach and enables 
dissolution within the intestinal pH. The permeation enhancer opens tight junctions 
and promotes paracellular transport whilst the citric acid transiently decreases the 
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intestinal pH to prevent degradation of the peptide by intestinal proteases and 
peptidases, which function optimally at neutral pH. Accordingly, Tarsa therapeutics 
developed an oral salmon calcitonin formulation, OSTORA®, using the 
Peptelligence™ technology and completed Phase III clinical trials in post-menopausal 
osteoporotic patients [93]. The FDA accepted the new drug application (NDA) for 
review, offering the possibility that OSTORA® (now called TBRIA™) could be 
cleared for marketing in 2016 [94].  
The Transient Permeation Enhancer (TPE) technology is an enteric-coated liquid-
filled capsule containing an oily suspension of the peptide drug and sodium caprylate 
(C8) in hydrophilic microparticles that are mixed with castor oil or a medium-chain 
glyceride and caprylic acid. The FDA approved the orphan status for the Octreotide 
formulation, Octreolin® developed by Chiasma Pharma, which recently completed 
Phase III clinical trials with TPE technology. Chiasma claims that the technology 
protects the peptide from enzymatic digestion and transiently opens tight junctions. It 
was demonstrated that an oral dose of 20 mg octreotide using TPE technology can 
achieve similar pharmacokinetics as 0.1 mg octreotide SC (a relative oral 
bioavailability of less than 1 %), and the safety profiles were also comparable. This 
product is also expected to be on the market in 2016 [95]. 
Emisphere Technologies uses SNAC (sodium N-[8-(2-hydroxybenzoyl)amino] 
caprylate or salcaprozate sodium), 5-CNAC (N-(5-chlorosalicyloyl)-8-aminocaprylic 
acid), 4-CNAB (4-[(4-chloro2-hydroxy-benzoyl)amino]butanoic acid) and SNAD (N-
(10-[2-hydroxybenzoyl]-amino) decanoic acid) as absorption enhancers. These 
excipients form non-covalent complexes with peptides or proteins, protect them from 
digestive enzymes and improve the permeation across the intestinal epithelium 
through transcellular pathway. The Novo Nordisk product candidate, semaglutide 
(NN9924) is a new glucagon-like peptide-1 (GLP-1) analogue that can help type 2 
diabetes patients achieve substantial lowering of blood glucose with a low risk of 
hypoglycaemia. Semaglutide, is provided in a tablet formulation with the absorption-
enhancing excipient, SNAC, included in the Eligen® carrier concept. SNAC does not 
cause histological damage to the intestinal epithelium and successfully completed 
phase II trials in 2015 [96]. 
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Table 4 (a): Oral peptide formulations in clinical use and clinical development (systemic action) 










Oral tablet  (small peptide 























Octreoline™ Octreotide  TPE® Acromegaly and neuroendocrine 
tumors 
Phase III complete Chiasma Pharma [99] 
Semaglutide Glucagon-like peptide- Eligen® platform  Type 2 Diabetes Phase IIIa  Novo Nordisk [6] 
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Oral tablet, absorbed along 
pharyngeal mucosa into 
lymphatic system 
Idiopathic pulmonary fibrosis 
(IPF) 







Diabetes Phase III Biocon [100] 
Oral HDV-1 Insulin 
Hepatic-Directed Vesicle 
insulin (Liposomal tablets) 




Capsulin Insulin Axcess™ technology Diabetes Phase III  Diabetology [32] 












Oral tablet Endometrosis Phase IIb 




ORMD-0801 Insulin POD™ Diabetes Phase IIb  Oramed [105] 
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NN1953 Long acting insulin GIPET® platform Diabetes Phase II  Novo nordisk [106] 
NN1954 Long acting insulin GIPET® platform Diabetes Phase II  Novo nordisk [106] 





Type 2 Diabetes 
 
Phase II  Novo nordisk [106] 
Nodlin Insulin 
Nanoparticle Oral Delivery 
(NOD) tech 








Insulin modification to 
enhance stability and 
absorption 
Diabetes Phase II Nobex [108] 










GIPET® platform Prostate cancer Phase I Merrion [110] 
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Covalent link of amphiphilic 
oligomers  
Congestive heart failure  Phase I Nobex Corporation [111] 















Proxima concepts, developed an Axcess™ delivery system based on an oral capsule 
that contains the protein or peptide as well as undisclosed GRAS excipients such as 
permeation enhancers and solubilizers to enhance transcellular absorption. Capsulin, 
is an enteric-coated insulin capsule developed by Diabetology, Ltd based on 
Proxima ś proprietary Axcess delivery system and is currently under Phase III clinical 
trials. The same technology is also currently used to develop Capsitonin (calcitonin) 
and CaPTHymone (parathyroid hormone) for the indications of osteoarthritis and 
osteoporosis, respectively, both under Phase IIb clinical trials [114]. 
Oramed is currently using its Protein Oral Delivery (POD) technology to develop an 
insulin pill, now in Phase IIb clinical trials. POD is an enteric-coated capsule 
containing an oily suspension of the peptide drug, an enzyme inhibitor (soy bean 
trypsin inhibitor, aprotinin) and an absoprtion enhancer (EDTA or bile salt), in 
omega-3 fatty acids. Results from Phase IIa clinical trials showed that POD 
technology significantly reduced gylcemia in a small group of type 1-diabetes patients 
and this technology was safe and well tolerated [105]. 
Sodium caprate (C10), is one of the main constituents of the GastroIntestinal 
Permeation Enhancement Technology (GIPETTM), an enteric coated solid dosage 
form currently designed by Merrion Pharmaceuticals to protect the peptide in the 
acidic gastric medium and ensure its release in the small intestine. It is anticipated that 
the GIPET has the potential to boost permeation of such peptides as acyline (Mer 
104), a gonadotropin-releasing hormone antagonist under phase I clinical trials for 
treatment of prostate cancer, and is currently licensed to Novo Nordisk for several 
oral insulin formulations; (NN1952, NN1953, NN1954, NN1956) and GLP-1 agonists 
(NN9926), which have completed Phase I clinical trials [110]. 
The robotic pill is one of the most recent and novel technology platforms, developed 
by Rani Therapeutics for the oral delivery of large molecules including peptides, 
proteins and antibodies. This robotic pill consists of a capsule made of biodegradable 
material (PLGA), which contains a valve separating citric acid and sodium carbonate 
in two chambers. The capsule also contains a balloon-like structure containing sugar 
microneedles preloaded with peptides [115]. The capsule dissolves in the small 
intestine exposing the valve, causing the citric acid and sodium carbonate to react 
together releasing carbon dioxide that inflates the balloon. As a result the 
microneedles loaded with the drug push into the intestinal wall (intra-enteral 
injection), before detaching from the capsule and slowly dissolving. Rani therapeutics 
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in partnership with Novartis is currently employing this technology to develop an oral 
insulin product. Preclinical studies showed very promising results with oral 
bioavailability over 50 %. Traverso et al also recently demonstrated proof-of-concept 
experiments in swine that microneedle-based delivery has the capacity for improved 
bioavailability of macromolecules (e.g. insulin). The pill’s needles are initially coated 
by a pH-responsive coating which dissolves in the desired location in the GI tract, 
revealing the microneedles (solid, drug-containing microneedles fabricated from 
biocompatible polymers). These detach from the capsule and become lodged in the GI 
tissue, where they slowly release their payload. Moreover, the authors showed that 
microneedle-containing devices can be passed and excreted from the GI tract safely 
[116]. These findings strongly support the potential of implementation of microneedle 
technology for use in the GI tract. 
The Nanoparticle Oral Delivery technology, developed by NOD Pharmaceuticals, 
together with its subsidiary, Biolaxy, comprises enteric coated and bioadhesive 
calcium phosphate nanoparticles with sizes between 5 – 200 nm in the final dosage 
form of a capsule. The formulation is obtained by combining the peptide with calcium 
phosphate in the presence of PEG salts of fatty acids (e.g. caprylate, sodium caprate) 
and bile salts as precipitating agents. The obtained calcium phosphate nanoparticles 
are then enteric-coated using cellulose acetate phthalate and a bioadhesive polymer, 
carbomer. Nodlin is an oral insulin formulation for basal insulin supplementation 
currently in Phase II trials in China whilst Nodexen (phase I) is an oral exenatide 
formulation. Both formulations are developed by Shangai Biolaxy using the NOD 
technology platform [117]. 
TNT Pharma utilizes the company ś proprietary cell-targeted, bio-nanotechnology-
based system called Nanoves® for the oral delivery of HDV-IFN and Parathyroid 
hormone currently in phase I and preclinical trials, respectively. The NanoVes System 
is composed of 20 – 50 nanometer sized phospholipid-based bio-nanoparticles that are 
compatible with both subcutaneous (SC) injection and oral delivery. The active 
pharmaceutical ingredients are incorporated into the carrier by electrostatic and 
hydrophobic interactions and are delivered to the desired cellular targets. This level of 
cell targeting and delivery is supported by a large database of histopathological results 
that show clear endocytosis of the NanoVes System, in vitro and in vivo, including 
human pharmacological data [109]. Oshadi Drug administration developed the Oshadi 
ICP an oral formulation consisting of: insulin, proinsulin and C-peptide in the Oshadi 
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carrier. This invention comprises, pharmacologically inert silica nanoparticles having 
a hydrophobic surface, a polysaccharide, and a biologically active protein or peptide 
suspended in an oil. The company carried out Phase II clinical trials in type 1 diabetes 
patients in 2014.  
With regard to peptide modification, a polyethylene glycol side chain at position 
B29 improves the stability and increases the solubility of insulin (IN-105, by Biocon), 
promoting its rapid absorption. IN-105 is currently under Phase III clinical trials 
which have showed that timing of the IN-105 administration before meals is crucial to 
achieve a substantial glucose lowering effect [118]. 
 
3.3.2. Local delivery via the oral route  
Most of the oral peptides in the market or in advanced developmental stage are 
characterized by local GIT activity. For instance, Constella oral capsules used for the 
treatment of irritable bowel syndrome (IBS) with constipation (produced by Allergan 
and Iron wood Pharmaceuticals) contain the peptide linaclotide, which works locally 
in the gut, where it binds to receptors called guanylate cyclase C receptors, found on 
the walls of the intestine. It reduces abdominal pain and increase the amount of fluid 
in the gut, which helps loosen the stools and speed up their movement through the 
bowel [119].  
Taken as a tablet once-a-day, plecanatide designed by Synergy pharmaceuticals, 
mimics the function of natural uroguanylin by working locally in the upper GI tract to 
activate and regulate fluid movement required for normal bowel function. Whilst 
dolcanatide, is designed to be highly stable and resistant to proteolysis in gastric and 
intestinal fluids but still operate in the same manner as natural uroguanylin. Phase III 
clinical trials were completed in 2015 with exceptionally good results and NDA were 
filled in early 2016 [120].  
Enzymes such as pancreatic lipases have been routinely administered orally for 
decades (such as Creon), they are adapted by nature to the GIT environment and there 
has been a misconception that they do not need any strategic delivery. However, there 
is also innovation in this area. For example, Sollpura® (Liprotamase, Phase III) and 
Zenpep®, (marketed, 2009) are formulations intended for pancreatic enzyme 
replacement therapy (PERT) and for low digestive enzyme levels developed by 
Anthera and Forest pharmaceuticals, respectively [121].
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Table 4 (b): Selected oral peptide formulations under clinical development (local GIT action). 




















Modified peptide for resistant 
against proteolysis  
Chronic idiopathic constipation 
(CIC) & Ulcerative colitis (UC)  




Macrilen™ Ghrelin antagonist  
Chemical modification of 
peptide  
Adult growth hormone 
deficiency (AGHD) 
















PLD-116 Undisclosed peptide  Delayed-release capsule  Inflammatory bowel disease Phase II PLIVA [126] 







4. General remarks and conclusions 
As outlined in this article, it is clear that several pharmaceutical companies have led 
the efforts to develop “needle free” protein/peptide therapeutics and the most popular 
route being investigated is the oral route, more especially for metabolic disorders. 
This is mainly influenced by the fact that from a patient perspective, the oral route is 
simpler, cost effective and more convenient.  
General setbacks, which are common across all mucosal delivery routes, arise due to 
the excipients added in most of the formulations including penetration enhancers and 
enzyme inhibitors. Many of these delivery strategies may compromise the barrier 
function of the epithelia to incoming toxins, and implications of their long-term use in 
managing chronic disease such as diabetes should be considered. These possible 
implications raise concerns and cause both the general public and the FDA to be 
cautious with these innovations; hence their development and advancement into the 
market are hindered. 
Mucosal systemic bioavailabilities should be reproducible and reliable to achieve a 
regulatory filing, but incompatibility of hydrophilic peptide and protein drugs with 
hydrophobic delivery carriers can produce uncontrolled drug release which also 
handicapped the advancement to the market. Moreover, mucosal bioavailabilities are 
still much lower than those of injected doses, and therefore much higher doses must 
be administered to have the same effect. For more expensive peptide and protein 
drugs, this could preclude their mucosal delivery and the toxicity implications of 
administering relatively large doses of peptide and protein drugs remain a concern. 
Needle phobia and stress leading to low patient compliance plus the inconvenience 
and side effects associated with injecting drugs have encouraged scientists to 
investigate and exploit all promising noninvasive routes for peptide/protein delivery. 
In this review we presented the most common and highly sought-after, ‘noninvasive’ 
mucosal routes, specifically; nasal, pulmonary and oral. Many approaches have been 
used to study various strategies to overcome the inherent barriers to peptide uptake 
across mucosal routes. Each of the various routes has its own set of favorable and 
unfavorable properties and these were outlined. Amongst the three routes discussed 
here, tremendous work has been done for oral peptide delivery (including insulin). 
Although extensive human clinical studies are still required for most of the peptides 
presented here, especially of long-term clinical applications, taken together, the 
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technologies and developments described here are likely to increase the number of 
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Nanocarriers can overcome critical barriers associated with the oral route of 
administration including: (i) the harsh gastrointestinal environment (pH range 1.2-
7.4) with high concentrations of enzymes specialized in digestion, (ii) the thick 
mucus barrier (100 μm) subjected to continuous turn-over, and (iii) the intestinal 
epithelium, which acts as a gatekeeper and is poorly permeable to 
macromolecules [1, 2]. Our group pioneered the development of a delivery 
platform, named as polymer nanocapsules, consisting of an oily core surrounded 
by one or more layers a hydrosoluble polymers [3]. Specific prototypes including 
chitosan nanocapsules and polyarginine nanocapsules have been found efficient 
for the delivery of peptides and anti-cancer drugs [4]. These nanosystems 
portrayed remarkable penetration enhancing properties and stability in biological 
media, which was further enhanced by introducing PEG-stearate into the shell 
composition [4, 5]. 
 
Protamine is a natural cationic polymer with the intrinsic capacity to translocate 
through mammalian cell membranes. This ability has been attributed to its 
arginine-rich sequence, which promotes direct interaction with cell surface 
domains and subsequently facilitates cellular internalization [6–8]. Protamine is 
an FDA approved drug indicated for reverting the anticoagulant effects of heparin. 
It is also present as an excipient, in a parenteral insulin formulation (NPH, Neutral 
Protamine Hagedorn) [9–12]. 
 
Our group has designed a variety of nanocarriers involving protamine. Namely, 
Protamine nanoparticles and nanocapsules were designed for the delivery of 
peptides and antigens, whereby they improved their cell internalization[13, 14]. 
More recently, the group developed multilayered nanoparticles made of protamine 
and polyarginine in combination with polysaccharides, dextran sulphate and 
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3. Protamine could be a promising biomaterial for the development of 
nanocapsules for the efficient oral delivery of macromolecules such as insulin. 
The ability of protamine to translocate through biological cell membranes 
could be combined with the capacity of lipids and surfactants to enhance the 
intestinal permeation of drugs.  
4. The rational selection and combination of protamine with other polymers with 
stabilizing and muco-penetration properties, including PEG and other 
polysaccharides, could result in an optimized nanocarrier system able to 
associate the peptide, protect it from degradation and deliver it across the 
epithelial barrier.  
 
Objectives  
Based on the background evidence and hypothesis outlined, the main goal of the 
present work is to rationally design and develop a new protamine based nanocarrier 
system for the efficient oral delivery of peptides using insulin as a model peptide drug.  
For this purpose the overall aim is split into the following objectives with their 
specific tasks; 
1) Development of insulin loaded protamine nanocapsules  
1. To prepare and characterise protamine nanocapsules (blank and insulin loaded) 
with regard to their physicochemical properties, mucodiffusion, stability upon 
incubation in intestinal biological media and stability during storage.  
2. To evaluate their ability to load insulin, prevent the degradation of the peptide 
by pancreatic enzymes and study the in vitro release profile. 
3. To demonstrate the stability of insulin loaded protamine nanocapsules in 
different simulated intestinal media and confirm the conformational structure 
of insulin after encapsulation.  
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The results corresponding to the work described here are presented in Chapter 2: 
Rational design and in vitro characterization of protamine-based nanocapsules for oral 
peptide delivery. 
 
2) Assessment of the in vitro mechanistic and toxicity of protamine nanocapsules  
4. To determine the toxicity, penetration and mechanism of action of the 
nanocapsules using in vitro cell models simulating the different mucosal 
barriers (e.g. enterocytes and mucus) of the intestinal epithelium. 
5. To evaluate the toxicity and permeation enhancing property of the 
nanocapsules ex vivo in human intestinal tissue.  
The results corresponding to the work described here are presented in Chapter 3: The 
interaction of protamine nanocapsules with the intestinal epithelium 
 
3) Evaluation of particle interaction with the epithelial barrier including 
biodistribution and in vivo efficacy of the nanocapsules  
6. To elucidate the in vitro immunological response of protamine and polysialic 
acid coated protamine nanocapsules in dendritic cells  
7. To study the biodistribution of the fluorescent protamine nanocapsules after 
their oral administration to mice  
8. To determine the in vivo efficacy bioactivity of the new nanocarrier in non-
diabetic rats.  
The results corresponding to the work described here are presented in Chapter 4: 
Protamine nanocapsules: a versatile vehicle for oral insulin delivery.  
In addition to these major objectives we have also aimed to explore new technologies 
for the production of protamine nanocapsules, i.e. the self-emulsifying technique 
which could exclude the use of organic solvents and consequently simplify the 
preparation method. However, because this technology was used as a proof of concept 
 
 103 
and only applied for a different model peptide (cyclosporine), the corresponding data 
will be presented in Annex 1: Development and characterization of solvent-free 
















Rational design of protamine nanocapsules as carriers for 








Peptides represent a promising therapeutic class with the potential to alleviate many 
severe diseases. Along with the increased understanding of the biological barriers, the 
development of nanoparticulate carriers, aimed at producing “needle-free” 
pharmaceutical products represents a challenging but promising strategy. The 
objective of this work has been the rational design of polymer nanocapsules (NCs) 
intended for the oral delivery of peptide drugs. For this purpose, we selected insulin 
as a model peptide. The polymer shell of the NCs was made of protamine, a 
polypeptide selected for its cell penetration properties. For the formation of the lipid 
core a variety of components were investigated with respect to their capacity to help 
the NCs to overcome the intestinal barriers and also to entrap and control the release 
of insulin. From this screening, we selected specific nanocapsules compositions, 
which contained PEG stearate 40 (PEGst 40) and sodium glycocholate (SGC), as 
surfactants. In addition, we studied the potential benefit of a double 
protamine/polysialic acid (PSA) layer in terms of preserving the stability and 
controlling the release of the loaded peptide. Insulin-loaded protamine nanocapsules, 
prepared by the solvent displacement method, exhibited an average size of 300 nm, a 
neutral surface charge and a spherical shape. Stability studies performed in simulated 
intestinal media containing enzymes indicated that protamine NCs were stable and 
able to protect insulin from the harsh intestinal environment and that this capacity 
could be further enhanced with a double PSA-Protamine layer. Moreover, these NCs 
were able to control the release of insulin for up to 6 h. Finally, these NCs could be 
freeze-dried and stored at room temperature without alteration of the colloidal 
stability upon resuspension in intestinal fluids. In conclusion, both, single layer and 
double layer protamine/PSA NCs, fulfil a number of key properties that are expected 






1. Introduction  
The number of peptide drugs in the industry pipelines has significantly increased in 
the last decades due to their high therapeutic efficacy and excellent selectivity. 
Unfortunately, their utility has been counter-limited due to their difficulties for 
crossing barriers and, hence the impossibility of being administered by the oral route 
[1]. Advances in nanomedicine have opened new opportunities for the oral delivery of 
biomolecules [2]. Indeed, a variety of nanocarriers, among them, liposomes [3], 
nanogels [4], polymeric nanoparticles (NPs) [5–7] and nanocapsules (NCs) [8], have 
been reported to reduce the exposure of the associated peptide to the adverse 
conditions in the GI tract and enhance its transport across the intestinal mucosa. 
Having as a reference the original work by Damgé et al. [9] which showed for the 
first time the possibility to enhance insulin absorption using poly(cyanoacrylate) NCs 
our group explored the potential of chitosan NCs for the oral administration of salmon 
calcitonin [10]. The positive results were attributed not only to the composition of 
these nanocapsules but also to their structural organization. NCs are composed of a 
core, which may act as a protective reservoir for drug and a surrounding shell [11], 
which can be rationally designed in order to confer the NCs with adequate stability, 
mucodiffusion, and permeability properties [12]. Therefore, such a delivery vehicle 
offers interesting opportunities for a rational design intended to further enhance the 
already shown potential for oral peptide delivery 
 
From our perspective, another type of NCs of potential interest for oral peptide 
delivery is the one making use of the cationic polypeptide protamine. These NCs, 
which were originally designed in our research group for the delivery of antigens [13], 
might help enhancing the transport of peptides across the intestinal epithelium. In fact, 
protamine is known to exhibit membrane-translocation properties attributed to its 
arginine-rich sequence [14], and because of this special property, protamine has been 
proposed for enhancing nose-to brain delivery [15] as well as for enhancing insulin 
intestinal absorption [16]. In this latter work, the authors found that the systemic 
pharmacological bioavailability of insulin conjugated with low molecular weight 
protamine (LMWP) increased 5-fold compared to native insulin during in situ loop 
absorption tests in rats. Moreover, from the toxicological point of view, protamine has 
the advantage of being part of formulations approved by the FDA. Namely, it is used 
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to revert the anticoagulant effects of heparin and it is also part of a long-acting 
injectable insulin formulation [17, 18]. 
 
On the other hand, taking into account the cationic charge of protamine, we found it 
important to explore the value of adding to the nanocapsules and extra-layer of 
polysiaclic acid (PSA). The rationale was that by virtue of the hydrophilicity of PSA, 
we could form a “watery cloud” around the nanocarrier system that might hamper the 
interaction of the NCs with other molecules, e.g. proteolytic enzymes [19, 20]. In fact, 
the chemical conjugation of PSA to peptides [21] or the decoration of nanocarriers 
using this polymer [20] are approaches that have been exploited to protect peptide 
molecules from degradation and improve their pharmacokinetics after parenteral 
administration. On the other hand, taking into account that PSA is naturally a mucus 
component, it was presumed that this extra-layer would facilitate the mucodiffusion 
of the NCs across the intestinal mucus layer. 
 
Based on this information, the aim of this study has been to rationally design and 
develop protamine and protamine/PSA NCs particularly adapted for oral peptide 
delivery. With this aim in mind, we have explored formulation strategies intended to 
facilitate the entrapment and the controlled release of insulin, used as a model peptide, 
and to provide the NCs with the capacity to overcome the intestinal barriers 
(degradation, mucodiffusion and interaction with intestinal epithelium). For this, we 
also selected auxiliary ingredients including stabilizers such as PEG-stearate and 
sodium glycocholate, which has an additional role as a penetration enhancer [22, 23].  
 
2. Materials and methods  
2.1. Materials 
Protamine sulfate of low molecular weight (5 kDa), used in this work was purchased 
from Yuki Gosei Kogyo, Ltd., (Tokyo, Japan). The stabilizing surfactants, 
polyoxyethylene 40 and 100 monostearate (PEGst-40 and PEGst-100), were 
purchased from CRODA Europe Ltd, (Snaith, UK), whilst sodium cholate (SC) and 
sodium glycocholate (SGC), from Dextra, (Reading, UK). Caprylic/capric triglyceride 
(Miglyol® 812) was purchased from Cremer, Oleo Division, (Witten, Germany). 
Colominic acid sodium salt (Polysialic acid, PSA) was purchased from Nacalai 
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Tesque, INC, (Tokyo, Japan). Insulin glulisine (Apidra®) was obtained from Sanofi 
(Paris, France). Rhodamine 6G was purchased from empBIOTECH, (Berlin, 
Germany). Triton x-100 was purchased from Sigma Aldrich (St.Louis, USA), whilst 
anhydrous monobasic sodium phosphate, maleic acid, calcium chloride, sodium 
oleate (purity >82%) and acetic acid were purchased from Scharlab (Barcelona, 
Spain). Pancreatin (8 % USP specification), was purchased from Biozym (Hamburg, 
Germany). Sodium taurocholate, lecithin, sodium hydroxide and glyceryl monooleate 
were obtained from Fluka (Buchs, Switzerland). Mucin was purchased from sigma 
Aldrich (Spain). Organic solvents were of HPLC grade and all other products used 
were of reagent grade purity or higher.  
 
2.2. Preparation of protamine nanocapsules  
Blank protamine NCs were prepared by the solvent displacement technique following 
the procedure described and optimized by our group [24]. Initially, for the core, 
Miglyol® with a combination of different surfactants (SC, SGC, PEGst-40 and 
PEGst-100) and different concentrations, were explored and finally for the selected 
formulation, PEGst-40 (16 mg), SGC (5mg) and Miglyol® (62.5 µL) were dissolved 
in 3ml ethanol to obtain a clear lipid phase. Acetone (1.95mL) was then added and 
this organic phase was immediately poured over 10 ml of an aqueous phase 
containing 0.15% w/v protamine. The elimination of organic solvents was performed 
by evaporation under vacuum (Rotavapor Heidolph, Germany), to obtain a NC 
formulation with a constant final volume of 5mL. Subsequently; protamine NCs were 
isolated by ultracentrifugation (Optima™ L-90K, Ultracentrifuge, Beckman Coulter, 
USA) at 30000 rpm for 1h (at 15 ºC) and resuspended in ultrapure water to the initial 
volume.  
Optionally, protamine NCs were provided with an additional coating layer consisting 
of PSA. For this purpose, a volume of 5mL, protamine NCs (concentration 18.66 
mg/mL) was incubated with 1ml solution of PSA at a concentration 3 mg/mL. The 
final Protamine:PSA ratio was of 5:1 (w/w).  
 
Insulin-loaded protamine and PSA-protamine NCs were prepared following the same 
procedure for blank NCs (section 2.2), by incorporating insulin (1.5 mg, dissolved in 
0.01M HCl, 0.05 mL) into the lipid phase before mixing it with the aqueous phase 




2.3. Physicochemical and morphological properties of protamine NCs 
The average hydrodynamic diameter, polydispersity index (PDI) and zeta potential of 
protamine NCs were measured by a Zetasizer® Nano-ZS, Malvern instruments, 
(Worcestershire, UK) after dilution (50x) with ultrapure water. The transmission 
electron microscopy (TEM, Joel 2010, 80kV, Philips, Netherlands) was used to 
analyze the shape and surface properties of the NCs. For TEM analysis samples were 
deposited on a copper grid and stained with 2% (w/v) ammonium molybdate solution, 
allowed to dry and then viewed under a the TEM.  
 
2.4 Mucodiffusion studies on protamine nanocapsules  
To study mucodiffusion, a capillary (0.6 square internal diameter (ID) mm x 0.12 wall 
(mm), VitroCom, New Jersey), as filled up to three quarters from one end with mucin 
(5% (w/v) mucin in SIF). Then, rhodamine 6G-labeled protamine nanocapsules were 
introduced through the opposite end of the capillary using a syringe pump (flow rate = 
14 µL.m-1) in a vertical position without disturbing the mucin-nanocarrier interface. 
The capillary was then incubated for 10 minutes at 37 °C, after which it was analysed 
under a fluorescence microscope (Leica AF6000, Leica microsystems, Germany). The 
diffusion of the fluorescent nanocarriers through the mucin was monitored by taking 
snap-shots every 5 seconds. This allowed us to determine the time taken by the 
nanocarriers to diffuse across 1 mm of the mucin gel. Chitosan (CS) NCs containing 
exactly the same core as protamine NCs were used as a control since CS is well 
known for its mucoadhesion property.  
 
2.5. Association efficiency (AE%) and loading capacity (LC) 
The association efficiency (%) was determined using the direct method, which 
involves the extraction of insulin from the NCs by the complete disruption of the NCs. 
Briefly; insulin loaded NCs (0.1 mL) were digested using a combination of 
acetonitrile (0.1 mL), Triton™ X-100 (0.05 mL) and 0.1 % TFA (0.75 mL). Then the 
formulation was vortexed at a high speed to obtain a clear aliquot. To corroborate this 
data, free insulin in the aqueous phase (undernatant) was quantified after isolating the 
NCs (indirect method). The concentration of insulin in both cases was determined by 
reverse phase liquid chromatography (HPLC). A 25 μL aliquot of each sample was 
injected in triplicate onto the HPLC column. Chromatography was performed using a 
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Agilent 1100 series auto-sampler, equipped with an Agilent 1100 series controller and 
Dual Absorbance Spectrometer (Agilent 1100 series, Agilent technologies, Germany) 
with an ATRP11 column (Symmetry C8 5 µm (3.9 x 20 mm)) (Waters, Spain) and a 
UV detector set at 227 nm. The flow rate was set to 2 mL/min. The gradient was 
obtained by mixing proportion of phase A (0.1 % TFA) and phase B (acetonitrile:0.1 % 
TFA, 8:2). Initially, the mobile-phase composition was 25% B; a linear gradient was 
applied to reach a composition of 25% B after 4min. Quantification was achieved by 
comparing observed peak area ratios of insulin in the samples to a calibration curve 
obtained under the same experimental conditions. Linearity was observed in the range 
from 0.005 to 0.5mg/mL with a correlation coefficient above 0.9995. The detection 
limit (LOD) was 0.001mg/mL and the quantification limit (LOQ) was 0.005 mg/mL. 
The association efficiency (AE%) and loading capacity (LC%) were calculated using 
Equation 1 and 2:  
 
Equation 1 𝑨𝑬 % =  
𝑰𝒏𝒔𝒖𝒍𝒊𝒏 𝒊𝒏 𝒅𝒆𝒔𝒕𝒓𝒖𝒄𝒕𝒆𝒅 𝒏𝒂𝒏𝒐𝒄𝒂𝒑𝒔𝒖𝒍𝒆𝒔 
𝑻𝒐𝒕𝒂𝒍 𝒊𝒏𝒔𝒖𝒍𝒊𝒏 
  × 𝟏𝟎𝟎 
 
Equation 2 𝑳𝑪 % =  
𝑻𝒐𝒕𝒂𝒍 𝒊𝒏𝒔𝒖𝒍𝒊𝒏 × 𝑨𝑬 
𝑻𝒐𝒕𝒂𝒍 𝒘𝒆𝒊𝒈𝒉𝒕 𝒐𝒇 𝑵𝑪𝒔
 × 𝟏𝟎𝟎 
 
2.6. Conformational stability of loaded insulin 
To evaluate the conformational stability of insulin against preparative stress, circular 
dichroism (CD) spectroscopy was used. For this study, the destruction method used in 
section 2.4 above, could not be applied since the presence of Triton™ X-100 
interfered with the spectrum reading during analysis. For this purpose, protamine and 
PSA-protamine NCs were completely disrupted using a combination of chloroform, 
methanol and acidified milliQ water at pH 3.46 to obtain a final concentration of 
insulin at 0.125 mg/ml. The aliquots were then centrifuged at 14000 rpm for 10 
minutes at 25 °C to obtain a clear supernatant, which was collected and analysed for 
insulin conformation by CD. A solution of insulin in the same medium at a 
concentration of 0.125 mg/ml was used as a control. Spectra were collected at 20°C, 
using a 0.5 nm step size, over a wavelength range of 180–280 nm, using a 1 mm 
quartz cylindrical cell; a band width of 1 nm and a scanning speed of 500 nm/minute, 
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with a 0.25 second response time, were applied (Jasco J-1100; Jasco Corp, Tokyo, 
Japan). 
The α-helical content of the protein was estimated according to the following equation: 
 





Where, θmrd is the mean molar ellipticity per residue at 208 nm (deg cm2 d/mol). 
Raw data from the experiment, expressed in terms of θd (the ellipticity in units of 
mdeg) were converted to mean molar ellipticity (θmrd) per residue, using the 
following equation: 
 





Where, M is the insulin molecular weight (Da), C is the insulin concentration (mg/ 
mL), L is the sample cell path length (cm), and N is the number of amino residues 
[25]. 
 
2.7. Colloidal stability of protamine/polysialic acid NCs and release studies in 
simulated biological media 
The colloidal stability of the NCs was assessed by monitoring the size, PDI and count 
rate (particle concentration). Different simulated intestinal media were used (prepared 
according to the USP XXIV) in order to mimic the intestinal environment after oral 
delivery. Simulated intestinal fluid (SIF) at pH 6.8 and biorelevant media simulating 
preprandial and postprandial conditions in the upper small intestine, including fasted-
state simulated intestinal fluid (FaSSIF) and fed-state simulated intestinal fluid 
(FeSSIF), were also employed in this study according to the updated (V2) versions 
described by Jantratid et al. in order to better mimic in vivo conditions. FaSSIF-V2 
has a lower amount of lecithin, whereas FeSSIF-V2 combines the postprandial 
changes in pH, buffer capacity, osmolality, and bile component concentrations, in 
addition to lipolysis products; glyceryl monooleate and sodium oleate, with in vivo 






Table 1: Compositions of simulated intestinal fluid (SIF), fasted state, simulated 
intestinal fluid (FaSSIF-V2) and fed state simulated intestinal fluid (FeSSIF-V2). 
Adapted from Jantratid et al. [27]. 
Composition/medium SIF FaSSIF-V2 FeSSIF-V2 
Sodium taurocholate  3 mM 10 mM 
Lecithin  0.2 mM 2 mM 
Maleic acid  19.12 mM 55.02 mM 
Glyceryl monooleate  - 5 mM 
Sodium oleate  - 0.8 mM 
Sodium hydroxide 15.4 mM 34.8 mM 81.65 mM 
Sodium chloride  68.62 mM 125.5 mM 
Pancreatin  - 100 units/mL 
Calcium chloride  - 5 mM 
Monobasic potassium 50 mM - - 
pH  6.5 5.8 
 
For the stability studies, insulin loaded protamine NCs were diluted 50x and 
incubated under moderate shaking at 37 °C in the different media: SIF, pH 6.8, 
FaSSIF-V2, pH 6.5 and FeSSIF-V2, pH 5.8. Samples were collected at times 0, 0.5, 1, 
3 and 6 h. The FeSSIF-V2 samples were centrifuged at 5000xg for 5 minutes to 
eliminate pancreatin aggregates before analysis. The evolution of size distribution, 
PDI and count rate of the NCs were monitored by dynamic light scattering on a 
Zetasizer® Nano-ZS, Malvern, UK.  
For in vitro release studies, insulin loaded NCs were incubated in SIF, pH 6.8 and 
FaSSIF-V2, pH 6.5 at a ratio of 1:20, NCs to the medium and shaken at 100 rpm at 
37°C using a constant-temperature shaker. At specified time intervals (0, 0.25, 0.5, 1, 
3 and 6 h); the supernatant was collected by ultracentrifugation (section 2.2). The 
concentration of insulin in the supernatant was determined by reverse phase HPLC 
method (section 2.4). 
 
 
2.8. Insulin stability in simulated intestinal fluids containing enzymes  
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The ability of protamine NCs to protect the associated insulin was evaluated by 
quantifying the amount of insulin remaining in the NCs after proteolysis. For this 
purpose, insulin-loaded protamine NCs, PSA-protamine NCs and free insulin solution 
(as control) were diluted by 1:1 v/v with FeSSIF-V2 then incubated in a 37 °C 
incubator and shaken at 100 rpm for up to 2 hours. At predetermined time intervals (0, 
0.25, 0.5, 1 and 2 h), 500 μL aliquots were withdrawn and the enzyme activity of 
pancreatin in the samples was terminated by the addition of 300 μL ice-cold 0.1 M 
HCl. The samples were subsequently treated with acetonitrile (0.01 mL) and Triton x-
100 (0.01 mL) and vortexed, to disrupt the NCs and extract insulin, which was then 
analyzed by HPLC to determine the amount of insulin remaining in the NCs. 
 
2.9. Stability during storage 
The colloidal stability of insulin-loaded NCs was followed during a period of 6 
months at different temperatures (4 °C, 25 ºC and 40 °C) and RH conditions, as 
recommended by ICH guidelines. Samples of the three different batches were 
withdrawn at predetermined time intervals, followed by determining particle size, zeta 
potential and insulin leakage coupled with observing the suspension appearance to 
ensure continued stability. 
 
2.10. Freeze-drying studies  
Insulin-loaded protamine NCs and PSA-protamine NCs (1% w/v) were lyophilized 
(Labconco Corp, USA) in presence/absence of trehalose or sucrose at 5 % (w/v) as 
cryoprotectors. Samples were frozen at -20 ºC and then subjected to an initial drying 
step at -40 ºC followed by a secondary drying at 0 ºC, both steps lasting for 43 hours 
at a high vacuum atmosphere (200 mTorr). Finally the temperature was increased 
slowly up to room temperature (+22 ºC) till the end of the process. The freeze-dried 
formulations were resuspended in ultrapure water by manual shaking and their 
physicochemical characteristics were evaluated as mentioned in section 2.3.  
 
2.11. Statistical 
Statistical analysis was performed using GraphPad Prism 5 program (CA, USA). One-
way ANOVA in multiple comparisons was applied for comparisons. Differences were 




3. RESULTS AND DISCUSSION 
In this study, protamine NCs were rationally designed taking into account different 
criteria: (i) their capacity to load and control the release of insulin, while protecting it 
from degradation in intestinal fluids; (ii) their colloidal stability in intestinal fluids; 
(iii) their penetration across the mucus layer and, (iii) their ability to interact with the 
underlying epithelium.  
 
3.1. Preparation and characterization of protamine and protamine/polysialic 
nanocapsules  
Protamine NCs are reservoir-type systems composed of an oily core and a protamine-
coating layer. As indicated earlier, all ingredients and their organization into the 
nanostructure were rationally selected. The selection of protamine was motivated by 
its cell penetrating properties [14] and its already shown capacity to enhance the 
intestinal insulin absorption [16]. On the other hand, a second layer around protamine 
was formed with PSA, with the idea of enhancing the colloidal stability in the 
presence of enzymes [21]. The lipid core, i.e. Miglyol (a medium chain 
Caprylic/capric triglyceride), of the NCs was expected to help protecting the peptide 
cargo from degradation as well as to enhance its intestinal permeability [28, 29]. The 
surfactants selected to disperse the oil in the external water phase were PEG stearate 
and bile salts. The presence of the PEG molecules oriented towards the external 
aqueous phase was thought to enhance the stability of the NCs in the presence of 
enzymes [30, 31], as well as promote their diffusion across the mucus [32, 33]. Two 
types of PEG-stearates with PEG chain lengths of 40 and 100 units (PEGst-40 and 
PEGst-100) were initially selected and compared. On the other hand, two different 
bile salts sodium cholate (SC) and sodium glycocholate (SGC), known for the 
penetration enhancing properties were also selected and compared. The structural 
organization of these nanocapsules is illustrated in Figure 1. 
 
The results of the physicochemical characterization of prototypes selected from an 
extensive screening of ingredients in different quantities are presented in Table 2. The 
chosen prototypes emanated from stability studies (discussed later on) and their 
acceptable physicochemical properties. The results indicate that for the compositions 
selected (described in the Materials and Methods section 2.2), the size of the NCs is 
 
 118 
within the 200-300 nm range (PDI < 0.3) irrespective of their composition. On the 
other hand, the zeta potential values varied between -6 mV/+30 mV depending on the 
type of polymer shell (PSA vs. protamine) and also on the type of PEG stearate used 
(PEGst-40 vs. PEGst-100), (Table 2). The positive charge on protamine NCs, as 
compared to the negatively charged control nanoemulsions, is an indicator of the 
presence of the protamine shell around the lipid core. On the other hand, the type of 
surfactant also influenced the resultant surface charge. Namely, the use of SGC 
resulted in NCs with a higher negative charge, as compared to that of those produced 
with SC (p<0.05). This result may be attributed to the glycol moiety, which is present 
in SGC molecule but not in the SC molecule. Surprisingly, the presence of PEGst-100 
(Mw 2KDa) gave a higher negative charge in the nanoemulsions and a higher positive 
charge in the nanocapsules compared to PEGst-40 (Mw 4KDa) (p<0.05). This result 
led us to hypothesize that, as the amount of PEGst added to the formulation was the 
same, the longer PEGst-100 chains are sparsely dispersed on the surface of the oily 
cores, thus leaving more bile salt acid molecules exposed to the surface.  
 
In a second step, nanocapsules containing PEGst-40 were provided with a second 
coating layer of PSA. The positive charge of the nanocapsules was supposed to enable 
the ionic interaction with PSA. The presence of this extra layer was confirmed by the 
charge inversion of the NCs containing PSA and protamine, as compared to those 
having only the protamine layer (Table 2). The chemical structure of PSA and the 
schematic representation of the components and their arrangement in the NCs are 
illustrated in Figure 1 and 2, respectively. The double layer PSA/protamine 
nanocapsules was expected to help improving the stability of the nanocapsules in the 
presence of proteolytic enzymes. This expected role, could be explained by two 
different mechanistic perspectives. First, it is known that both, macromolecules and 
nanocarriers coated/linked to hydrophilic polymers, i.e. PSA, are shielded from 
opsonisation [19, 20, 35], and this shielding results in their greater stability in the 
blood circulation. On the other hand, it has been reported that the presence of 
negatively charged functional groups, i.e. carboxylic moieties, in polymeric materials 
may result on the inhibition of the proteolytic enzymatic activity by chelating the 
Ca2+ ions required for normal enzymatic activity [35]. Despite these attractive 
properties of PSA, to our knowledge, there is no work reported, on the use of PSA-





Figure 1: Chemical structure of polysialic acid (PSA), also named as colominic 
acid 
 
Table 2: Physicochemical properties of protamine and PSA-coated protamine 
NCs with their corresponding nanoemulsions, (mean ± SD, n=3, #*p<0.05 significant 
difference between nanoemulsions containing PEGst40 and PEGst100, and SC and 
SGC, respectively). 




Size (nm) PdI ζ-pot 
(mV) 
Size (nm) PdI ζ-pot 
(mV) 
Size (nm) PdI ζ-pot 
(mV) 
40 
SC 198 ± 7 0.1 -13 ± 5 207 ± 18 0.1 +6 ± 5 200 ± 16 0.2 -4 ± 1* 
SGC 214 ± 15 0.2 -21 ± 2* 288 ± 20 0.2 +8 ± 4 261 ± 24 0.2 -6 ± 4* 
#
100 
SC 205 ± 16 0.2 -25 ± 2 210 ± 25 0.2 +28 ± 5 - - - 
SGC 221 ± 13 0.2 -32 ± 1* 238 ± 16 0.3 +30 ± 2 - - - 
 
The size of the nanocapsules was confirmed by TEM analysis. The images presented 
in Figure 3, also illustrate the spherical shape of the NCs and different appearance of 
the single layer protamine nanocapsules as compared to the double layer 













Figure 3: TEM images of blank protamine NCs (A) and PSA-coated protamine 
NCs (B).  
 
 3.2.  Mucodiffusion studies on protamine nanocapsules  
To check if the NCs are able to penetrate through mucus, their diffusion rate in mucin 
(SIF + 5% mucin) was studied in a preliminary mucodiffusion study where the 
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mucodiffusion enhancing property of PEGst-40 was compared to that of PEGst-100. 
Herein, protamine NCs containing PEGst-40 were found to diffuse more rapidly 
through the mucin gel compared to chitosan NCs. Interestingly, the substitution of 
PEGst-40 with PEGst-100 in the nanostructure led to a clear reduction in the 
mucodiffusion rate of the NCs. Protamine NCs containing PEGst-100 (Mw 5KDa) 
took twice the time (300 seconds) taken by protamine NCs containing PEGst-40 (Mw 
2KDa) (150 seconds) to diffuse across 1 mm of the mucin gel. These results are in 
agreement with the higher positive charge observed for protamine nanocapsules 
containing PEGst 100, which may hamper the diffusion of these nanocapsules. As 
explained, the hypothesis is that PGEst-40-containing nanocapsules would have a 
more dense coating of low molecular weight PEG, as compared to those containing 
PEGst-100, and, would, thereby facilitate the mucodiffusion of the nanocapsules [36]. 
Similar results have been reported for polystyrene particles (200 and 500 nm). Those 
coated with 2 KDa PEG were found to diffuse faster through mucus compared to the 
same NPs with higher MW PEG [37]. 
 
3.3. Insulin association and stability 
Taking into account that insulin is a hydrosoluble polypeptide with and IP of 4.75, the 
strategy for its entrapment within the oily core was based on tuning its solubility and 
ionization degree using different pH media. As expected, the results shown in Table 3, 
indicate that both, the pH of the insulin solution and the presence of cholate bile salts 
influence the insulin association efficiency to the NCs (*p<0.05). The highest AE % 
values were obtained when insulin was dissolved in 0.01M NaOH, pH 9.2 in the 
absence of a bile salt and also when insulin was dissolved in 0.01M HCl, pH 2 These, 
apparently contradictory results could be explained as follows. At pH 9.2, insulin has 
an important net negative charge, which may help its interaction with the positively 
charged protamine and, thus its encapsulation is favoured in the absence of a bile salt. 
On the contrary, association to the NCs was highly dependent on the type of bile salt. 
In this case, the positively charged insulin was supposed to interact with the 
negatively charged bile salt surfactants in the lipid core. The higher association 
observed for the nanocapsules containing SGC as compared to those containing SC, 
might be due to the presence of the glycol moiety in the SGC molecule. In fact, the 
longer hydrophilic side chain has been associated with higher interaction and activity 
of SGC compared to SC. [38]. 
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Table 3: Association efficiency (AE%) and physicochemical properties of insulin 
loaded protamine and PSA-coated protamine NCs with insulin (IP=4.75) at different 
pH, (mean ± SD, n=3, p<0.05 statistical difference in #size and in *AE).  















9.2 #425 ± 82 +2 ± 1 76 ± 9 6.2 364 ± 43 -1 ± 1 48 ± 7 5.0 
2.0 298 ± 83 +1 ± 2 *22 ± 5 5.6 - 
SC 
9.2 287 ± 46 +3 ± 2 27 ± 5 5.3 - 
2.0 266 ± 75 +8 ± 3 38 ± 4 5.1 206 ± 14 -5 ± 3 32 ± 4 4.7 
SGC 
9.2 295 ± 56 +4 ± 1 29 ± 2 6.0 - 
2.0 #382 ± 29 +6 ± 3 *62 ± 16 5.2 321 ±3 3 -4 ± 1 51 ± 6 4.8 
 
Regarding the effects of the amount of each of the components in the NCs on the AE % 
of insulin, it was observed that whilst the presence of SGC and PEGst-40 confers 
advantageous properties to the system, such as enhanced stability, high amounts of 
these components compromise the insulin AE. We found that there is an optimum 
balance between the amounts of the components used that favoured the loading of 
insulin.  
 
Although the HPLC analysis used to quantify the association efficiency provided a 
good indication of the insulin stability (100% insulin was recovered after analysis of 
associated and non-associated insulin), a subsequent circular dichroism (CD) analysis 
was performed as the conformation of insulin is critical for its optimal therapeutic 
effect. Since α-helices are one of the elements of the secondary structure, the 
quantitative analysis of the structural change of insulin could be evaluated by the 
content of the preserved α-helices. Figure 5 shows the CD spectra of insulin 
(glulisine) secondary structures before and after the formulation process. The far-UV 
CD band at 208 nm primarily arises from the α-helix structure. The calculated 
percentage of α-helix in insulin glulisine (control) and insulin glulisine entrapped in 
protamine NCs and PSA-protamine NCs are 38.0, 36.8 and 38.4 % respectively. In 
other words, no significant conformation change was noted after loading insulin into 





Figure 5: CD spectra of free insulin glulisine and insulin glulisine associated in 
protamine NCs and PSA-protamine NCs after the formulation process. The insulin 
concentration was kept constant at 0.125 mg/ml at pH3.46 in all aliquots. (Mean ± SD, 
n=3, *p<0.05). 
 
3.4. Colloidal stability of protamine-based NCs in biological fluids 
To ascertain that the NCs preserve their physicochemical properties under 
physiological conditions we evaluated the colloidal stability of nanocarriers in 
simulated intestinal fluids including simple SIF, FaSSIF-v2 and FeSSIF-v2. The 
stability of the NCs was determined by monitoring the size, PDI, and count rate of the 
NCs using the DLS technique. Preliminary stability studies revealed that PEGst-40 
conferred a greater stability to the NCs than PEGst-100 in SIF and this was attributed, 
as indicated in section 3.1, to the possibility to form a more uniform coating on the 
shell as compared to PEGst-100. Hence, the PEGst-40 was selected for further 
analysis. Moreover, since the surface properties and composition of the NCs is known 
toplay an important role in their stability properties, the influence of the type of bile 
salt and polymer coating on the stability of the NCs in the presence of enzymes was 
investigated. For comparison purposes a formulation without any cholic acid salt 
(PrNCs no Cholate) was also investigated. The results showed that the three 
protamine NCs were stable in SIF (data not shown). However, a steady increase in 
size and a decrease in count rate was observed upon incubation of the NCs in FaSSIF-






















could be attributed to the high ionic strength and/or to the interaction of the 




Figure 6: Evolution of the particle size (continuous line) and count rate of insulin 
loaded Protamine NCs without bile salts, with SC and SGC following incubation in 
FaSSIF-V2 (mean ± SD, n=3, p<0.05 significant difference #size and *count rate for 
all formulations compared to their size and count rate at time 0 h).  
 
The stability of the NCs provided with an extra coating layer of PSA is shown in 
Figure 7(B). The results indicate that the stability of the NCs was improved by the 
presence of PSA. Moreover, the formulation containing SGC showed enhanced 
stability compared to the formulation containing SC and the formulation without 
cholate, since the count rate of this formulation remained constant, which suggests 
that the number of particles in suspension was maintained throughout the experiment. 
From these observations, it can be concluded that PSA and SGC have a synergetic 
effect on improving the stability of the NCs by providing a protective shell and 
because of their enzyme inhibition property. The order of stability of the PSA-coated 
formulations can be ranked as follows: PrNCs+SGC > PrNCs+SC > PrNCs-no 
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Figure 7: Evolution of the particle size (continuous line) and count rate of insulin 
loaded protamine NCs (A) and PSA-coated protamine NCs (B), without bile salts, 
with SC and SGC, following incubation in FeSSIF-V2 containing pancreatin, (mean ± 
SD, n=3, *p<0.05 significant difference in count rate for all formulations in (A) and 
for only the formulations with SC and without cholate in (B) compared to their count 
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3.5. In vitro release studies in simulated intestinal fluids 
Figure 8 A and B illustrate the in vitro release behaviour of protamine NCs and PSA-
coated protamine NCs (containing PEGst-40 and SGC) in SIF at pH 6.8 and FaSSIF-
V2 at pH 6.5. In both media a biphasic release pattern with a rapid and constant 
insulin release, followed by a slow sustained release over 4 hours was observed. The 
initial release phase could correspond to the release or diffusion of some insulin 
loosely associated to the shell of the NCs. This kind of biphasic profile has been 
previously reported for solid lipid nanoparticles (SLNs) and chitosan nanocapsules 
[39, 40]. Protamine NCs post coated with PSA showed improved controlled release of 
the insulin in both media, however, this difference was not found to be statistically 
significant (p>0.05). Comparing the release profile from the two different media it 
was observed that the insulin release was slower in simple SIF, compared to FaSSIF-
V2, this being particularly noticeable after one-hour incubation. This could be due to 
the fact that the FaSSIF medium has higher ionic strength and a higher concentration 
of surfactants (lecithin, sodium taurocholate), which might contribute to the alteration 




























Figure 8: In vitro release profiles of insulin from protamine NCs and PSA-
protamine NCs incubated in SIF (A) and in FaSSIF-V2 (B), (mean ± SD, n=3, 
*p<0.05). 
 
3.6. Protection of the insulin from proteolysis 
The ability of the NCs to preserve the associated insulin against degradation by 
enzymes was studied by incubating insulin-loaded protamine NCs and PSA-
protamine NCs and free insulin solution (control) in FeSSIF-V2. The results in 
Figure 9A indicate that free insulin, was totally degraded in the first 15 minutes. In 
contrast, insulin entrapped into protamine NCs was highly preserved from 
degradation, maintain between 55 – 75 % insulin in the same period of time (15 min). 
Moreover, the presence of bile salts, and notable SGC, significantly contributed to 
enhance the stability of the encapsulated insulin. This stabilizing role of the 
nanocapsules was even more intense when they were provided with the external 
coating of PSA (Figure 9B). This behaviour, expected in the rational design of the 
nanocapsules, was attributed to the shielding effect of the PSA layer, which could be 
able to reduce the attachment of the degrading enzymes [20]. Moreover, both PSA 
and SGC could have a role in terms of inhibiting the activity of proteases [41].  
 
Overall, protamine-based NCs containing bile salts showed a potential for the 


























additional coating layer of PSA. It should also be taken into account that some of the 
observed insulin degradation could be attributed to its release in the medium as 





Figure 9: Stability profiles of the associated insulin after incubation of (A) 

























































p<0.05 significant difference of PSA-PrNC+SGC compared to #PSA-PrNC+SC and 
*PSA-PrNC no Cholate).  
 
3.7. Stability during storage  
To determine the stability of the NCs under storage conditions, insulin-loaded 
protamine NC suspensions were stored at 4 ºC and 25 ºC and size and insulin leakage 
(AE %), were monitored for a period of 6 months. Table 4 below shows the 
variations of size and AE of protamine NCs and PSA-protamine NCs over a period of 
6 months. Both formulations maintained their nanometric size (and count rate) for the 
duration of the study at 4 ºC. However, both formulations were only stable for 7 days 
at room temperature (25 ºC).  
 
Table 4: Physicochemical properties and insulin leakage from protamine NCs and 
PSA-protamine NCs during storage at 4 °C, (mean ± SD, n=3). 
 

















PrNCs 396±24 68±8 394±41 52±5 344±63 41±4 374±47 31±4 
PSA-PrNCs 341±54 59±6 314±32 50±3 278±45 43±2 277±21 37±5 
 
 
3.8. Freeze drying studies  
The conversion of the colloidal NCs into a dried state was considered as a strategy to 
further incorporate the nanocapsules into a solid dosage form [42]. It has been 
previously reported that the addition of cryoprotectants to nanoformulations is 
necessary in order to protect them during the freezing process. In this study, different 
concentrations of insulin-loaded protamine NCs were freeze-dried in presence and/or 
absence of cryoprotectants (trehalose or sucrose at 5 %). As shown in Figure 10A 
and B, the reconstituted powders of both formulations protamine NCs and PSA-
protamine NCs, maintain their initial nanometric properties even without the use of 
cryoprotectants. Therefore, the presence of the protamine coat and the combined 
PSA-protamine coat around the oily core of the NCs play an important protective role 
during freeze-drying [43]. This is a quite unique behaviour for the nanocapsules with 
important technological consequences as it avoids the dry dilution and, thus, the final 





Figure 10: Physicochemical properties (Particle size and zeta potential) of 
protamine NCs and PSA-protamine NCs after lyophilization at different NC 
concentrations (a) and at 11.3 mg/ml NC concentration in the presence of 5% sucrose 
or 5 % trehalose (b), after resuspension in water (mean ± SD, n=3).  
 
 
The results of the in vitro release of insulin from freeze-dried NCs was also 
determined. It is evident from Figure 11 that converting protamine based NCs into 
powder also improved their in vitro release profile by promoting more controlled 
release and reducing the amount of insulin initially release in the first 30 minutes 
(compared to NCs in suspension). This change in the release behaviour could be 
associated to the compaction of the NC’s shell during the freeze-drying process. This 
is a very promising feature for the nanocarrier system as it shows that converting the 
NCs into powder enhances the properties of the NCs by promoting controlled release 

























































































Figure 11: In vitro release profiles in FaSSIF-V2 (B) of lyophilized Protamine 
NCs and PSA-Protamine NCs, resuspended in milliQ water to the initial volume. 
(Mean ± SD, n=3, *p<0.05).  
 
Finally, the effect of storage temperature and relative humidity on the stability of 
freeze-dried NCs was tested through an accelerated stability study, according to ICH 
conditions and guidelines. Freeze-dried insulin loaded protamine NCs and PSA-
protamine NCs were kept at 25ºC ± 2ºC / 60% ± 5% RH, and their physicochemical 
properties were monitored and recorded over a period of 6 months. Figure 12 shows 
that the physicochemical properties of the NCs did not change during a period of the 
study. These results affirm the concept that freeze drying improves the stability of 
colloidal systems since the NCs stability which was initially compromised at room 
temperature for the NC suspensions was preserved by converting the NCs into dry 






























Figure 12: Physicochemical properties of freeze-dried protamine NCs and PSA-
protamine NCs stored at 25ºC ± 2ºC / 60% ± 5% RH over a period of 6 months, 
(mean ± SD, n=3, *p<0.05).  
 
4. CONCLUSIONS  
In this work we report for the first time NCs consisting of an oily core and double 
layer PSA/protamine as a candidate delivery technology for the oral administration of 
peptides. These NCs, which were rationally designed in order to confer them with the 
capacity to withstand the multiple barriers associated to the intestinal tract, were also 
able to load a significant amount of insulin and control its release in simulated 
intestinal media containing bile salts and proteolytic enzymes. Moreover, the 
conversion of the NCs into a powder led to an improvement of their stability at room 
temperature and of their controlled release capacity. Therefore, this novel nanocarrier 
system could be considered as a promising candidate for improving the oral delivery 
of peptide drugs, such as insulin. In vitro and in vivo mechanistic studies presented in 
the next chapter were aimed to elucidate the interaction of these nanocapsules with 
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Single-layer protamine and double layer polysialic acid (PSA)/protamine 
nanocapsules (NCs) were designed in order to be used as carriers to facilitate the 
transport of macromolecules across the intestinal epithelium. The rational for the 
design of these NCs was based on that protamine is a non-toxic yet potent cell-
penetrating peptide, which is capable of translocating protein cargos through cell 
membranes. On the other hand, PSA is a low molecular weight polysaccharide, which 
has been used to enhance the stability of macromolecules and nanocarriers. The 
objective of this work was to study in vitro the mechanism of interaction of these NCs 
with different cell models, (Caco-2, Caco-2/Raji and Caco-2/HT29-MTX) and also 
with colonic human tissue. For this, the fluorescent marker, TAMRA was covalently 
linked to protamine. The interaction and transport of the NCs with the Caco-2 cells 
(measured by fluorescence) was found to be concentration, temperature and size 
dependent. In all cases, the double layer PSA-protamine NCs exhibited a significantly 
higher transport compared to protamine NCs. On the other hand, the transport of the 
NCs was significantly higher in the co-culture (Caco-2/Raji monolayer) compared to 
the monoculture model (Caco-2 monolayer), implying that M-cells are involved in the 
transport of these nanosystems. On the contrary, no significant differences in the 
amount of fluorescence transported in Caco-2/HT29-MTX compared to Caco-2 
monolayer was observed, thus making evident the mucodiffusion properties of the 
NCs. Moreover, both systems were observed within the epithelium of human 
intestinal tissue without any cytotoxicity effects, thus reflecting their safe interaction 









The intestinal mucosa is a large interface that consists of a monolayer of epithelial 
cells connected by tight junctions and protected by a thick mucus layer. Although this 
mucosa is highly specialized in the absorption of nutrients, i.e. aminoacids, it 
represents a phenomenal barrier for the absorption of large molecules, e.g. peptide 
drugs [1]. As a consequence, the development of strategies to make the oral 
administration of peptides feasible has become a primary goal in the 
biopharmaceutical world [2]. The possibility to deliver peptides by the oral route is 
particularly critical in the case of drugs used in the treatment of chronic diseases. In 
the specific case of anti-diabetic drugs (e.g. insulin and glucagon-like peptide (GLP-
1), their administration by the oral route has the additional advantage of simulating 
the normal physiological pathway i.e. via hepatic portal circulation [3]. Indeed, 
insulin transported across the intestinal epithelium would directly reach the liver, the 
target organ for pancreas-secreted insulin, whereas injected insulin goes directly into 
the systemic circulation and only a limited amount (20 % of injected dose) becomes 
effective at the target site.  
 
A variety of strategies attempting to provide structural protection and improved 
absorption of peptide drugs have been disclosed. These include the use of enzyme 
inhibitors [4] and absorption enhancers [2], chemical modification [5, 6] and 
encapsulation of peptide drugs within microspheres [7], nanoparticles [8] and 
nanocapsules [9]. Some of these nanocarriers have been shown to protect peptides 
from degradation by intestinal enzymes [10, 11]. The subsequent barrier, the mucus 
layer, has been found to be more difficult to overcome and, hence, the development of 
muco-diffusive nanocarriers has become a crucial challenge in the area of 
nanoparticle-based oral peptide delivery [12, 13]. In addition to this, the interaction of 
nanocarriers and transport of the associated peptide across the intestinal epithelium, 
which is supposedly highly dependent on the nature of the nanocarrier, remains 
poorly understood. 
 
Based on this background information, the aim of this work was to study the 




PSA/protamine NCs across the intestinal epithelium, using insulin as a model peptide. 
The oily core of these NCs is composed of Miglyol oil, and it contains insulin 
together with the penetration enhancer, sodium glycocholate (SGC). The shell of the 
NCs is made of protamine, which has the role of facilitating the interaction with the 
epithelium and PEG-stearate, which is supposed to facilitate the transport of the NCs 
across the mucus layer [14]. In addition, an extra layer of PSA was added to the NCs 
with the aim of preventing their interaction with proteolytic enzymes followed by the 
degradation of the associated insulin. PSA, a polysaccharide that forms part of the 
mucus in mammals, is a non-toxic and biodegradable polymer [15] that has already 
been used to improve the stability and lengthen the circulatory half-life of proteins 
[16]. For example, in a recent study, polysialylated insulin was found to exhibit a 2-
fold longer half-life compared to normal insulin following subcutaneous injection in 
mice [17]. Moreover peptide loaded nanocarriers have been decorated with PSA to 
protect the peptide from degradation and to improve their function following 
parenteral administration. For these reasons, we hypothesized that coating the 
nanosystem with PSA may render it with muco-penetrative properties allowing it to 
penetrate the intestinal mucus layer.  
 
To achieve the above-indicated objective different in vitro cell monolayer models 
simulating the different mucosal barriers (e.g. enterocytes and mucus) of the intestinal 
epithelium were adopted [18], [19]. The influence of parameters that could potentially 
affect the toxicity and mechanism of interaction with the monolayers, including 
particle size, surface composition, particle concentration as well as time and 
temperature of exposure were investigated. Finally, the results in terms of cytotoxicity 
and mechanism of interaction were compared with those obtained upon contact of the 
NCs with human intestinal tissue mounted on a Ussing chamber.  
 
2. Materials and methods  
2.1.  Materials  
Protamine sulfate of low molecular weight (5 kDa), used in this work was purchased 
from Yuki Gosei Kogyo, Ltd., (Tokyo, Japan). The stabilizing surfactants, 




glycocholate (SGC), Dextra, (Reading, UK). Caprylic/capric triglyceride (Miglyol®)) 
840, Cremer, Oleo Division, (Witten, Germany). Colominic acid sodium salt 
(Polysialic acid, PSA, Nacalai tesque INC, (Tokyo, Japan). Insulin (insulin glulisine) 
was obtained from Sanofi (Paris, France). 5-TAMRA, SE (5-
carboxytetramethylrhodamine, succinimidylester, single isomer), was purchased from 
emp Biotech, (Berlin, Germany). Alexafluor® 488 phalloidin was purchased from Life 
Technologies, (Eugene, USA). Triton X-100, chlorpromazine, filipin III and Alcian 
blue were purchased from Sigma-Aldrich, (Leuven, Belgium). All cell culture media 
and reagents were purchased from Invitrogen (Merelbeke, Belgium). Organic solvents 
used were of HPLC grade. All other products used were of high purity or reagent 
grade.  
2.2.  Preparation and characterization of protamine nanocapsules 
2.2.1 Preparation of insulin-loaded protamine nanocapsules 
Insulin loaded protamine NCs were prepared by the solvent displacement technique 
following the procedure described by our group [14]. Briefly, PEGstearate-40 (16 mg), 
sodium glycocholate (5 mg) and Miglyol® (62.5 µL) were dissolved in 3 ml ethanol. 
Acetone (1.95 mL) was then added to this lipid phase followed by the addition of 1.5 
mg insulin dissolved in 50 µL 0.01M HCl. This organic phase was immediately 
poured over 10 ml of an aqueous phase containing 0.15 % w/v protamine. The 
elimination of organic solvents was performed by evaporation under vacuum 
(Rotavapor Heidolph, Germany), until a final volume of 5 mL. Finally the 
nanoparticles were isolated by ultracentrifugation (Avanti® J-E, Ultracentrifuge, 
Beckman Coulter, USA) at 30,000 rpm for 1 h (at 15 ºC).  
 
Nanocapsules with a double protamine/polysialic acid polymer layer were obtained 
upon addition of 0.1 mL of PSA solution (concentration: 3 mg/mL) to a volume of 0.5 
ml of NCs (concentration: 18.6 mg/mL) under magnetic stirring for up to half an hour. 
The final Protamine:PSA ratio was of 5:1 w/w).  
 
2.2.2. Preparation of TAMRA-labelled protamine nanocapsules 
For cell uptake studies, fluorescent protamine NCs were prepared with TAMRA-




sodium bicarbonate buffer (1 mL, pH 8,60) and TAMRA (10 mg/mL in DMSO) was 
slowly added under mild stirring. After 1 h incubation (mild stirring) at room 
temperature, the labelled protamine was dialyzed for 72 h to remove free TAMRA 
(SnakeSkin, cellulose membrane MW 3.5 KDa, Thermo, Spain). The obtained 
polymer conjugate (TAMRA-protamine) was freeze-dried and NCs were prepared 
according to the procedure described in 2.2. 
 
2.2.3. Determination of particle size and zeta potential distribution 
The mean size and polydispersity index (PDI) of the particle size distribution of 
protamine NCs were measured after dilution with ultrapure water by dynamic light 
scattering using a Zetasizer Nano series DTS 1060 (Malvern instruments, Malvern, 
UK). The zeta potential was measured by laser-Doppler anemometry after diluting the 
samples in water (Zetasizer®, NanoZS, Malvern Instruments, Malvern, UK). 
 
2.2.4. Insulin association efficiency (AE %) and loading capacity 
(LC %) of the nanocapsules 
The association efficiency (AE %) of insulin was determined after isolation of the 
NCs. The amount of free insulin in the aqueous phase (indirect method) and also that 
associated to the NCs (direct method) was determined by HPLC (described below). 
For the extraction of insulin from the NCs, 0.1 mL of the NCs suspension 
(concentration: 18.6 mg/mL) were mixed with acetonitrile (0.1 mL), 0.1 % 
trifluoroacetic acid (TFA) (0.75 mL) and Triton™ X-100 (0.05 mL). The mixture was 
vortexed at a high speed to obtain a clear solution.  
Quantification of insulin by HPLC  
The amount of insulin loaded into the NCs was quantified by HPLC (Agilent model 
1100 series LC and a diode-array detector set at 214 nm). The chromatographic 
system was equipped with a reversed-phase 125 × 4 mm Supersphere®100- RP-18e-
125-4 column (particle size 4 µm). The mobile phase, eluted at 1 mL/min, was a 
mixture of phosphate buffer (0.1 M, pH 2.3) and acetonitrile (44:56, v/v). The column 
was set at 35°C and the injection volume was 10 µL. Calibration curves ranging from 
5 µg/mL up to 1,050 µg/mL (r2=0.999) were obtained. The limit of quantification 




Samples were transferred into auto-sampler vials, capped and placed in the HPLC 
auto-sampler. Each sample was assayed in triplicate. The concentration of insulin in 
the aliquots was used to calculate the association efficiency (AE %) using equation 1  
 
Equation 5 𝐴𝐸 % =  
𝐴𝑚𝑜𝑢𝑛𝑡 𝑜𝑓 𝑖𝑛𝑠𝑢𝑙𝑖𝑛 𝑖𝑛 𝑑𝑒𝑠𝑡𝑟𝑢𝑐𝑡𝑒𝑑 𝑁𝐶𝑠 
𝑇𝑜𝑡𝑎𝑙 𝑖𝑛𝑠𝑢𝑙𝑖𝑛 
  × 100 
 
2.2.5. Assessment of in vitro behaviour of nanocapsules in cell 
culture media: insulin release, TAMRA release and colloidal stability 
Insulin loaded TAMRA-labelled NCs were incubated in Hank ś Balanced Solution 
Salt (HBSS), used for in vitro cellular assays, at a dilution ratio of 1:50, NCs:HBSS 
(v/v), a final NC concentration of 0.37 mg/mL, and shaken at 100 rpm at 37 °C. At 
specified time intervals (0, 0.5, 1, 2, 4 and 6 h), insulin released was evaluated after 
isolating the NCs by ultracentrifugation (Avanti® J-E, Ultracentrifuge, Beckman 
Coulter, USA) at 30,000 rpm for 1 h (at 15 ºC). The concentrations of insulin in the 
aqueous medium were determined by reverse phase HPLC method (section 2.2.3.). 
The stability of the NCs was determined in cell culture medium DMEM and transport 
buffer HBSS. Briefly, the NCs were diluted 50x with the relevant medium, DMEM or 
HBSS (NC concentration: 0.37 mg/mL) and shaken at 100 rpm at 37 °C. The size and 
count rate (number of particles) of the NCs were monitored at specific time intervals 
(0, 0.5, 1, 2, 4 and 6 h). 
 
The absence of leakage of TAMRA from the NCs during the transport studies was 
also evaluated. Insulin loaded TAMRA-labelled NCs (1 mL of 2 mg/mL) were placed 
in dialysis devices (Spectra/Por Float-A-Lyzer G2, MWCO: 5KD, Spectrum 
Laboratories, USA) and introduced into 50 mL of HBSS, maintained under magnetic 
stirring at 37 °C. At pre-determined time points (0, 0.5, 1, 2 and 4 h), samples were 
withdrawn from the medium and analysed using the fluorescence reader, (SpectraMax 
M3, Molecular devices) at 583 nm wavelength. The free TAMRA and TAMRA-





2.3. In vitro cell culture studies  
2.3.1. Cell cultures  
Caco-2 cells (clone 1) were kindly provided by Dr Federico Benetti (Veneto nanotech, 
Venice, Italy) and used from passage 18 to 28. Human Burkitt's lymphoma Raji B cell 
line was purchased from American Type Culture Collection (Manassas, VA, USA) 
and used between passages x+5 to x+10. Caco-2 cells were grown in DMEM 
supplemented with 10% (v/v) inactivated fetal bovine serum, 1% (v/v) non-essential 
amino-acids (NEAA), 1% (v/v) L-glutamine, and 1% (v/v) of penicillin–streptomycin 
(PEST) at 37 °C under a 10% CO2/90% air atmosphere. Raji cells were grown in 
suspension, cultivated in RPMI medium supplemented with 10% (v/v) inactivated 
fetal bovine serum, 1% (v/v) NEAA, 1% (v/v) L-glutamine, and 1% (v/v) PEST, at 
37 °C in a 5% CO2/95% air atmosphere. HT29-MTX cells were kindly provided by 
Dr T Lessufleur (INSERM UMR S 938, Paris, FR) and used between passages x+16 
and x+20 [20]. HT29-MTX cells were grown in DMEM supplemented with 10 % (v/v) 
heat inactivated fetal bovine serum, 1% (v/v) NEAA, 1% (v/v) L-glutamine, and 1% 
(v/v) PEST in a humidified incubator with 5 % CO2 atmosphere at 37 °C. 
2.3.2. Cytotoxicity studies 
Cell viability was assessed after the co-incubation of 20,000 Caco-2 cells/well on a 
96-well tissue culture plate (Costar® Corning® CellBIND Surface) with the 
formulations, protamine NCs and PSA-protamine NCs in dispersion in culture 
medium (concentration range: 0.5 to 8 mg/mL). After 2, 6 and 24 h of incubation, the 
cells were rinsed with PBS and incubated at 37 °C for 3 h with 100 μL 0.5 mg/mL 3-
(4,5-dimethylthiazol-2-yl)-(2,5-diphenyltetrazolium bromide) solution (Sigma-
Aldrich, Belgium) (MTS assay). Cellular supernatants were then transferred into a 
new 96-well plate and the amount of soluble formazan produced by cellular reduction 
of MTS was determined by recording absorbance at 490 nm with Synergy 4 
microplate reader (BioTek Instruments, Inc., Winooski, USA).  
Before performing MTS assay, 50 µL of cell culture media were transferred into a 
new 96-well plate, mixed with 50 µL of working reagent for LDH detection (LDH 
assay) (Roche Diagnostics Belgium, Vilvoorde, Belgium), and incubated for 20 min 
at room temperature in the dark. The reaction was stopped by adding 25 µL of stop 




absorbance at 500 nm with Synergy 4 microplate reader [21]. The IC50s for the 
different formulations were calculated using the GraphPad Prism 5 program 
(California, USA).  
2.3.3. Interaction of TAMRA-Protamine nanocapsules with Caco-
2 cell monolayers 
The interaction of TAMRA-protamine NCs and TAMRA-PSA-protamine NCs with 
Caco-2 cells was quantitatively and qualitatively studied using flow cytometry (FACS) 
and confocal laser scanning microscopy (CLSM), respectively. For the flow 
cytometry study, Caco-2 cells were seeded in 24-well cell culture plates at a density 
of 5x105 cells per well and allowed to adhere for 48 h until confluency. For the 
transport studies, cells were co-incubated with a-400 μL of a TAMRA-protamine NCs 
or TAMRA-PSA-protamine NCs suspension in transport buffer (NC concentration 1, 
1.5 or 2 mg/mL) corresponding to a final insulin concentration of 4, 8 and 12 g/mL, 
respectively.  
After 2 h of co-incubation, cells were washed three times with PBS and detached 
from the plates by trypsinization. Cells were then centrifuged at 1,500 x g (Eppendorf 
centrifuge 5804 R, Daigger scientific Inc., USA) the supernatant was discarded and 
the cells were resuspended in PBS. Fluorescence was measured using a BD FACS 
Verse flow cytometer and BD CellQuest software (Becton Dickinson Biosciences, 
San Jose, CA, US). Cell fluorescence was quantified by measuring the fluorescence of 
TAMRA (red) at 583 nm. For cell viability measurements, the TOPRO-3 reagent was 
employed (blue). The reagent was added to each sample at a final concentration of 10 
µg/mL, and, after 10 min of incubation, the fluorescence corresponding to dead cells 
was measured at 642 nm. For each sample, 10,000 events were collected. The data 
were subsequently analysed using the FlowJo data analysis software package 
(TreeStar, USA). 
For subsequent imaging, transwell inserts were fixed in paraformaldehyde (PFA) 4 % 
were gently washed in HBSS. Actin was stained with 200 μL of Alexafluor® 488 
phalloidin (1:50) in buffered HBSS + 0.2 % (v/v) Triton X-100 for 10 min in the dark 
to reveal cell borders as described by des Rieux et al. [22]. Cell nuclei were stained 
with DAPI (1:20). Subsequently, inserts were washed in HBSS, cut and mounted on 




Data were analysed by the Axio Vision Software (version 4.8) to obtain y-z, x-z and x-
y views of the cell monolayers. 
2.4. Transport across intestinal cell monolayers Cell culture models 
2.4.1. Caco-2 and Raji cell monolayers (Follicle-associated 
epithelium model) 
Caco-2 cells were seeded at a density of 5 x 105 cells/well onto Matrigel® (BD 
Biosciences, Belgium) (10 μL/mL in DMEM)-coated Transwell® polycarbonate 
inserts (12 mm insert diameter, 3 μm pore size) (Corning Costar, Cambridge, U.K.) 
and cultivated over 21 days. The medium was replaced every second day. The 
inverted follicle-associated epithelium (FAE) model was obtained by co-culturing 
Raji and Caco-2 cells as previously reported by des Rieux et al. and Beloqui et al. [1, 
23]. Briefly, after 3 to 5 days of Caco-2 seeding, inserts were inverted, a piece of 
silicone tube was placed into the inserts and maintained until day 21 in large Petri 
dishes. The medium was replaced every other day, until day 9 to 11 when Raji cells 
were then added on top of the Caco-2 cells for the conversion of the Caco-2 cells into 
M cells at a density of 2.5 x 105 cells/well [23]. 
 
For the assessment of FAE model functionality, in each experiment transport studies 
were conducted under the aforementioned conditions with commercial fluorescent 
carboxylated nanoparticles (0.2 μm) (Gentaur, Belgium). A nanoparticle suspension 
(400 μL at a concentration of 4.5x109 NPs/mL) was added on the apical side and 
inserts were incubated at 37 °C for 2 h. After this incubation time, basolateral 
solutions were then sampled and the number of transported nanoparticles was 
measured by FACS (BD FACS Verse). Nanoparticle transport was expressed as mean 
± SD.  
2.4.2. Caco-2 and Caco-2/HT29-MTXcell monolayers (mucus 
model) 
The influence of the mucus was studied by co-culturing Caco-2 and HT29-MTX, 
seeded at a density of 5 x 105 cells/well in a 3:1 ratio (Caco-2:HT29-MTX) and 
maintained until day 21 [24]. The medium was replaced every after two days.  
 
The Alcian blue staining technique was employed to demonstrate the presence of acid 




culture [19]. For this purpose, both the Caco-2 monoculture and the Caco-2/HT29-
MTX co-culture were grown and seeded as described above. After confirming the 
integrity of the monolayer by measuring the TEER, cells were washed 2 x with HBSS 
and fixed with 4 % Paraformaldehyde (PFA) for 30 min, then rinsed 3x with PBS and 
stained with 1 % Alcian blue at pH 2.5 for 1 h. They were then washed 3x with PBS, 
mounted on slides and viewed under a microscope (Axioskop 40, Carl Zeiss 
Microscopy, LLC, New York, United States) equipped with the Zen lite 2012 
software for capturing images.  
 
In all cases the integrity of the monolayers was corroborated by measuring the trans-
epithelial electrical resistance (TEER), before and after the transport studies on day 21. 
These measurements were carried out at 37 °C using an epithelial voltohm meter 
(EVOM, World Precision Instruments, Berlin, DE). TEER values over 250 Ωcm2 for 
both Caco-2 and Caco-2/HT29-MTX monolayers and values above 160 Ωcm2 for 
Caco-2/Raji monolayers were used. TEER values after transport studies were not 
significantly different to initial values unless otherwise stated. 
 
All transport experiments were conducted at 37 °C (or 4 °C) by adding a volume of 
400 μL at 12 μg/mL insulin concentration in HBSS on the apical side and 1 mL of 
HBSS on the basolateral side. After the specific incubation time (1, 2 or 4 h), samples 
were collected from the basolateral side and the amount of fluorescence (TAMRA) 
was measured using a fluorescence plate reader (λEx=540 and λEm=570).  
The absence of cytotoxicity in the presence of the NCs was assessed by measuring the 
LDH activity released from the cytosol of damaged cells in the apical medium after 
each transport experiment (procedure in section 2.3.2). The cell monolayers were then 
washed twice in cold HBSS to stop endocytosis or uptake of NCs and fixed in PFA 4% 
for subsequent staining and imaging.  
 
2.5. Mechanism of interaction of insulin–loaded protamine NCs with Caco-2 
and Caco-2/Raji monolayers 
To evaluate the mechanism of interaction of protamine and PSA-protamine NCs with 
Caco-2 cells and Caco-2/Raji cells, the monolayers were pre-incubated for 1h at 




chlorpromazine at 10 μg/mL was used as an inhibitor of receptor-mediated and 
clathrin-mediated endocytosis [25, 26] and Filipin III (1 μg/mL), was used for the 
inhibition of caveolae and clathrin-mediated pathways by cholesterol depletion [27, 
28]. After 1 h of incubation with the inhibitors formulations were added onto the 
apical side of the monolayer and co-incubated for 2 h. Control transport studies were 
carried out in transport buffer without inhibitor solutions.  
The absence of cytotoxicity in the presence of inhibitors was assessed by measuring 
the LDH activity released from the cytosol of damaged cells into the apical medium 
after the interaction experiments following the same procedure in section 2.3.2. 
 
2.6. Interaction of TAMRA-protamine nanocapsules with human intestinal 
tissue  
Intestinal tissues collected immediately after the surgery, were immediately 
transferred into a vessel containing ice cold, oxygenated Krebs-Ringer buffer (KRB) 
and quickly transported to the laboratory. Upon arrival, the epithelium was dissected 
away from subepithelial tissues and mounted in horizontally as well as vertically 
oriented Ussing chambers with 9 mm openings between the two chambers. The 
basolateral chamber was filled with glucose containing KRB, while the glucose in the 
apical chamber was substituted with mannitol in order to avoid SGLT-induced tight 
junction opening. The chambers were kept at 37C and bubbled with 95% O2 /5% 
CO2 for the duration of the experiment. To assure continued tissue viability, the 
electrophysiology of the tissues was monitored throughout the experiment. After 
mounting the tissues were allowed to equilibrate for 40 min with two medium 
exchanges [29]. 
 
Protamine NCs and PSA-protamine NCs (5 mg/mL) were then added to the donor 
chambers. Aliquots of 20-100 µL, were withdrawn at 0, 30, 60, 90 and 120 min from 
the receiver and donor compartments. The sample volume in the receiver 
compartment was replaced with fresh KBR. At the end of the experiment continued 
viability of the tissues was tested by addition of the cAMP-agonist forskolin. Viable 
tissue with oxidative metabolism will form cAMP in response to forskolin leading to 
an opening of CFTR Cli channels, the response was monitored as changes in potential 




labelled NCs was analysed by quantifying the amount of the fluorescence dye found 
in the receiver chamber using a plate fluorescence reader (λEx=540 and λEm=570) [29]. 
For imaging, the tissue specimens were rinsed and fixed in 4% formalin for 24h. Then 
they were embedded in paraffin and sectioned to a thickness of 5μm. Nanocapsules in 
each section were visualized by LSCM using the fluorescent marker TAMRA. 
2.7. Statistics 
Statistical analysis was performed using the GraphPad Prism 5 program (CA, USA). 
Normal distribution was assessed with the Shapiro–Wilk normality test. One-way 
ANOVA in multiple comparisons followed by Tukey's post-hoc test was applied 
according to the result of the Bartlett's test of homogeneity of variances for the 37 °C 
and 4 °C transport comparisons. All other analyses were performed using a Student's 
t-test. Differences were considered statistically significant at *p<0.05. Results are 
expressed as mean ± SD. 
3. Results and discussion  
In this work, we studied the interaction of protamine-based NCs with the intestinal 
epithelial cells and the mucus layer as important barriers to successful oral peptide 
delivery. Preceding work showed that NCs consisting of an oily core and a poly(alkyl 
cyanoacrylate) coating are potential carriers for improving insulin absorption [9]. The 
NCs studied here present the same structure, although the components were rationally 
selected and organized in order to overcome specific biological barriers, i.e. the 
mucus layer and the underlying epithelium. The selection of protamine was based on 
its its ability to penetrate cell membranes, as it is an arginine rich polypeptide [30, 31]. 
On the other hand, the formation of a double layer with PSA was aimed at increasing 
stability and enhance the penetration of the NCs through the mucus layer by avoiding 
the interaction with the extracellular matrix including proteins [32]. Finally, the 
surfactants, SGC and PEG-stearate were added to the nano-composition, with the 
objective of enhancing the penetration properties of the nanocarrier as well as their 
colloidal stability and mucodiffusion properties.  
 
3.1. Physicochemical properties, stability and release behavior of protamine 
nanocapsules 




displacement technique, a mild and easily scalable preparation technique. The particle 
size, zeta potential and association efficiency of the two formulations are summarized 
in Table 1. The particle size range for both formulations is between 300 – 400 nm. 
The zeta potential for protamine NCs was +6 ± 3 mV whilst PSA coated protamine 
NCs showed a slightly negative zeta potential (-4 ± 1 mV), confirming the presence of 
PSA on the outer shell. The insulin association efficiency was 62 ± 16 % and 51 ± 9 % 
for protamine and PSA-protamine NCs respectively.  
Table 1: Characteristics of protamine NCs and PSA-protamine NCs (mean ± SD, n=9, 
*p<0.05) 
Formulation Size (nm) 
ζ-potential 
(mV) 
AE % LC% 
Stability in 
HBSS 
Protamine NCs 382 ± 69 +6 ± 3 62 ± 16 1.0 ± 0.03 Stable (6h) 
PSA protamine 
NCs 
301 ± 84 -4 ± 1 51 ± 9 0.8 ± 0.01 Stable (6h) 
 
In vitro stability and insulin release studies were performed to ensure that the 
transport buffer, HBSS, does not compromise the stability of the NCs and does not 
cause a burst release of the associated insulin. The results shown in table 1, indicate 
that the stability of the NCs was not compromised upon incubation in the transport 
buffer medium (HBSS) during 6 h at 37 °C. On the other hand, for both, protamine 
and PSA-protamine NCs, less than 30 % of the associated insulin was released in the 
same period of time (6 h). Comparable data were obtained when the NCs were 
incubated in SIF and SGF for 6 h, confirming their stability in simulated 
gastrointestinal media. Moreover, no TAMRA leakage from the NCs was observed 
over the period of 0 to 6h in HBSS. 
3.2. Cytotoxicity of protamine nanocapsules in Caco-2 cells 
The cytotoxicity of the different types of NCs was studied in order to estimate the 
highest safe concentration of NCs that can be used for subsequent mechanistic studies. 
Two different incubation times, 2 h and 6 h were tested as they fall within the average 
transit time in the intestinal tract. As shown in Figure 1, protamine NCs were found 
to induce no significant cytotoxicity (p>0.05) after 6 h incubation at concentration 
range of 0.5 to 2 mg/mL. However, the highest concentration tested, 8 mg/ml, 




regardless of the incubation time, implying that cytotoxicity of protamine NCs is 
concentration dependent. 
 
Figure 1: Cytotoxicity of insulin-loaded protamine (PrNCs) and polysialic acid 
coated PSA-PrNCs on Caco-2 cell viability measured by MTS assay (mean ± SD, n=3, 
N=2, *p>0.05). 
 
3.3. In vitro evaluation of nanocapsule interaction with the intestinal barrier  
3.3.1. Intracellular uptake in Caco-2 and Caco-2/Raji monolayers 
The adherence and internalization of the fluorescent NCs into the Caco-2 monolayers 
was studied using confocal microscopy and flow cytometry. Figure 2(a) represents 
the y-z, x-z and x-y view of Caco-2 and FAE monolayers after 2 h incubation with 
TAMRA-labelled protamine NCs and TAMRA-labelled PSA-protamine NCs. The 
images show that the two formulations were internalized by the cells up to a certain 
extent, although a significant amount was also localized on the surface of the cell 
monolayers. Based on this, it could be expected that the NCs would release the 
associated insulin on the surface or into the enterocytes  
The interaction of the nanocapsules with the Caco-2 monolayers was also 
quantitatively analyzed by flow cytometry. In this study, the TOPRO-3 reagent was 
employed to measure cell viability and untreated cells were used as controls. As 
shown Figure 2(b), the cellular uptake of both, protamine NCs and PSA-protamine 



























NCs, was concentration (dose) dependent. This observation is consistent with des 
Rieux et al., who found that transport of yellow-green carboxylated particles 
(Fluospheres®) was concentration dependent [22]. Interestingly, as observed by 
confocal microscopy, at all concentrations PSA-protamine NCs exhibited 
significantly higher count values (p<0.05) than protamine NCs. Initially, this result 
was surprising as, in general, the cell internalization of positively charged 
nanoparticles is more important than that of negatively charged ones [31, 33]. 
However, there is also the possibility that the PSA coating minimizes the interaction 
of the NCs with the proteins present in the cell culture medium, thereby enhancing 








Figure 2: (a) CLSM images showing y-z, x-z and x-y sections of Tamra-labeled 
protamine formulations (red). Cell membranes are stained in green with Alexafluor® 
488 phalloidin. (b) Cellular uptake of Tamra-protamine NCs and PSA-protamine NCs 
at different NC concentrations, 1 (A), 1.5 (B) and 2 (C) mg/ml in Caco-2 cells, 
measured by flow cytometry. (Mean ± SD, n=3, N=3, *p<0.05, ***p<0.001) 
 
3.3.2. Permeability across model cell monolayers 
3.3.2.1. Caco-2 vs Caco-2/Raji cell monolayers 
The ultimate goal of this work was to evaluate the potential of protamine and 
PSA/protamine NCs to transport protein drugs such as insulin across the epithelial 
barrier. For this, the enterocyte-like model (Caco-2 monolayers) and the FAE model 
(Caco-2/Raji co-culture), containing M cells, were employed. The conversion of 
Caco-2 cells into M-cells in the FAE model was confirmed by measuring the number 
of fluorescent commercial carboxylated particles transported using flow cytometry [1, 
23]. The results of this control study indicated that the number of transported 







































































































































532±133 vs.108±91 nanoparticles, respectively n=6, *p<0.05)  
The ability of the NCs to cross the cell monolayers was estimated by quantifying the 
amount of fluorescent maker covalently linked to protamine, detected in the 
basolateral side compared to the initial amount added in the apical side of the 
monolayer [22, 34]. Figure 3 represents the fluorescence detected in the basolateral 
side of Caco-2 and FAE monolayers, after 1, 2 and 4 h incubation time. In agreement 
with previous work [22, 35]. Overall, the results show that the transport of both 
protamine NCs and PSA-protamine NCs, measured in terms of fluorescence, was 
increasing over the time in both types of monolayers and that this transport was 
significantly higher in the FAE monolayer as compared to the Cacco-2 monolayer 
(*p<0.05). Moreover, as observed in confocal microscopy studies (section 3.3.1), the 
transport was significantly higher for the NCs with a PSA layer.  
The explanation of the higher transport observed in the FAE monolayer, as compared 
to the Caco-2 monolayer, could be found in the intrinsic nature of the M cells, which 
unlike the neighbouring absorptive enterocytes, lack a highly organized apical brush 
border and glycocalyx, and are poorly equipped with digestive enzymes [36]. They 
also possess a high transcytotic capacity and are able to transport a broad range of 
materials, including nanoparticles [37]. Moreover, protamine has been shown to enter 
primary human dendritic cells (DCs) in a dose-dependent manner [38]. The transport 
profile observed in this study correlated with other similar studies where less than 10 % 
of the NPs added to the apical side were transported to the basolateral side [22]. The 






Figure 3: Influence of NCs composition in their transport over the time across the 
Caco-2 and FAE monolayers. Fluorescence (%) represents the amount of fluorescence 
transported to the basolateral side in comparison to that initially added in the apical 
side, (mean ± SD, n=3, N=2; *p<0.05). 
 
Subsequently, the NCs were evaluated for their ability to enhance the intestinal 
paracellular transport by monitoring the alternation of TEER, which correlates to the 
tightness of the cell layer. Figure 4 shows that the prototypes tested resulted in an 
significant reduction of TEER after 4 h incubation time (*p < 0.05). However, after 
the removal of the NCs and the replacement with fresh medium, the initial TEER was 
completely recovered. These results suggest that protamine-based NCs could induce a 
transient opening of tight junctions (TJs) between Caco-2 cells, especially as an effect 
of time. This phenomenon was mainly associated to the presence of protamine in the 
nanocapsules. In fact, the permeabilizing effect of protamine has already been 
reported by several authors using a fish model [39], a rat brain perfusion model [40] 
and the intestinal perfusion model in rats [41] and the effect was found to be dose 
and/or time dependent. Although the mechanism is still unclear, the authors presumed 
that protamine might interact with intracellular calcium transfer or cause disruption of 
the microfilaments on the tight junction proteins. In addition, this effect was also the 
hypothetical mechanism by which the intestinal absorption of insulin was promoted 


























by its conjugation to protamine [5]. On the other hand, the fact that the effect on 
TEER was transient and reversible is very important since loss of the tight junction 
barrier function is undesirable as it may lead to the penetration of pathogens and other 
harmful immunoreactive antigens into the mucosa. The results of this study also 
showed that the extra layer of PSA does not alter the penetration enhancing properties 
of the NCs. Consequently, it could be inferred that somehow, the hidden protamine 
layer interacts with the anions on the cell surface and the TJ proteins along the cell 
membranes [42].  
 
Figure 4: Effects of protamine NCs and PSA-protamine NCs on the transepithelial-
electrical-resistance (TEER) values of Caco-2 and Caco-2/Raji monolayers (mean ± 
SD, n=3, N=3; **p<0.05). 
 
3.3.2.2. Caco-2 vs Caco-2/HT29-MTX cell monolayers  
Caco-2 and HT29-MTX cells represent the two most abundant cell populations in the 
intestinal epithelium, enterocytes and goblet cells, respectively. Therefore, co-cultures 
of Caco-2 cells and mucus-producing goblet cells HT29-MTX would provide a drug 
absorption model incorporating the mucus barrier [19]. Acid mucins produced by 
goblet cells were stained with Alcian blue to verify the presence of mucus on the 
surface of the Caco-2/HT29-MTX monolayers. Caco-2:HT29-MTX cells seeded at a 



























3:1 proportion exhibited a homogenous mucus layer, depicted by the monodispersed 
blue layer on the surface of the co-culture corresponding to the mucus layer produced 
by the HT29-MTX cells (Figure 5B). This blue layer is not observed in the Caco-2 
monoculture ratifying the absence of mucus (Figure 5A). Hence the Caco-2:HT29-
MTX co-culture in a 3:1 proportion used in this study is a reliable model to predict 
the behavior of the NCs when in close contact to intestinal mucosa as it maintains 
better in vivo/in vitro correlation relevance [43]. 
 
The permeability profiles of the NCs, measured in terms of fluorescence, are shown in 
Figure 5C. The statistical analysis of these data indicated that there are not 
significantly different in the amount of fluorescence transported in Caco-2/HT29-
MTX compared to Caco-2 monolayer for either protamine NCs or PSA/protamine 
NCs. This observation suggests that the presence of mucus did not hinder the 
permeation enhancing property of the nanocarriers. In a similar study, Shan et al., 
found no significant difference in the transport of nanoparticles (NPs) across the 
Caco-2/HT29-MTX-E12 co-culture in the presence or absence of mucus, implying 
that the presence of the mucus did not hinder the internalization of these NPs. This 
observation was attributed to the structure of the NPs as they possessed a 
nanocomplex core composed of insulin and a cell penetrating peptide (CPP), coated 






Figure 5: Caco-2 monolayer (A) and Caco-2/HT29-MTX (B) stained with Alcian 
blue, demonstrating the presence of mucus (magnification 400x) and Transport of 
PSA coated and uncoated protamine NCs in Caco-2 and Caco-2/HT29-MTX 
monolayers after 2 h incubation (C) (mean ± SD, n=3, N=3) 
 
3.4. Mechanistic study of NC transport across Caco-2 cells  
3.4.1. Influence of temperature 
Nanoparticles have been reported to predominantly enter cells actively by pinocytic or 
endocytic uptake at 37 °C [45]. Conformably, we observed a significant reduction of 
transport at 4 °C which implies that the membrane is involved during transport of 
these formulations since membrane fluidity is highly restrictive at 4 °C (Figure 6). It 
is known that several proteins and enzymes are sensitive to temperature, thus active 
processes are inhibited by lowered temperatures [25]. Further studies were carried out 























Figure 6: Influence of temperature on transport in Caco-2 and FAE monolayers after 
2 h of incubation at 37 °C and 4 °C (mean ± SD, n=3, N=2; ***p<0.001). 
 
3.4.2. Characterization of NC endocytosis mechanism  
In order to elucidate the specific mechanisms involved in the uptake of protamine-
based NCs and the transcytosis of the cargo, transport studies were performed in the 
presence of inhibitors and compared to transport without inhibitors (controls). The 
formulations were co-incubated with chlorpromazine (10 μg/mL), which reduces the 
number of coated pits associated receptors at the cell surface by disrupting the 
assembly of clathrin [46]. Under this particular condition a reduction (30 %) in 
fluorescence internalized into the cells and transported to the basolateral side was 
observed (**p<0.01, ***p<0.001) (Figure 7). This implies that clathrin is involved in 
the transcytosis of protamine NCs and cargo. Caveolae-mediated endocytosis was 
evaluated by incubating cells with the NCs in the presence of 1 μg/mL Filipin III. 
Filipin disrupts the caveolae structure by binding to sterols such as cholesterol and 
disorganizing caveolae proteins [46]. A significant decrease (approximately 80 %) in 
fluorescence transported to the basolateral side was observed in the presence of 
Filipin III (***p<0.001) (Figure 7).  
























Figure 7: Comparison of transport under clathrin and caveolae inhibitors, 
(chlorpromazine and Filipin III respectively), in Caco-2 and FAE monolayers after 2 
h incubation with inhibitors. Untreated cells used as controls and fluorescence (%) 
represents the amount of fluorescence transported to the basolateral side in 
comparison to that in the basolateral side of the respective control, (mean ± SD, n=3, 
N=3; *p<0.05,**p<0.01, ***p<0.001).  
 
Collectively, the data presented here suggest that caveolae and clathrin are both 
involved in the transcellular transport of cargo by protamine-based NCs, although 
caveolae (80% decrease) transport is predominantly higher than clathrin (30% 
decrease). Caveolae-mediated endocytosis involves clustering of lipid raft 
components on the plasma membrane into flask-shaped invaginations formed by the 
interaction of different proteins mainly caveolin with the cellular membrane [47]. 
Roger et al., reported that caveolae was predominantly involved in the transcytosis of 
paticlaxel (Ptx)-loaded LNCs when they found a significant decrease in the amount of 
Ptx transported across Caco-2 cells to the basolateral after co-incubation LNCs with 
filipin [28]. These results are in agreement with Rejman et al., who suggested that 
caveolae flask-shaped invaginations are able to internalize larger particles more easily 


























































used could completely inhibit NP-uptake in different cell types and concluded that 
there is a possibility that multiple pathways are used simultaneously to internalize the 
same NP [25]. Moreover, the ability of protamine to enhance membrane translocation 
has been reported [42]. Different mechanisms have been postulated for this property, 
including the fact that the basic guanidine group of the arginine forms stable hydrogen 
bonds with sulfates or phosphate present in biological membranes. This interaction is 
considered essential for membrane translocation and can consequently improve the 
cellular uptake of protamine-based nanosystems [50]. 
 
The implications and fate of internalized nanoparticles is debatable. Hillaireau et al 
described polymeric nanoparticles as efficient vehicles that can be modified to ferry 
their cargo to the target site. In this manner, it is predicted that internalized 
nanoparticles are degraded and hence release the drug into the enzymatic environment 
(lysosomes) or directly into the cell cytoplasm [51]. In this study, it was observed that 
both formulations used multiple endocytosis pathways to enter the cells, which 
implies that once within the cells the cargo can be released in different organelles i.e. 
within the cytoplasm, the Golgi complex, endoplasmic reticulum or even in the 
lysosomes, depending on the specific pathway. Hence the amount of fluorescence 
detected on the basolateral compartment could be the TAMRA-protamine or free 
TAMRA, transcytosised at the basolateral as a product of the nanocarrier degradation 
that occurs intracellularly [39], [47]. Moreover, a considerable amount of insulin was 
detected in the cell monolayers (intracellular) and in the basolateral receiving 
chamber but this data are not conclusive and are pending validation.  
 
3.5. Transport of TAMRA-protamine NCs in human intestinal tissue 
The permeation enhancing property of protamine NCs was further explored in human 
intestinal tissue, estimated by quantifying the amount of fluorescence accumulated in 
the basolateral chamber. Figure 8 shows the accumulation of fluorescence in the 
basolateral side over a period of time obtained from the vertical Ussing chamber as 
the permeation effect was more pronounced in this chamber compared to the 
horizontal chamber. It was observed the amount of fluorescence that crossed to the 
receiving chamber increased over time, for both prototypes. The confocal microscopy 




images show fluorescence protamine nanocapsules attached mainly on the surface of 
the epithelium with a low amount of fluorescence located within the epithelium. In 
addition, some fluorescence, which could be attributed to the labelled polymer or 
simply to the fluorescent marker, was found to be across the tissue and transported to 
the basolateral side (Figure 9). However, dialysis of the transcytosed material in a 3.5 
KDa cut-off dialysis device showed that the majority of the detected fluorescence 
displayed a size below this cut-off, suggesting significant break-down of the 
nanoparticles during transit of the intestinal tissue. In addition, efforts to quantify the 
amount of insulin transported to the receiving chamber are on going and at this point, 
no insulin was detected in this model. This could be attributed to the high enzyme 
activity associated with the intestinal tissue and the low amount of insulin used.  
 
 
Figure 8: Transport of protamine NCs and PSA coated protamine NCs in human 
intestinal epithelia after 2 h incubation. Fluorescence (arbitrary units) represents the 
detected amount of fluorescence transported to the basolateral side measured as a 








Figure 9: Confocal images showing the transport of protamine NCs (a) and PSA-
protamine NCs (b) in human intestinal epithelia.   
 
It is critical to assure the viability of the tissue during and even after the experiment. 
In this study forskolin response was used to estimate tissue physiological function 
after the experiments. After adding the cAMP agonist forskolin to the tissues, viable 
tissue that is able to perform oxidative metabolism will form cAMP in response and 
stimulate increased short-circuit current (Isc) due to CFTR Cl- channel activation [52]. 
As shown in Figure 10, no apparent change in forskolin response was observed in the 
tissues after incubating them with protamine NCs and PSA-protamine NCs. Moreover, 
there was no LDH leakage observed after incubating the tissues with the nanocarriers 
(data not shown). This study shows protamine NCs have the capacity to transport 
cargo across intestinal tissue without compromising the viability, confirming the 
safety and non-toxicity of these nanocarriers even in this more realistic in vivo 
condition and using a higher concentration of the NCs (5 mg/ml).  
 
 
Figure 10: Forskolin response of human intestinal tissues after 2 h incubation with 
protamine NCs and PSA-protamine NCs at 5 mg/ml NC concentration. 
 
4. Conclusion 
The results of this work have led to the conclusion that insulin-loaded into NCs with a 
single protamine or a double PSA/protamine layer exhibit a very low toxicity in the 
Caco-2 cell culture models and also in human intestinal tissue. The NCs interacted 
with the monolayers and affected both, the transcellular and paracellular mechanisms 
of transport. With respect to the first one, irrespective of their composition, the NCs 
were internalized in a dose and time dependent manner mainly via the caveolae and 
clathrin endocytic pathway.  With respect to the second one, NCs led to a significant 












































but reversible decrease in the TEER values of the monolayers On the other hand, he 
presence of raji cells in the monolayer led to a significant increase in the permeation 
properties of NCs, whereas the presence of mucus-secreting cells did not interfere 
with the NCs internalization permeability was not affected by the presence of mucus. 
All in all, based on these in vitro studies, protamine-based NCs exhibit a promising 
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Nanocarriers made of polycationic polymers with penetration enhancing properties 
are gaining increasing attention for oral peptide delivery. It has been hypothesized 
that the combination of these polymers with other biomaterials with additional 
penetration properties, controlled release and stabilizing properties i.e. lipids and 
surfactants may further increase the potential value of these nanocarriers. Protamine-
based nanocapsules (NCs) made of one single protamine layer or a double polysialic 
(PSA)/protamine layer were shown to exhibit these properties. The aim of this work 
was to evaluate the in vitro immunotoxicity and the in vivo biodistribution and 
efficacy of these nanocapsules for oral insulin delivery. Results showed that 
protamine nanocapsules did not induce any toxicity or immunological response in 
dendritic cells (DCs) at the concentration range of 0 to 16 mg/mL. The biodistribution 
profile of the fluorescently nanocapsules following oral administration to healthy 
mice showed that the nanocapsules are retained in the gastrointestinal tract (GIT) for 
at least 6 h. On the other hand, the pharmacological studies indicated that the 
subcutaneous (s.c.) injection of insulin-loaded protamine nanocapsules resulted in a 
glucose reduction (30%) with a delayed peak (2 h) and longer duration (3 h) 
compared to the control (free insulin solution) with a peak at 0.5 h and 2 h duration. 
The same formulation, administered intra-duodenally to healthy rats (4 h fasting) 
resulted in a moderate reduction of the glucose levels (20% reduction), which lasted 
for up to 7 h. This work raises prospects that protamine based nanocapsules may have 









Insulin is one of the most important therapeutic drugs for the treatment of diabetes 
mellitus. It is commonly administered subcutaneously, which can lead to pain, 
allergic reactions, hyperinsulinemia, and even failed glycemic control due to non-
compliance [1]. Consequently, obtaining an oral insulin formulation is one the highest 
priorities in a number of pharmaceutical industries. This interest relies on the fact that 
oral insulin administration would not only avoid the inconveniences associated with 
injections, but could also mimic the physiological fate of insulin hence provide better 
glucose homeostasis [2]. However, in order to make oral delivery for insulin possible, 
two major obstacles must be overcome, namely, the lack of insulin stability in the 
gastrointestinal tract (GIT) and its poor intestinal permeability. A variety of strategies 
have been investigated to achieve this goal [3], however, so far the success in terms of 
insulin reaching the clinical development phase has been very limited [4]. 
 
The use of nanotechnologies to develop nanocarriers for oral insulin delivery is one of 
the strategies that has received significant attention. The basis for this development 
has been that nanocarriers can protect the peptides against the harsh gastric 
environment including enzymatic degradation, while controlling drug release and 
increasing their absorption in the small intestine [5]. Due to their high surface-to-
volume ratio, nanocarriers can significantly increase their cellular contact with the 
intestinal epithelium, thereby offering more chances for the drug to get across this 
epithelium [6][7]. Among the different nanosystems investigated for oral insulin 
delivery, it is important to highlight the pioneering work by Damgé et al., who 
showed that poly(alkylcyanoacrylate) nanocapsules were able to increase the oral 
absorption of insulin [8, 9]. Since that time until now, the biopolymers that have 
received the greatest deal of attention for oral insulin delivery are chitosan [10–12], 
PLGA [13–16] and polyanhydrides [17–19]. Our group has contributed to this field 
through the design of nanocarriers made of chitosan and lipids [20, 21], which were 
shown to enhance the absorption of insulin [22] and salmon calcitonin [23, 24]. More 
recently our group introduced the use of polyarginine (PArg) nanocapsules for oral 
peptide delivery, as they were found to decrease the trans-epithelial resistance and 
closely interact with the intestinal epithelium (Lollo et al., Submitted). This positive 




Protamine nanocarriers have also been designed in our group with the initial idea of 
using them for enhancing the transport of antigens across the nasal mucosa [25]. This 
development was based on the known capacity of protamine to enhance the 
penetration of proteins across cell membranes [26]. This study and others showing the 
possibility to enhance insulin absorption using protamine [27] portrayed protamine 
nanocapsules as a potential nanocarrier candidate for enhancing insulin absorption. In 
addition to this, it is worth to mention protamine has been approved by the FDA as 
one of the excipients in an insulin formulation [28].  
 
Based on these premises, the main aim of this work was to elucidate the potential of 
protamine-based nanocapsules as an effective oral drug delivery system for insulin 
(and other similar peptides). Nanocapsules consisting of an oily core containing 
sodium glycocholate as a penetration enhancer, and coated with a single protamine 
layer or a double PSA/protamine layers were prepared and characterized with respect 
to their toxicity profile and the capacity to induce immunological response in 
dendritic cells (DCs). Biodistribution studies were also carried out in healthy mice 
after oral administration to provide information about the specific interaction and 
retention time of the nanocarriers in the different regions of the gastrointestinal 
mucosa. Finally, in vivo studies were performed in healthy rats in order to elucidate 
the pharmacological activity of insulin loaded protamine based nanocapsules after 
subcutaneous (s.c.) injection and intra-duodenal administration.  
 
2. MATERIALS AND METHODS  
2.1. Materials  
Protamine sulfate of low molecular weight (5 kDa, pharma grade), was purchased 
from Yuki Gosei Kogyo, Ltd., (Japan). Insulin glulisine (Apidra®, Mw 5823 Da) was 
kindly provided by Sanofi S.A. (Paris, France). Polyoxyethylene 40 monostearate 
(PEGst-40, pharma grade), was purchased from CRODA Europe Ltd, (UK), whilst 
sodium glycocholate (SGC, pharma grade), was obtained from Dextra, (UK). 
Caprylic/capric triglyceride (Miglyol® 812, pharma grade) was purchased from 
Cremer, Oleo Division, (Witten). DiD (1,1'-dioctadecyl-3,3,3',3'-
tetramethylindodicarbocyanine perchlorate) was supplied by Invitrogen (Spain). 
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Organic solvents were of HPLC grade and all other products used were of reagent 
grade purity or higher.  
 
2.2. Preparation and characterization of insulin loaded protamine 
nanocapsules  
The surfactants, PEGst-40 (16 mg) and sodium glycocholate (5 mg) together with 
Miglyol® (62.5 µL) were dissolved in 3 mL ethanol to obtain a clear lipid phase. 
Acetone (1.95 ml) was added to this organic phase followed by insulin glulisine (1 mg, 
dissolved in 0.01M HCl, 0.05 ml). This mixture was immediately poured over 10 ml 
of an aqueous phase composed of 0.15 % w/v protamine. The organic solvents were 
removed by evaporation under vacuum (Rotavapor Heidolph, Germany), to obtain a 
nanocapsule formulation with a constant final volume of 5 ml. Finally, protamine 
nanocapsules were isolated by ultracentrifugation (Optima™ L-90K, Ultracentrifuge, 
Beckman Coulter, USA) at 30 000 rpm for 1h (at 15 ºC) and resuspended in ultrapure 
water to the desired NC concentration. Optionally, protamine NCs were post-coated 
with polysialic acid (PSA) to improve their stability properties against enzymatic 
degradation of the loaded peptide. For this purpose, a volume of 5 ml, isolated 
protamine nanocapsules (concentration 18.66 mg/ml) was incubated with a volume of 
1 ml solution of PSA at a concentration 3 mg/ml. The final protamine:PSA ratio was 
of 5:1 (w/w). The concentration of nanocapsules was determined taking into account 
all components in the formulation.  
 
The amount of insulin associated to the NCs was quantified by reverse phase liquid 
chromatography (HPLC). For this purpose, the nanocapsules were digested using a 
combination of acetonitrile and Triton™ X-100 (2:1, v/v) and the amount of insulin 
associated to the nanocapsules was measured by HPLC (Chapter 2, section 2.2). 
Particle size, polydispersity index (PDI) and zeta potential of the NCs were 
determined by Dynamic Light Scattering (DLS) using Malvern Zeta-Sizer (NanoZS, 
ZEN 3600, Malvern Instruments, Worcestershire, UK) fitted with a red laser light 
beam (λ=632.8 nm), at 25 °C after dilution with ultrapure water.  
 
The nanocapsules loaded with the fluorescent dye DiD, used for in vivo imaging 
studies, were prepared as described above. In this case, 0.02 ml of DiD stock solution 
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in ethanol (2.5 mg/ml) was added to the organic phase before nanocapsules 
preparation. The final concentration of DiD in the formulation was 10 μg/ml. To 
determine the encapsulation efficiency of DiD-loaded nanocapsules, the system was 
centrifuged (30 000 rpm, 1h, 15°C) to eliminate the non-encapsulated dye. After this 
step, the encapsulation efficiency and release were calculated indirectly by the 
difference between the total amount of DiD in the formulation and the free dye in the 
undernatant. These samples were analyzed a λ = 646 nm, by fluorescence 
spectroscopy (EnVision Multilabel Plate Reader, Perkin Elmer, Massachusetts, MA, 
USA). 
2.3. Cell culture: murine bone marrow-derived dendritic cells (BM-DCs) 
Tibias and femurs from C57BL/6 mice were removed using sterile techniques and 
bone marrow (BM) was flushed. Red blood cells were lysed with ammonium chloride. 
5x105 BM-cells were plated in a 6-well plate, in a final volume of 3 ml of medium 
supplemented with 20ng/mL mouse recombinant GM-CSF and 100ng/mL of IL-4. 
The cultures were maintained at 37°C in 5% CO2-humidified atmosphere. On day 3 of 
culture, floating cells were gently removed, and fresh medium with cytokines was 
replaced. Culture medium was RPMI 1640 (Euroclone) with 2mM L-glutamine, 
10mM HEPES, 20 μM 2-ME, 150U/mL streptomycin, 200U/mL penicillin, and 10% 
heat-inactivated FBS (Biochrom). 
 
On day 6 protamine nanocapsules and PSA-coated protamine nanocapsules were 
added at different concentrations (0, 0.5, 1, 2, 4, 8, 16, 25 mg/mL) to the DC culture 
and incubated for 1 day with the aim of studying their potential effects on DC 
viability and maturation. Cultures of DCs treated with 1μg/mL of lipopolysaccharide 
(LPS, Sigma) were used as a positive control for DC maturation and untreated cells 
were used as the negative control. On day 7, DCs were recovered from plates, stained 
with Trypan Blue (Sigma) for cell count or stained for flow cytometric analysis. Cell 
vitality was evaluated by using 7-AAD Viability Staining Solution (eBioscience) as 
outlined in the manufacturer’s instructions.  
 
For FACS analysis Fcγ receptors were blocked with IgG2b from HB-197 hybridoma 
(LGC PromoChem) for 10 min at 4°C and surface markers of interest were stained for 
20 min at 4°C with the following rat anti-mouse conjugated antibodies: anti-MHC-II 
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Ia-Ie FITC (BDBiosciences, 2G9 clone), anti-CD11c PE (BioLegend, N418 clone) 
and biotinylated anti-CD86 (eBioscience, GL1 clone). Then, samples were incubated 
with APC-conjugated streptavidin 1:1000 (BD Biosciences) for 30 min at 4°C. MHC-
II and CD86 were considered as markers for DC maturation and reported as mean 
fluorescence intensity (MFI) [29]. Data were acquired on a FACSCalibur flow 
cytometer (BD Biosciences) and then analyzed by using the softwares FlowJo v10 
(Tree Star, Inc.) and Excel (Microsoft). Final data were normalized on the non-treated 
sample (negative control). 
 
 
Figure 1: Schematic representation of experimental steps to determine the effects 
of protamine-based nanocapsules on DC viability and maturation.  
 
 
After a 24-h incubation time with NCs at two different concentrations (1 and 4 mg/ml) 
DCs culture media were harvested, centrifuged to remove cells and frozen at -80°C. 
The concentration of TNF-α, IL-1β, IL-12 p70, IL-10 and IFN-γ released by DCs was 
assessed by ELISA following eBioscience’s protocol. Briefly, flat-bottomed 96-well 
MaxiSorp plates (Nunc) were coated with capture antibody overnight at 4°C. Plates 
were rinsed three times with PBS-0.05% Tween-20 (Sigma) and blocked with assay 
diluent for 1 h at RT. After one wash, serially-diluted standards and samples were 
added and incubated 2 h at RT. Then, plates were rinsed three times and the 
biotinylated detection antibody was added and kept for 1 h at RT. Wells were washed 
three times, incubated with horse radish peroxidase-conjugated avidin for 30 min at 
RT, washed again and incubated with the chromogenic substrate TMB (eBioscience) 
until colour was fully developed but not yet saturated. Finally, the reaction was 
stopped with phosphoric acid 1 M. Measurements were made at a wavelength of 450 
nm subtracting the specific emission at 540 nm on a Victor microtiter plate reader 
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(Perkin Elmer). The concentration of each cytokine was calculated by applying the 
sample absorbance to the standard’s calibration curve.  
 
2.4. In vivo biodistribution study 
One week before the experiment BALB/c mice were placed on a low manganese diet 
to reduce auto-fluorescence. Moreover, abdominal fur was removed by depilation and 
the animals were fasted 24 h before administration of the formulation. Then, 0.2 ml of 
isolated DiD-labelled protamine NCs (NC concentration: 18.66 mg/mL and DiD 
concentration of 10 μg/mL), were administered to mice by oral gavage. In vivo 
biodistribution was performed by total body scanning at different time points (0, 1, 3, 
6, 24 h) on isoflurane/oxygen-anaesthetized animals, using the Optix MX2 scanner 
(ART Inc., Saint-Laurent, Canada). Bioluminescent images were acquired with the 
Optix OptiviewTM (ART Inc.) acquisition software.  
 
To further examine the interaction of NCs with the intestinal epithelium by confocal 
microscopy the intestines were dissected after treatment, washed with PBS and fixed 
in 4% PFA for 3 to 4 hours at 4 °C. Thereafter they were treated and stored at -80 °C 
for subsequent cryostate processing. Samples were then cut into and 10 µm thick 
cryoslices using a Leica CM 1850 CM cryostat and transferred to slides (SuperFrost 
Plus, Thermo Scientific). Confocal images were acquired with Leica TCS SP5 II 
microscope and further processed using ImageJ software. 
 
2.5. In vivo efficacy studies in non-diabetic rats  
All animal experiments were reviewed and approved by the ethics committee of the 
University of Santiago de Compostela (ref. 1500AE/12/FUN01/FIS02/CDG3) of 
according to the European and Spanish regulations for the use of animals in animal 
studies; performed therefore in compliance with the Directive 2010/63/EU of the 
European Parliament and Council. Male Sprague–Dawley rats (250–300 g) were 
obtained from the Central Animals House, University of Santiago de Compostela 
(Spain). They were kept under 12 h light/12 h dark cycles and were fed a standard 
laboratory rodent diet (Panlab A04, Panlab laboratories).  
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 2.5.1. Subcutaneous injection  
Male non-diabetic Sprague-Dawley rats (average weight 260 ± 12g) were fasted for 4 
h prior to the experiment, with free access to water. Protamine NCs were administered 
subcutaneously to the rats at an insulin dose of 1IU/kg. An equivalent dose of free 
insulin solution was administered to a different group of rats as a control. Blood 
samples were collected from the tail vein 30 min prior to the administration, to 
establish the baseline blood glucose level. At time points 30 min, 1, 1.5, 2, 3, 4, 5, 6, 7 
h after administration, the blood samples were collected to monitor the change in 
glucose levels following insulin-loaded protamine NCs or free insulin administration. 
The glucose levels were measured using a hand-held glucometer (GlucocardTM G+ 
meter, Arkray Factory, Japan). Administration and blood sampling were conducted 
without anaesthesia. 
 
2.5.2. Intra-intestinal administration study 
Male non-diabetic Sprague-Dawley rats (average weight 267 ± 11g), used for the 
intra-duodenal (ID) and intra-jejunal (IJ) administration underwent an operation 
where, a catheter was implanted surgically into the duodenum or jejunum of each rat 
with the proximal end of the cannula tunneled subcutaneously to exit at the back of 
the neck, and sutured. The rats were allowed to recover for 6 days and were 
monitored for recovery and weighed everyday. They were fasted for 4 hours before 
the experiment with free access to water. Formulations (insulin-loaded protamine 
nanocapsules and blank protamine nanocapsules) were injected intraduodenally at a 
constant volume of 300 μL at a dose of 50 IU/kg. Before administration (0h), blood 
samples were withdrawn and initial blood glucose levels were measured using a hand-
held glucometer (GlucocardTM G+ meter, Arkray Factory, Japan). During the 
experiment, 0.2 mL aliquots of blood were collected from the jugular vein at pre-
determined time intervals (2, 4, 6 and 8h) whilst glucose levels were measured every 
hour. The pharmacological availability (PA) of oral insulin loaded protamine-based 
NCs was determined based on a 100% availability of the control insulin solution 
administered subcutaneously to the healthy rats at a dose of 1 IU/kg. Plasma glucose 
levels were plotted against time, and the area above the curve (AAC) below the 100% 




Equation 6: PA% = 
𝐴𝐴𝐶 𝑜𝑟𝑎𝑙 𝑁𝐶÷𝐷𝑜𝑠𝑒
𝐴𝐴𝐶 𝑠𝑐 𝑖𝑛𝑠𝑢𝑙𝑖𝑛÷𝐷𝑜𝑠𝑒
×  100 
 
2.6. Statistical analysis 
Statistical analysis was performed using the GraphPad Prism 5 program (CA, USA). 
All analyses were performed using the Student's t-test and differences were 
considered statistically significant at *p<0.05, unless stated otherwise.  
 
3. Results and discussion  
The nanocarriers investigated in this work were NCs consisting of an oily core, which 
contained insulin and the penetration enhancer SGC. These oily cores were stabilized 
with the surfactant PEG-st and also with a polymer coating made of a single 
protamine layer or a double PSA/protamine layer. The selection of protamine was 
motivated by previous works, which indicated the capacity of arginine-rich peptides 
to enhance the absorption of peptides through different mucosa [27]. Furthermore, the 
inclusion of a lipid core was based on the recognized ability of lipids to protect 
macromolecules, as well as to enhance their intestinal permeability. The obtained 
protamine NCs, prepared by the solvent displacement technique, had a size below 400 
nm, and a low positive or negative zeta potential, for protamine or PSA/protamine 
NCs, respectively. This almost neutral charge was attributed to the presence of PEG-
st around the oily nanodroplets (Table 1). The association of insulin resulted in a size 
increase whilst there were no significant variations after the labelling of the 
nanocapsules with DiD. 
 
Table 1: Physicochemical properties, insulin association efficiency (AE) and 
loading capacity (LC) of the nanoemulsion (NE), Protamine nanocapsules, PSA-
Protamine nanocapsules and DiD-labelled protamine nanocapsules. (Mean ± SD, n=3). 
Formulation Size ± SD 
(nm) 
PDI Z-pot ± SD 
(mV) 




Protamine NCs Blank  264 ± 18 0.2 +8 ± 2 - - 
Insulin loaded  391 ± 35 0.3 +5 ± 2 65 ± 9 1.0 
PSA-Protamine NCs Blank  215 ± 12 0.2 -6 ± 3 - - 
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Insulin loaded 366 ± 27 0.2 -3 ± 4 52 ± 11 0.8 
DiD-Protamine NCs Blank  302 ± 21 0.2 +6 ± 3 - - 
 
3.2. In vitro toxicity and immunological evaluation 
3.2.1. Toxicity of nanocarriers in murine bone marrow-derived dendritic cells 
(BM-DCs) 
The therapeutic use of peptide and protein drugs, especially when repeated 
administrations over prolonged periods are required, is often compromised by the 
possibility of immunotoxicity through the activation of dendritic cells (DCs) [30]. 
Therapeutics should not induce DC mortality or maturation and therefore we found it 
crucial to evaluate the interaction of protamine nanocapsules with immune cells 
(DCs). The results shown in Figure 2, panel A indicate that protamine and 
PSA/protamine NCs are non-toxic to DCs at concentrations up to 16 mg/mL (insulin 
concentration, 0.23 mg/mL). However, while protamine nanocapsules did not activate 
DC maturation, PSA/protamine/ nanocapsules did. This is shown in (Figure 2, panel 
B) which depicts the percentage of activated DCs (those DCs that expressed 
maturation markers).  
 
Under conditions of infection or inflammation, DCs encounter activating signals that 
may mature and activate DCs simultaneously. DC activators include pro-
inflammatory cytokines and bacterial or viral products such as LPS, CpG motifs, and 
double-stranded RNA. They induce the maturation and activation of DCs, allowing 
DCs to present antigens to the immune system [31]. Activated DCs can be 
distinguished from resting and immature DCs by the expression of higher levels of 
MHC class II and the expression of co-stimulatory molecules such as CD80 and 
CD86 or for the production of cytokines such as interleukin (IL)-12.  
 
The effect of protamine-based nanocapsules on DC maturation was further evaluated 
by measuring the expression of two DC markers; MHC-II and CD86. The results 
shown in Figure 2, panel C, D, E indicate that 24h after incubation with protamine 
nanocapsules, DCs expressed relatively low levels of surface MHC-II proteins and 
co-stimulatory molecule CD86 compared to PSA-coated protamine nanocapsules. The 
comparison between blank protamine nanocapsules (white bars) with insulin-loaded 
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protamine nanocapsules (lighter grey bars) shows that the presence of insulin inside 
nanocapsules had no additional effects on DC maturation. However, the levels were 
significantly higher for the nanocapsules containing PSA, these values being 
remarkable even at low concentrations. 
 
 
Figure 2: Effects of protamine and polysialic acid (PSA/protamine NCs on DC 
vitality (A) and maturation (B). Vitality of cell cultures was evaluated by Trypan blue 
staining. Percentages of matured DCs obtained (alive) and their MFI (mean 
fluorescence intensity) were determined by FACS analysis on DCs (C,D,E). MHC-II 
and CD86 are used as markers of DC maturation (mean ± SE, n=3).  
 
 
In agreement with the previous data, the analysis by ELISA shows that the presence 
of protamine nanocapsules in the cultures did not induce the release of the 
inflammatory cytokines TNF-α, IL-1β, IL-12 (p70) and IL-10 in the culture medium 
compared with negative control (Figure 3). However, blank and insulin-loaded-PSA-
protamine nanocapsules induced a higher cytokine release, which was comparable to 
the positive control in the case of TNF-α and IL-12 (Figure 3). Altogether, these 
observations show that the PSA-coating can stimulate proliferation and maturation of 
in vitro-differentiated murine DCs. These data are in contradiction with the fact that 
polysialylation has been used to abrogate both the immunogenicity and antigenicity of 
injected peptides and proteins whilst preventing proteolytic degradation and 
prolonging their half lives [17]. However, some concerns remain pertaining to the 
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utility of PSA coatings for oral peptide delivery, since its binding to the surface of the 
carrier system may alter the immunological response. It is also worth mentioning that 
all excipients used in this formulation are pharmaceutical grade, except for the PSA 
polymer. Hence, one of the next steps include more studies to understand if these 
effects depend on PSA molecule per se or on some contaminants remaining from its 
synthesis/association to protamine nanocapsules.  
 
 
Figure 3: Release of different inflammatory cytokines evaluated in the 
supernatant of DC cultures either in presence or absence of protamine and polysialic 
acid/protamine nanocapsules at two different concentrations assessed by ELISA 
(mean ± SE, n=3). 
 
Overall, this study shows that protamine-based nanocapsules are non-toxic to DCs, 
and that PSA coated NCs induce DC maturation, which may imply that this 
formulation could cause inflammation of the epithelium. It would be interesting to 
investigate in vivo if this inflammation occurs and if it causes any damage or irritation 
to the intestinal epithelial membrane.  
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3.3. In vivo studies  
3.3.1. Biodistribution of protamine nanocapsules  
The total body scanning following oral administration discloses that the DiD-labelled 
protamine nanocapsules produced a signal that remained confined mainly to the 
stomach and the small intestine, with an emission peak at one hour post-
administration, and a decrease at 24 h after administration (Figure 4A). The 
histogram on the left shows the mean of total photons emitted from regions of interest 
(ROI) around the peritoneal cavity (Figure 4B). Consequently, the number of photons 
was high after the first hour of administration and gradually decreased over time. The 
prolonged retention of the protamine nanocapsules could be related to their potential 
interaction with the GI mucosa, which in turn increases the prospects for these 
nanocapsules to improve permeability of the loaded peptide across the mucosa. 
Similar results were reported for polyarginine nanocapsules (Lollo et al., submitted). 
 
 
Figure 4: Representative fluorescence images of mice at 1h, 3h, 6h and 24h 
following oral administration of DiD-labelled protamine NCs (A), and photons 
emitted from regions of interest (ROI) around the peritoneal cavity (B), Mean n=3 ± 
SD.  
 
A more in depth analysis of the interaction of the fluorescent NCs in the intestinal 
mucosa was performed by dissecting the intestines of mice at 1 h after oral 
administration of the NCs. As shown in Figure 4 C, at this time point (after 1h) 
protamine NCs appear to be localized in the mucus layer covering the intestinal villi. 
This effect may imply that protamine NCs do not diffuse through the mucus. This 
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interpretation would disagree with the results observed in the Caco-2/HT29-MTX co-
culture (mucus-secreting cells) model. Nevertheless, this observation was made only 
one hour after administration and, hence further studies are needed to have a more 




Figure 4C: Confocal images showing the interaction of (A) free DiD (control) and (B) 
DiD-protamine NCs with mouse intestinal tissue (duodenum) 1h after oral 
administration. (20X magnification with air objectives).  
 
3.3.2. In vivo biological activity of insulin loaded protamine nanocapsules  
To determine the bioactivity of the encapsulated insulin, insulin-loaded protamine 
nanocapsules were injected subcutaneously into fasted healthy rats. The insulin 
bioactivity was measured by monitoring blood glucose levels and comparing the 
response to an equivalent dose of free insulin solution (1 IU/Kg). As shown in Figure 
5, after the s.c. injection of the insulin solution, the glucose level rapidly decreased by 
40% at 0.5 h and this effect lasted for 2 h, followed by the recovery of the glucose 
level back to ≈100%. On the contrary, the administration of insulin-loaded protamine 
DiD 









nanocapsules led to a moderate and constant reduction of the glucose level, from 10% 
up to 30% reduction within the first hour and this effect was maintained for 3h. The 
relative bioavailability of the insulin-loaded protamine NCs was found to be 78.9±3 
when compared to the free insulin control (*p<0.05) (Table 2), suggesting that not all 
the insulin is released from the NCs within the first 8 hours.  
 
From this study it was evident that the insulin maintained its bioactivity and that 
encapsulating insulin in protamine nanocapsules generated a unique profile compared 
to the free insulin i.e. a delayed and more controlled release of the insulin leading to a 
moderate response, which lasts for a longer duration than that of the free insulin 
(control). These results correlate with the observations we previously made in our in 
vitro release studies in simulated intestinal media (Chapter 2), where insulin release 
gradually increases up to ≈50% at 1h which is then followed by a constant and 
controlled release up to ≈70% after 6h. Hence, it is appropriate to assert that the 
method employed for the preparation of insulin loaded protamine nanocapsules 
preserves insulin and that this nanosystem is suitable for the delivery of peptides as it 
controls the release and does not compromise the bioactivity.  
 
 
Figure 5: Standardized hypoglycemic effect following subcutaneous injection of 
insulin loaded protamine nanocapsules and free insulin saline solution (control) at 
1IU/kg to healthy rats. Expressed in blood glucose % of initial. (Mean ± SEM, n=13).  
 






















3.3.4. In vivo intra-intestinal administration of insulin loaded protamine 
nanocapsules 
Based on these favourable preliminary observations, insulin loaded nanocapsules 
were administered intra-duodenally and intra-jejunally to non-diabetic rats. Intra-
duodenal administration of insulin-loaded protamine nanocapsules (50 IU/kg), led to a 
moderate reduction of glucose levels (≈20%) after 1 h, which was maintained 
throughout the duration of the experiment (8 h). This effect was significantly different 
to the one observed for the blank protamine nanocapsules (placebo control) and the 
free insulin (control), where no response was observed at all (Figure 6). As shown in 
Table 2, the relative pharmacological bioavailability (compared with that of free 
insulin administered subcutaneously) of insulin was 1.5% and 1% when administered 
intraduodenally in the form of protamine and PSA-coated protamine NCs, 
respectively. However, no response was observed for free insulin solution after 
intraduodenal administration. These results suggested that although a low 
bioavailability is observed, the protamine-based NCs still protect a fraction of insulin 
from degradation and enhance its intestinal absorption as compared to free insulin. No 
significant difference (p>0.05) was observed at each time point between intra-
duodenal and intra-jejunal administration (results not shown).  
 
 
Figure 6: Standardized hypoglycemic effect following intra-duodenal (ID) 
administration of insulin loaded protamine (n=11) and PSA-coated NCs (n=15), at 
50IU/kg, blank protamine NCs (placebo, n=12), and free insulin saline solution (n=16) 



















Insulin Protamine NCs 
Insulin PSA-Protamine NCs





at 50IU/kg to healthy rats. Expressed as blood glucose % of initial. (Mean ± SEM, 
significant difference ***p < 0.05 compared to placebo control).  
 
Table 2: Parameters for plasma glucose levels and relative pharmacological 
bioavailability for protamine NCs (n=11) and PSA-coated NCs (n=15), following 
intraduodenal administration at 50IU/kg, compared to free insulin (n=13) by S.C at 1 
IU/kg. Data represents the mean ± SE, *p<0.05 significant difference between 




Cmin (%) Tmin (h) AAC PA% 
Insulin S.C. 1 59 ± 3 0.5 101.1 ± 12 - 
Protamine S.C. 1 75 ± 5 2 *79.8 ± 6 78.9 ± 3 
Protamine NCs 
I.D. 
50 80 ± 3 3 83.3 ± 7 1.65 ± 0.5 
PSA-Protamine 
NCs I.D 
50 85 ± 6 1.5 51.3 ± 9 1.01 ± 0.8 
Cmin, minimum plasma glucose concentration (% of initial); Tmin, time to Cmin; 
AAC, area above the plasma glucose levels time curves; PA%, relative 




The glycaemic response in healthy rats observed in this study is relatively low 
(modest) when compared to other reported glycaemic responses in diabetic rats [12]. 
This difference is due to physiological differences of the two models i.e. the 
autoregulation process triggered by exogenous insulin in the blood supresses the 
endogenous secretion of insulin by β-cells in healthy rats whereas this autoregulation 
phenomenon does not exist in diabetic rats [33]. However, in this study we preferred 
to work with non-diabetic rats in order to reduce the variability in the data associated 
to the induction of diabetes using streptozotocin (STZ), which can lead to varying 
degrees of hyperglycaemia amongst rats due to beta cell deficiency/failure. Moreover, 
because of the beta cell deficiency the animals become prone to hypoglycaemia and 
very sensitive to insulin. Which implies that even a minor amount of insulin may 
produce a drastic reduction of glucose. Hence, we hypothesized that even a minor 
response in healthy rats would be much more admissible in terms of clinical relevance 
as compared to a diabetic rat model. Not surprising, low responses and even no 
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response at all have been reported for healthy rats following intra-gastric 
administration of insulin loaded nanoparticles [33, 34]. Nonetheless, some authors 
have reported good responses in non-diabetic rats. On this regard some authors found 
that a glycaemic response could only be observed when the healthy rats were given a 
glucose challenge, confirming that the insulin loaded in NCs is indeed absorbed into 
the blood circulation but the effect could be suppressed by autoregulation [8, 33]. 
 
Other authors using the same model (non-diabetic rats) have some differences in their 
experimental protocols compared to ours; for instance, they administer the insulin 
carriers intra-ileally [35]. The ileum is associated with less enzymatic activity and a 
high amount of M-cells when compared to the duodenum and jejunum hence higher 
absorption occurs in this region. Moreover, in most cases, we found that the rats were 
subjected to longer fasting periods e.g. 24 to 48 h [15, 34, 36, 37]  
 
Although, these differences in the experimental procedures used could justify the 
differences in the data reported we also had a number of hypothesis that could explain 
the limited in vivo performance of the NCs, namely (i) The positive in vitro stability 
and insulin release data of the NCs might be slightly different in the in vivo situation; 
(ii) The limited transport of the NCs across the intestinal epithelium. In fact, even 
though fluorescence associated to the nanocapsules was found to cross the 
monolayers (Caco-2 and Caco-2/Raji), this transport was not particularly high and the 
amount of insulin transported remains to be elucidated; (iii) The formulation 
administered in vivo exhibited a high viscosity that could impede its miscibility with 
the intestinal fluids and hampered the adequate diffusion of the NCs across the mucus. 
  
Finally, we should emphasize the fact that the experimental protocol and animal 
model used in this study is not the one typically used to assess the efficacy of insulin 
nano-formulations. Determining the concentration of insulin available in the blood, to 
ascertain if the glucose levels are indeed a reflection of the amount of insulin 
absorbed into the blood circulation is also one of the next steps of this work and it is 
expected to shed light on the absorption of insulin. Ultimately, the final aim is that the 
formulation will be incorporated into a final dosage form such as protective 
microbeads or enteric-coated capsules to improve the performance of the system in 






In this work protamine nanocapsules were evaluated for their potential as nanocarriers 
for oral peptide delivery. Protamine nanocapsules did not induce maturation of DCs 
implying that the oral administration of this formulation would not induce an 
undesirable immunological response. The results obtained following subcutaneous 
injection of insulin-loaded protamine nanocapsules in healthy rats confirmed that the 
bioactivity of the insulin is preserved. On the other hand, following intra-jejunal and 
intra-duodenal administration of the formulation, a moderate reduction of the glucose 
levels was observed and this effect was maintained for at least 8 h. While these data 
provide a preliminary efficacy proof of concept of oral insulin delivery using 
protamine nanocapsules, they also raise concerns about the most appropriate in vitro 
and in vivo model and protocols to be adopted in order to deduce meaningful data that 
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The oral modality of administration is the most desirable route of delivery, especially 
in the case of drugs used for chronic treatments, i.e. diabetes. Unfortunately, this 
modality of administration has phenomenal barriers, which hamper the absorption of 
peptide from the GIT. The use of peptide nanocarriers that can prevent enzymatic 
degradation, control the release and favour the interaction of the peptide with the 
small intestine is nowadays considered a technological strategy worthwhile to explore 
[1].  
 
In this work protamine-based NCs were rationally developed for the oral delivery of 
peptides, using one of the most challenging peptides, insulin, as a model drug. The 
natural polyaminoacid, protamine was selected as the corona of the NCs because of 
its ability to increase cellular internalization and its mucointeraction property which 
can enhance mucosal delivery of peptides [2]. The inner lipidic core was mainly 
composed of Miglyol, a medium chain caprylic capric tryglyceride, well known for 
it ś penetration enhancing property and for protecting peptides from degradation [3, 
4]. Whilst, sodium glychocolate is a remarkable bile acid salt surfactant that prevents 
proteolytic degradation of peptides and promotes their absorption [5]. Another 
surfactant molecule, PEGst-40 (PEG, 2 KDa), was added to be located at the oil/water 
interphase, as it was found essential for the colloidal stability of the nanocarrier and 
was supposed to improve its mucodiffusion properties [6]. Optionally, the protamine 
NCs were provided with an additional coating layer of polysialic acid (PSA), a low 
molecular weight polysaccharide that was intended to form a shield around the NCs to 













Physicochemical and pharmaceutical characterization of insulin-loaded 
nanocapsules 
Using these biomaterials, protamine NCs were prepared using the solvent 
displacement method, a simple and fast method that is easy to scale-up [8]. PSA was 
added as an external coating layer through ionic interaction with protamine and its 
presence around the shell was confirmed by the charge inversion of the NCs. The NCs 
obtained were characterized according to size, zeta potential, and insulin loading 
capacity (Table 1). The nanometric size (<500 nm) and nearly neutral surface charge 
of the NCs was found to be adequate for the oral delivery of insulin, since these 
properties could promote their penetration across the intestinal mucosa. Moreover, the 
introduction of the protamine shell around led to formulations with an acceptable 
insulin association efficiency (AE%), a fact that underlines the importance of the 
polymeric core in preventing the diffusion of insulin out of the nanosystem into the 








Table1: Physicochemical properties, insulin association efficiency (AE%) and 
loading capacity (LC%), including stability properties of protamine-based NCs as 














NE 345 ± 13 -21 ± 1 35 ± 11 No stable  - - 
Protamine NCs 382 ± 69 +6 ± 3 62 ± 16 
Stable in 
FaSSIF/FeSSIF  
70 ± 1% 72 ± 3 
PSA-Protamine 
NCs 
301 ± 84 -4 ± 1 51 ± 9 
Stable in 
FaSSIF/FeSSIF 
60 ± 2%  60 ± 4 
 
After optimizing the physicochemical properties of the protamine and PSA-coated 
protamine NCs it was critical to assess their stability and insulin release profile in 
different simulated intestinal media; SIF, FaSSIF-V2 and FeSSIF-V2. The studies 
revealed that the NCs are stable in these media, especially when they were provided 
with an extra coating layer of PSA. During this 6 h-incubation time in the FaSSIF 
medium, comparable to the fasted state in vivo, a biphasic insulin release pattern was 
observed (Figure 2). The peptide was gradually released within the first hour, 
followed by a constant release rate up to ≈70% of the encapsulated insulin at (6h) for 
both formulations. The stability and controlled release profile of the formulations 
were attributed to the core-shell structure of the NCs, where the presence of the 
polymeric shell provides a steric protection and prevents a rapid diffusion of insulin to 





Figure 2: In vitro release profiles of insulin from protamine NCs and PSA-
protamine NCs incubated in FaSSIF-V2 (B), (mean ± SD, n=3, *p<0.05).  
 
 
Proteolysis studies were then performed to elucidate the ability of the formulations to 
protect the associated insulin from enzymatic degradation. For this, insulin-loaded 
protamine NCs and PSA-protamine NCs and free insulin solution (control) were 
incubated in simulated intestinal fluid containing enzymes (FeSSIF-V2). It was 
evident that the presence of the extra coating layer of PSA reinforced the stability of 
the NCs (Figure 3). Moreover, the bile salt surfactant, SGC well known for inhibiting 
protease enzyme activity, also provided improved stability to the nanosystems, and 
significantly contributed towards preserving insulin from enzymatic degradation [11]. 
In contrast, for free insulin, a drastically rapid decrease of the insulin amount was 
observed, with approximately all the insulin degraded in the first 15 minutes. This 
observation highlighted the importance of encapsulating insulin as a stability 



























Figure 3: Stability profiles of the associated insulin after incubation of NCs in 
FeSSIF-V2 containing pancreatic enzymes (mean ± SD, n=3), significant difference 
(p<0.05) for PSA-PrNCs+SGC compared to *PSA-PrNCs+SC and #PrNC without 
cholate/free insulin. 
 
Mechanism of interaction of the nanocapsules with the Caco-2 monolayers and 
isolated human intestinal tissue 
Both formulations were nontoxic to Caco-2 cells at a NC concentration range of 0.5 to 
8 mg/ml for 2h and 6h incubation time. This confirmed the safety profile of the 
nanosystems for oral administration. Subsequently, the formulations were evaluated 
for their ability to promote paracellular transport by monitoring the TEER values of 
the cell cultures, which correlates to the modulation of the tight junctions (TJ). TEER 
values of the Caco-2 cell monolayers were not modified after 1 and 2 h-exposure to 
the NCs, however a significant reduction was only observed after 4 h incubation time. 
This behavior is in relation with one reported for other polycations, such as chitosan 
and polyarginine[12]. In the case of chitosan, it has been postulated that if interfres 
with the calcium transfer, thereby disrupting the TJs [14]. In the case of polyarginine, 
it has been described that the TJs opening is due to their transient internalization in 
cell–cell junctions via clathrin-mediated endocytosis [15]. In the case of protamine, 
although the mechanism by which it opens TJs has not been fully elucidated, it is 
presumed that it disrupts the microfilaments of the TJ proteins [13]. Importantly, the 
results obtained in this study indicate that the initial TEER was completely recovered 































feature since complete disruption of the TJs is undesirable as this may lead to the 
entry of pathogens and toxins.  
 
To further elucidate the mechanism through which protamine and PSA/protamine 
NCs might facilitate the absorption of peptide drugs, transport studies of the 
fluorescent nanocapsules (TAMRA covalently linked to the protamine shell) were 
performed in the presence of inhibitors. The results in terms of amount of 
fluorescence internalized by the cells suggested that nanocapsules might have been 
internalized into the enterocytes using both, caveolae (predominant) and clathrin 
pathways (Figure 4). Caveolae are extremely abundant at the surface of epithelial 
cells have been reported to be the predominant entry for particles above 200 nm, 
although multiple pathways are normally involved in this internalization process[18, 
19]. This mechanism was supposed to be favoured by the ability of protamine to 
enhance membrane translocation through its high content of arginines, which carry 
the guanidine group essential for cell membrane translocation [20].  
 
 
Figure 4: Comparison of transport under clathrin and caveolae inhibitors, 
(chlorpromazine and Filipin III respectively), A-Intracellular uptake of NCs and B-
Transport in Caco-2 and FAE monolayers after 2h incubation with inhibitors. 
Untreated cells used as controls and fluorescence (%) represents the amount of 
fluorescence transported to the basolateral side in comparison to that in the basolateral 
























































Since enterocytes (90%) and goblet cells (10%) represent the two most abundant cells 
in the intestinal epithelium, the co-culture of Caco-2 cells and mucus-producing 
goblet cells HT29-MTX was used as a transport model incorporating the mucus 
barrier. Caco-2:HT29-MTX cells seeded at a 3:1 proportion exhibited a homogenous 
mucus layer, which was found not affect the permeation enhancing property of the 
nanocarriers. The absence of a visible effect of the mucus on the interaction and 
transport of the fluorescence nanocapsules (Figure 5) was attributed to their neutral 
surface charge which was expected to facilitate the muco-penetration of eth 
nanocapsules [21].  
 
Figure 5: Caco-2 monolayer (A) and Caco-2/HT29-MTX (B) stained with 
Alcian blue, demonstrating the presence of mucus (magnification 400x) and Transport 
of coated and uncoated protamine NCs in Caco-2 and Caco-2/HT29-MTX 
monolayers after 2h incubation (C) (mean ± SD, n=3, N=3). 
 
The permeability enhancing property of the NCs was further explored in human 
intestinal tissue. Confocal images showed that TAMRA-labelled protamine and PSA-
protamine NCs interact with the intestinal epithelium, as fluorescence could be 
visualized within the epithelia (Figure 6). Most importantly, no toxic effects were 
found on the intestinal tissues after being in contact with both formulations (5 mg/ml 






















Figure 6: Confocal images showing the transport of Protamine NCs and PSA-
Protamine NCs in human intestinal epithelial tissue. 
 
Immunotoxicity of the nanocapsules 
Based on the positive response observed in the Caco-2 monolayers and in the isolated 
human tissue further in vitro immune-toxicity were performed in murine bone 
marrow-derived dendritic cells (BM-DCs). The results showed that both formulations 
are non-toxic to DCs. However, the presence of PSA showed the tendency to induce 
DC maturation, which may imply that this formulation could cause inflammation of 
the GIT. Surprisingly, this data contradict the fact that PSA has been reported to 
alleviate both the immunogenicity and antigenicity of injected peptides and proteins 
[22]. Moreover, this LPS effect which could be associated with the presence of PSA 
in the NCs might be overestimated in this in vitro cell model in comparison to the in 
vivo situation, hence correlating this data to in vivo data would shed more light. This 
is an important aspect in the development of therapeutics for the treatment of chronic 
diseases as it is crucial to ascertain that their repeated use would not provoke 
inflammatory diseases by activating dendritic cells.  
 
In vivo performance of the nanocapsules   
The in vitro results clearly underlined the value of the rational design. Indeed the 
developed nanocapsule formulations fulfilled a number of criteria, as indicated in the 
target product profile (Table 1). Based on these promising properties, we studied the 
in vivo interaction of the nanocapsules with the intestinal epithelium of mice using 
IVIS and confocal microscopy of intestine section. The results showed that the 
nanocapsules adhere to the intestinal epithelium, although no clear evidence of their 




Thereafter, in vivo efficacy experiments were performed in normal rats in order to 
assess the glucose response after insulin administration. In the first set of experiments. 
the bioactivity of the insulin-loaded NCs was compared to that of free insulin (control) 
following subcutaneous administration (Insulin dose: 1 IU/kg). The results showed 
that insulin maintained it's bioactivity after its association into both PSA coated and 
non-coated protamine NCs. However, the absorption rate was different from the NCs 
formulations as compared to the one of the insulin in solution. Indeed, because of 
their controlled release properties, the NCs led to a moderate response within the first 
hour, which gradually increased and lasted for a longer duration than that of the free 
insulin [23]. These results correlated with the observations made previously on in 
vitro release studies in simulated intestinal media (FaSSIF-v2), where 50% of the 
encapsulated insulin was only released after an hour, followed by a controlled 
(constant) release over a period of 6h. These data were also corroborated by circular 
dichroism (CD) studies, which confirmed that no conformational change occurred to 
the insulin structure after loading in NCs [24].  
 
Finally, the in vivo efficacy of the formulations was evaluated by intraduodenal and 
intrajejunal administration (50 IU/kg), to non-diabetic rats after 4 h fasting [25–27]. 
In both cases, a moderate decrease of blood glucose levels (20% reduction) was 
observed and this effect was maintained for the duration of the study. The modest 
response observed in this study (Figure 7), in comparison to reported studies in 
literature was attributed to several reasons including the type of animal model used 
(non-diabetic rats), the short fasting time (4 h) and the viscosity of the formulation 
which may hamper the miscibility with intestinal fluids and absorption of the NCs [23, 
28]. Most importantly it appears that most in vivo reports are based on diabetic rats 
and in these studies drastic glucose reduction is observed. Indeed this phenomenon is 
to be expected from a physiological point of view as the pancreatic islets is defective 
in this model and the blood insulin levels rise gradually together with the input of 
extraneous insulin due to lack of self–modulation function which is present in non-
diabetic rats. [29]. However, recently there has been a concern on the high variability 
of in vivo data and, in our study, we presumed that using non-diabetic rats would 





Figure 7: Standardized hypoglycemic effect following intra-duodenal 
administration of insulin loaded protamine NCs (50IU/kg, n=11), PSA-coated 
protamine NCs (50IU/kg, n=15), blank protamine NCs (placebo) (n=12) at the same 
NC concentration and insulin saline solution (50IU/kg, intraduodenally n=16 and 
subcutaneously 1IU/kg) in non-diabetic rats. (Mean ± SEM, *p < 0.05 significant 
difference for protamine NCs and PSA/Protamine NCs compared to the placebo 
control.  
 
In summary, this work highlights the flexibility of the nanocapsules delivery platform 
in terms of accommodating a number of ingredients based on a rational design. The 
results obtained also underline the relative value of the in vitro studies in terms of 
predicting the in vivo performance of oral peptide nanoformulations. The 
nanocapsules developed in this study meet several prerequisites for the oral delivery 
of peptides, such as their nanometric size, a neutral surface charge, an adequate 
colloidal stability and the capacity to control the release and prevent the degradation 
of insulin. What remains unclear is whether or not the apparent capacity of the 
nanocapsules to enter the intestinal mucosa can be extrapolated from in vitro to in 
vivo. Maybe an adequate final dosage form could help the nanocapsules to accomplish 
their goal. In the meantime, the effective adhesion or internalization of the 
nanocapsules and the intracellular release of insulin remains to be addressed. 
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This thesis project was focused on the design and development of an oily-core shell 
type, protamine-based nanosystem for the efficient oral delivery of insulin (and other 
similar macromolecules). The results obtained from the experimental work led to the 
following conclusions:  
 
1. Nanocapsules (NCs) with a single protamine or double protamine and 
polysialic (PSA) layer were successfully prepared using a simple solvent 
displacement method. These nanocapsules had the capacity to encapsulate insulin (62 
and 51 %), with a nanometric size (382 and 301 nm) for protamine and 
PSA/protamine NCs, respectively and were both characterised with spherical in shape 
a surface charge close to neutral.  
 
2. Protamine and PSA/protamine NCs were stable in simulated intestinal media 
and protected the loaded insulin from enzymatic degradation. The extra layer of PSA 
and the presence of the bile salt surfactant sodium glycocholate (SGC), reinforced the 
stability of nanosystem and minimized the enzymatic degradation of the loaded 
insulin.  
 
3. In vitro cell studies carried out in different cell culture models simulating the 
intestinal epithelium, showed that protamine and PSA/protamine NCs exhibit a very 
low toxicity. Moreover, these studies indicated that both types of NCs interact with 
the monolayers involving two different mechanisms, which maybe responsible for 
either a transcellular or paracellular transport of the associated peptide.  
 
4. In vivo studies performed in non-diabetic rats confirmed that the NCs are able 
to preserve the loaded insulin, maintain its bioactivity and minimizing its degradation 
by enzymes. Both formulations were able to promote the absorption of insulin and 









5. The nanocarriers developed in this study were converted into powder (freeze-dried 
form), stable during storage at room temperature (25 °C) and preserves the associated 
insulin for at least 6 months.  
 
Overall, the work presented here portrays protamine-based NCs as a potential 
nanocarrier candidate for oral peptide delivery. The extensive in vitro studies on these 
NCs highlights their stability in intestinal fluids and even during storage as an 
important property for the use of this nanocarrier in oral peptide delivery. Moreover, 
it was evident that the NCs could be modulated and adapted to improve the stability 
and peptide-release profile. The safety profile of the NCs both, in vitro and in human 
intestinal tissue, together with the penetration enhancing effect are also interesting 
properties for this nanocarrier. Although the in vivo efficacy studies showed a modest 
glucose response, the data presented here are still encouraging that adjustments in the 















Development and characterization of solvent-free protamine 
















Local delivery of drugs and biopharmaceuticals for the treatment of inflammatory 
bowel diseases remains a challenge. Innovative nanomedicines with appropriate 
properties raise the possibility of efficient drug targeting. Hence, the overall aim of 
this study was to develop and characterize a protamine-based nanosystem for topical 
delivery of therapeutics to inflamed intestinal mucosa. 
Protamine NCs with a new composition were prepared by the self-emulsifying 
process without the use of any organic solvent. A model lipophilic anti-inflammatory 
peptide, cyclosporin A, was encapsulated in the oily core, which was then post-coated 
with the protamine polymer. The loaded formulation was isolated from the free drug 
by gel filtration and the entrapment efficiency was determined using reverse phase 
high-performance liquid chromatography. Positively charged protamine NCs of 
approximately 160-180 nm with a high entrapment efficiency (95%) and drug loading 
capacity (5%), exhibiting a good stability in simulated intestinal media were obtained. 
The results demonstrated herein indicate the feasibility of the developed nanosystem 
















The encapsulation of highly hydrophobic compounds in polymeric lipid NCs, 
constituted by an oily core and a polymeric shell, improves their solubility, protects 
them against the harsh gastrointestinal (GIT) environment and enzymatic degradation, 
while enhancing permeability across the biological membranes [1]. Moreover, 
nanomedicines administered by the oral route are expected to accumulate in the 
inflamed mucosal tissues, thereby allowing specific drug targeting. Hence, 
nanocarriers are useful tools for the formulation of therapeutics intended for 
transmucosal modalities of administration, for both local and systemic effect [2]. 
Polymeric structures, depending on their surface composition and charge, are believed 
to adhere to the negatively charged mucosal compartments or positively charged 
inflammatory proteins. The nanometric size may, in turn, promote the penetration and 
impact their epithelial uptake as well as the uptake by macrophages or dendritic cells 
[3]. For example, Beloqui et al., proposed nanostructured lipid carriers as a targeted 
drug delivery system for the treatment of colitis [4]. Negatively charged budesonide-
loaded particles of 200 nm reduced the secretion of TNF-α by activated macrophages 
in vitro and prolonged residence time in the colon, decreasing the levels of pro-
inflammatory cytokines and TNF-α when tested in vivo in a murine model of dextran 
sulfate-induced colitis. Another parallelly developed prototype coated with cationic 
trimethylchitosan (TMC) showed enhanced mucoadhesion and the ability to open the 
tight junctions and thus increase the paracellular permeability in inflamed Caco-2 
monolayers. The main benefits of local therapy include the reduction of systemic 
adverse effects and increased drug concentration at the site of action. However, in 
order to be able to reach the intestinal mucosa, the nanocarriers must withstand harsh 
conditions of the gastrointestinal tract and enzymatic digestion of intestinal excretes 
[5]. 
Protamine is a well-known cationic polypeptide with an arginine rich character and 
cell-penetrating properties that may have the potential for use in the design of systems 
for transporting drugs to the mucous membrane surfaces [6]. Hence, the main 
objective of this study was to develop and characterize protamine-coated lipid-core 







nanocarriers to serve as a platform for topical delivery of pharmaceutical compounds 
to inflamed intestinal mucosa. 
2. Materials and methods 
2.1. Materials 
Glycerol monolinoleate (MaisineTM 35-1) used in this work was a kind gift from 
Gattefossé (France). Polysorbate 80 (Tween® 80), sodium deoxycholate (SDC), 
pancreatin 4 x USP and trehalose were purchased from Sigma-Aldrich (Spain). 
Polyoxyethylene 40 monostearate (PEGst-40) (Simulsol® M52) was obtained from 
Seppic (France). Protamine sulfate was purchased from Yuki Gosei Kogyo (Japan). 
Cyclosporin A was purchased from Fagron Iberica (Spain). All other products and 
chemicals used during the experiments and the chromatographic analysis were of high 
purity or reagent grade.  
 
2.2. Preparation of protamine NCs  
The formulation components were selected rationally to provide a nanocarrier with 
solubilizing and mucoadhesive properties. A new technique for the preparation of 
protamine NCs was developed. First, an oil-in-water nanoemulsion was prepared by 
blending the oil and surfactant in 2:3 ratio and dispersing them in the aqueous phase. 
Afterwards, the obtained nanoemulsion was post-coated with the polymer to form 
blank NCs. Briefly, the optimized nanosystem was prepared as follows: 0.10 g of 
Maisine 35-1 and 0.15 g of Tween 80 were mixed together by vortexing at 1200 rpm 
for 2 minutes. The aqueous phase was prepared by dissolving 0.03 g of PEGst-40 and 
0.05 g of SDC in 4.00 ml of ultrapure water, and then poured over the oil-surfactant 
blend while vortexing at 1200 rpm for 5 minutes. One ml of the prepared 
nanoemulsion was added to 1 ml of protamine solution (5.00 mg/ml) whilst stirring to 
obtain a NC formulation with a volume of 2 ml. The solution was gently stirred at 300 








2.3. Encapsulation of cyclosporin A 
A concentrated solution of cyclosporin A (CsA) in ethanol (20 mg/ml) was mixed 
with Maisine 35-1 and the drug-loaded system was prepared following the previously 
described procedure (see 2.1). Cyclosporin A-loaded protamine NCs, containing 0.5 
mg/ml of CsA, were characterized as defined in section 2.3. Then, the prepared 
nanosystem was isolated by size exclusion chromatography (SEC) using CentriPure 
P10 hydrated gel filtration columns (Zetadex-25, emp Biotech). The gel filtration 
method was validated for blank nanocarriers and for the solution of free cyclosporin 
A in ethanol in order to be able to separate the cyclosporin A-loaded NCs from the 
unencapsulated drug. In brief, the column was first equilibrated with 15 ml of 
ultrapure water (elution buffer). One ml of the formulation was then transferred to the 
column and allowed to enter the gel bed completely. The void volume was discarded 
and the cleaned sample was eluted with 1.6 ml of ultrapure water, recovering 1.2 ml 
of the formulation. Entrapment efficiency (EE%) was determined using the direct 
method by comparing the amount of drug in the final formulation of NCs to the initial 
amount added during preparation (Equation 1) using reverse phase high-performance 
liquid chromatography (RP-HPLC). First, the isolated NCs were digested in 
acetonitrile in order to extract CsA from the formulation and then centrifuged at 
14000 x g for 5 minutes to obtain a clear aliquot. This aliquot was injected in the C18 
HPLC column followed by isocratic elution (60% acetonitrile, 30% isopropanol, 10% 
water) at 60°C and UV detection at 205 nm (in-house method developed by Cuesta 
and Reimóndez Troitiño). The theoretical drug loading was calculated with regard to 
the mass of cyclosporin A and other components added during the preparation of the 
NCs (Equation 2). Finally, the drug loading capacity and yield were calculated using 
Equation 3 and Equation 4 respectively 
 
2.4. Determination of size and zeta potential  
The average diameter and polydispersity index (PDI) of protamine lipid NCs were 
characterized by dynamic light scattering after diluting the samples 1:100 with 
ultrapure water. Zeta potential was determined by laser-Doppler anemometry after 
1:100 sample dilution with potassium chloride 1 mM. The measurements were 








2.5. Stability studies of protamine nanocapsules in biological fluids 
Simulated intestinal fluid (SIF) pH 6.8 was prepared as described in European 
Pharmacopoeia (2011). Fasted state upper small intestine fluid (FaSSIF-V2) pH 6.5 
and fed state upper small intestine fluid (FeSSIF-V2) pH 5.8 were prepared according 
to Jantratid et al. (2008). Protamine NCs were incubated under moderate shaking at 
37°C in SIF, FaSSIF-V2 and FeSSIF-V2 in the presence of digestive enzymes from 
porcine pancreas. Samples were collected and measurements performed at time points 
0, 0.5, 1, 2 and 4 h. The samples incubated in FeSSIF-V2 were centrifuged prior to 
measurements at 13600 x g for 5 minutes at 20 °C to eliminate aggregates of 
pancreatin. Size distribution, polydispersity index (PDI) and count rate of the NCs 
were monitored by dynamic light scattering.  
 
2.6. Stability studies during storage 
Colloidal stability of blank NCs in storage was followed during a period of 1 week at 
4 °C, 25 °C or 37 °C. Samples of three different batches were withdrawn at 
predetermined time intervals, determining particle size and zeta potential (as 2.3) and 
describing the suspension appearance to ensure continued viability. 
 
2.7. Freeze-drying studies 
Blank and CsA-loaded NCs were freeze-dried in order to evaluate their ability to be 
transformed into a dry powder formulation. Three cryoprotectant solutions (glucose, 
sucrose and trehalose) at two different concentrations (5% and 10%) were studied. 
The influence of freezing temperature on the lyophilization process was also 
investigated. Optimized lyophilization of the blank and drug-loaded nanosystem was 
performed as follows: samples of NCs suspension (0.5 ml) containing the 
cryoprotectant trehalose (10%) were frozen overnight at -80 °C and then transferred 
to the lyophilizer. The initial drying step was performed for 24 h at -35°C and 2-10 
millitorr, followed by secondary drying for another 24 h at 0 °C and finally a third 







were resuspended with ultrapure water by vortexing for 5 min and then characterized 
for size, zeta potential and polydispersity index. 
 
2.8. Statistical analysis 
All the experiments and measurements were performed in triplicates (n=3) and the 
results are reported as the mean values ± standard deviation (SD). 
 
3. Results and discussion  
3.1. Preparation of protamine NCs 
Monodisperse protamine NCs (PDI=0.2) with the average size ranging from 160-180 
nm were prepared by a low-energy emulsification method without the use of any 
organic solvent or heat. The NCs had a positive zeta potential of +14 mV, indicating 
the presence of protamine around the oil-filled core, when compared to the 
corresponding nanoemulsion formulation. A long-chain monoglyceride/diglyceride 
mixture, i.e. Maisine 35-1, that works as an oil phase, enabled fine droplet formation 
in the presence of the non-ionic surfactant Tween 80 (HLB=15) upon dilution with 
water. The attachment of protamine to the system was possible after incorporation of 
an anionic surfactant, SDC, into the droplet surface. SDC led to a decreased zeta 
potential of the nanoemulsion and thus allowed the coupling of the positively charged 
polymer through electrostatic attractions. Thereby, the polymeric shell was formed 
around the lipid droplets. Protamine NCs were sterically stabilized by introducing 
polyethylene glycol chains (PEGst-40 stearate) on the NC surface. Steric stabilization 
of the colloidal system with a layer of adsorbed polymer was necessary to enhance the 
repulsive interaction forces and thus minimize particle aggregation. The developed 




























Figure 1: A schematic illustration of core-shell protamine NCs prepared by the 
solvent-free method. 
 
3.2. Encapsulation efficiency and drug loading capacity  
A model highly hydrophobic and anti-inflammatory drug, cyclosporin A, was 
encapsulated in the oily core of the nanocarriers. As indicated in Table 1, the 
entrapped drug did not influence the physicochemical properties of protamine NCs. 
The loaded system was isolated from the free drug by size exclusion chromatography 
and the concentration of cyclosporin A extracted from the digested formulation was 











Table 1: Physicochemical characteristics of blank and drug-loaded protamine NCs 
 
 
Protamine nanocapsules exhibited high encapsulation efficiency of cyclosporin A 
equal to 95%. The loaded formulation was freeze-dried, without any cryoprotectant, 
and the obtained powder was weighed in order to determine the yield of the 
nanocapsules and the drug loading capacity. These parameters were calculated to be 
equal to 87% and 5%, respectively. The latter corresponds to the theoretical drug 
loading value, i.e. 4.6%. 
 
3.3. Stability of CsA-loaded NCs in simulated intestinal fluids 
Similarly to the blank system, the cyclosporin A-loaded NCs were stable when 
incubated in SIF, FaSSIF-V2 and FeSSIF-V2 with pancreatic enzymes. As shown in 
Figure 2 and 3 below, the size and count rate of the particles remained relatively 
constant throughout the studies. Further, the incubation with biorelevant media did 
not affect the polydispersity index of the colloidal nanosystem. 
Protamine 
NCs 
Size (nm) PDI ζ-potential (mV) EE (%) LC (%) 
Blank 163 ± 8 0.2 +14 ± 2 N/A N/A 








Figure 2: Colloidal stability of CsA-loaded protamine NCs in FaSSIF-V2. 
 
 
Figure 3: Colloidal stability of CsA-loaded protamine NCs in FeSSIF-V2  
 
3.4. Freeze-drying of protamine NCs 
Initial freeze-drying performed without any cryoprotectant resulted in a collapsed 
cake that was not fully resuspendable. After the screening of different sugars, 10% 
trehalose was selected to protect protamine NCs from freezing damage. Polydispersity 







20°C. As indicated in Table 2, blank and drug-loaded NCs lyophilized under 
previously defined optimal conditions, could easily be resuspended with water 
retaining in principle their initial physiochemical properties.  
 
Table 2: Physicochemical properties of blank and CsA-loaded protamine NCs after 
freeze-drying. 
Nanosystem / conditions Size (nm) PDI ζ-potential (mV) 
Blank / before freeze-drying 179 ± 3 0.2 +15 ± 1 
Blank / after resuspension 196 ± 7 0.2 +19 ± 1 
CsA-loaded / before freeze-
drying 
198 ± 12 0.2 +15 ± 1 
CsA-loaded / after resuspension 176 ± 8 0.3 +10 ± 3 
 
4. Conclusions  
Overall, a nanosized carrier with physicochemical characteristics appropriate for 
mucosal administration of therapeutics was developed using a new and low-cost 
preparation method that allowed efficient entrapment of a lipophilic drug. In this 
study, protamine nanocapsules exhibited high encapsulation efficiency and drug 
loading capacity of cyclosporine A, stable in simulated intestinal fluids. From these 
successful preliminary results for the presented prototype the next steps include more 
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